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Abstract 
 
The P2X purinoceptor 3 (P2X3) plays a crucial role in signalling leading to 
chronic inflammatory pain and, thus, the P2X3 receptor provides a proven 
target for its treatment. Botulinum toxin type A (BoNT/A) is a potentially 
promising candidate drug for use in this situation. Long-acting botulinum 
neurotoxin type D (BoNT/D) inhibits inflammatory pain peptide release from 
cultured sensory neurons evoked by K+, bradykinin or capsaicin. The purpose 
of this project is to develop single-chain antibody variable fragments (scFv) 
recognising extracellular domains of P2X3, for use as a targeting agent to 
deliver protease and translocation domains of BoNT/A and BoNT/D (LC-HN/A 
and LC-HN/D) to pain-signalling neurons.  
A rabbit scFv library was generated, and phage display was applied for 
anti-P2X3 scFv recombinant antibody selection. After five rounds of 
bio-panning, followed by polyclonal phage ELISA, monoclonal ELISA, cross 
reactivity analysis, competitive ELISA, western blotting and 
immunofluorescence staining, anti-P2X3-257 scFv clones with high specificity 
and affinity were successfully selected. The scFv gene was fused to BoNT/A 
and BoNT/D and expressed as a fusion protein in E. coli. After purification, 
this protein was shown to enter sensory neurons and to cleave its neuronal 
target, VAMP2.  
The efficacy of this therapeutic will be further evaluated using established 
capsaicin-induced or formalin-induced rat inflammatory pain models.
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Chapter 1 
 
General Introduction 
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1.1 Inflammatory pain 
 
1.1.1 What is inflammatory pain? 
 
Inflammatory pain results from the activation of inflammatory cascades (which 
transport and develop the inflammatory response involving the local vascular 
system, the immune system and different cells at the injured location) and 
chemoreceptors (sensory receptors that transduce a chemical signal into an 
action potential) (Kidd and Urban, 2001). Many situations can lead to 
inflammatory pain, for instance, arthritis, extreme cold, penetration wounds, 
fractures, burns, vasoconstriction, infections and excessive stretching. It is a 
major challenge for health providers to address this issue as suffers represent 
approximately 20% of the adult population (Breivik et al., 2006). There 
remains an unmet need for its effective treatment, as traditionally used 
non-steroidal anti-inflammatory drugs, are short-acting and can cause serious 
side effects. 
Soluble N-ethylmaleimide-sensitive factor attachment protein receptor 
(SNARE) is a large protein superfamily which mediates vesicle fusion in yeast 
and mammalian cells. Three SNAREs were found to be important in 
inflammatory pain signalling pathways. They are synaptosomal-associated 
protein 25 (SNAP-25) located in the cell membrane, vesicle-associated 
membrane protein (VAMP, also known as synaptobrevin) in vesicular 
membrane and syntaxin 1 also in vesicular membranes. SNAP-25, VAMP and 
syntaxin 1 cause the release of peptides which mediate inflammatory pain, for 
instance, calcitonin gene-related peptide (CGRP) and substance P (SP) (Kidd 
and Urban, 2001; Meng et al. 2007). Both CGRP and SP play crucial roles in 
the transmission of pain (Datar et al., 2004). 
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1.1.2 Therapy for inflammatory pain 
 
1.1.2.1 The role of P2X3 in inflammatory pain 
 
The P2X receptor functions as an ionotropic (Na+, K+ and Ca2+) ligand-gated 
cationic channel (Radford et al., 1997). It is activated by extracellular ATP and 
mediates fast synaptic transmission (a process of releasing signalling molecules 
by the neuron which then binds to the receptors of another neuron for 
activation). The P2X receptor is made up of a number of P2X subunits, P2X1-7. 
The P2X subunits form hetero-oligomers which assemble to form the P2X ion 
channel. It was previously demonstrated by many researchers that all the P2X 
subunits especially the subunit P2X3 plays a crucial role in inflammatory pain 
signalling (Jarvis et al., 2002; Xu and Huang, 2002).  
ATP can be released and produces pain in humans by stimulating the 
nociceptors after tissue injury or visceral distension (Burnstock, 1996; 
Burnstock, 2000). It was reported that in several experimental models the 
responses to ATP are enhanced during inflammation (Kidd and Urban, 2001; 
Burnstock, 2009). P2X3 was proven to be involved in pain signalling through 
ATP released by inflamed tissues. Hence, it could be used as a molecular target 
for pain treatment (North, 2003). 
P2X3 is selectively expressed in certain pain-propagating neurons (i.e. dorsal 
root ganglion neurons and trigenminal ganglion neurons). Souslova et al. (2000) 
demonstrated that after deletion of the P2X3 gene, dorsal root ganglion neurons 
lost rapidly desensitizing ATP-gated cation currents, thus suggesting a role for 
ATP acting through P2X3 in inflammatory pain processing. P2X3 receptors 
expressed by dorsal root ganglion neurons play also a crucial regulatory role in 
inflammatory pain. Furthermore, Honore et al. (2002) reported that chronic 
inflammation-induced thermal hyperalgesia decreased, with reduction of the 
expression level of P2X3, by repeating administration of antisense 
oligouncleotides into the intrathecal space of rats. Jarvis et al. (2002) proved 
that a potent and selective blocker (A-317491) of P2X3 can reduce chronic 
inflammatory pain induced by Freund’s adjuvant. Cockayne et al. (2000) 
demonstrated that P2X3 is a proven target for drugs to treat inflammatory 
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diseases and associated pain because behavioural testing of P2X3 knock-out 
mice demonstrated its pivotal role in signalling leading to chronic 
inflammatory pain. Kaan et al. (2010) also reported that much less bone cancer 
pain behaviour was observed in a rat bone cancer pain model after the blocking 
of P2X3 receptors on peripheral and central terminals of nocioceptors. 
 
1.1.2.2 Dorsal root ganglion neurons (DRGs) 
 
Dorsal root ganglion neurons are cell bodies of neurons in the dorsal root 
ganglion (DRG), the nodule on the dorsal root of spinal nerve. DRGs were 
chosen as an in vitro model for therapy of inflammatory pain, as DRGs are 
among the most common and major sensory neurons in vertebrates. It is 
reported that during inflammatory pain DRG neurons were sensitized by a 
majority of identified signalling cascades (Kallenborn-Gerhardt and Schmidtko, 
2011). A high percentage of DRGs express P2X3 receptor (Table 1.1), i.e. on 
postnatal day seven, 72.6 ± 3.4% of DRG cells could be identified as P2X3 
receptor-positive cells (Ruan et al., 2004). 
 
Table 1.1 Expression of P2X3 receptor immunoreactivity in dorsal root 
ganglions (DGRs) in embryonic and postnatal development.  
 
* P<0.001 
 
Note: statistical significance indicated by asterisks relates to embryonic days 
E16 and E18, as compared with postnatal ages P7, P14 and adult (This table is 
modified from Ruan et al., 2004). 
 
 
 E16 E18 P1 P7 P14 Adult 
P2X3 
immunopositive 
DRGs (%) 
 
100 
 
97.2 ± 
1.5 
 
92.5 ± 2.2 
 
72.6 ± 3.4* 
 
47.5 ± 2.8* 
 
44.3± 3.5* 
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1.1.2.3 Pain relief by botulinum neurotoxins (BoNTs) 
 
Botulinum neurotoxins (BoNTs), which are produced by Clostridium 
botulinum, are known to be highly potent. BoNTs contain three domains (Fig. 
1.1 and table 1.2), a binding domain (HC), a translocation moiety (HN) and a 
Zn2+-dependent light chain (LC) (Lacy et al., 1998; Jin et al., 2006). BoNTs 
were proven to be effective for inflammatory pain treatment by inhibiting the 
release of pain-related peptides (i.e. CGRP or SP) by cleaving their specific 
intracellular SNAREs (i.e. SNAP-25 or VAMP) (Fig. 1.2 and Table 1.3). There 
are seven serotypes of BoNTs, BoNT/A-G. BoNT/A/C/E cleaves 
synaptosomal-associated protein 25 (SNAP-25), while BoNT/B/D/F/G cleaves 
vesicle-associated membrane protein (VAMP).  
Many researchers have suggested that BoNT is a promising candidate for 
treatment of pain. For instance, Mahowald et al. (2009) reported that 
intra-articular injection of BoNT/A into joints was effective in treating chronic 
inflammatory pain with no serious adverse effects. Kaufman and Karceski 
(2009) found that the injection of BoNT/A into both feet up to the ankle or 
mid-shin skin can relieve neuropathic pain in individuals with diabetes. 
BoNT/D was proved to be a strong candidate for inflammatory pain therapy by 
cleaving all VAMP isoforms I, II and III, and then inhibiting release of CGRP, 
one of the main mediators of inflammatory pain (Meng et al., 2007). It was 
also found that a re-targeted botulinum toxin type E (BoNT/E) is very effective 
in blocking the release of the pain-peptide, CGRP, from sensory neurons and 
attenuating pain signalling in brain (Meng et al., 2009). Moreover, another 
more advanced long-acting variant of BoNT/E has proved to be very potent 
and versatile as an inhibitor of CGRP release in an inflammatory pain model 
(Wang et al., 2009). 
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Fig. 1.1 Structure of botulinum neurotoxin. The botulinum neurotoxin consists 
of one light chain and one heavy chain which are connected by a disulfide bond. 
In the form of single chain (SC), toxins have relatively little potency as 
neurotoxins. Botulinum neurotoxin activation requires cleavage between amino 
acids 448 and 449 to form an active di-chain (DC), which is one light chain 
(L-chain, amino acids 1-448, 50 kDa) and one heavy chain (H-chain, amino 
acids 449-1295, 100 kDa) mutually connected by a disulfide bond. LC = light 
chain of botulinum toxin; HN = translocation domain of botulinum toxin; HCN = 
N-terminal binding domain of botulinum toxin; HCC = C-terminal binding 
domain of botulinum toxin; SC = single chain of botulinum toxin before 
separate light chain and heavy chain; DC = di-chain of botulinum toxin before 
separate light chain and heavy chain; MW = molecular weight markers and 
-S-S- = disulfide bond. 
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Fig. 1.2 Mechanism of BoNTs inhibition of inflammatory pain. Inflammatory 
pain involves both peripheral and central sensitization. BoNTs relieve 
inflammatory pain (central sensitization) by inhibiting the release of 
pain-related peptides, CGRP and SP by cleaving their specific intracellular 
SNAREs, SNAP-25 and VAMP during peripheral sensitization.  
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Table 1.2 Function of each domain of BoNT. 
 
Individual domains of BoNT Function 
Heavy chain binding domain (HC, 100 kDa): 
C terminal binding domain (HCC, 50 kDa) & 
N terminal binding domain (HCN, 50 kDa) 
Bind to gangliosides and high-affinity 
protein acceptors on cholinergic nerve 
terminals. 
Heavy chain translocation domain 
(HN, 50 kDa) 
Internalization and translocation of 
catalytic light chain across membranes. 
Light chain (LC, 50 kDa) Mediates toxic activity. Works as a 
Zinc-dependent endopeptidase for 
selective proteolysis and digestion of 
SNAREs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9 
 
Table 1.3 Target SNAREs cleaved, pain-peptide inhibited and function for 
different serotypes of BoNT (this table is modified from Dolly et al., 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2 The immune system 
 
1.2.1 Basic components of the immune system 
 
Throughout evolution the mammalian immune system has developed two arms 
of defence, the innate and the adaptive immune systems. Both systems function 
to defend against pathogen invasion and are linked. The immune system 
consists of organs, which were classified into central immune organs (i.e. 
thymus, bone marrow and Bursa of Fabricius) and peripheral immune organs 
(i.e. spleen and lymph nodes). The immune system utilizes immune cells, for 
example, lymphocytes, monocytes, macrophages, dendritic cells, neutrophils, 
eosinophils, basophils and mast cells, all of which work in concert for the 
BoNT 
serotype 
Target SNAREs 
cleaved 
Pain-peptide 
inhibited 
Function 
BoNT/A SNAP-25 CGRP Stop the transmission 
of pain 
BoNT/B VAMP I, II and 
III 
SP Stop the transmission 
of pain 
BoNT/C SNAP-25 and 
syntaxin 
CGRP Stop the transmission 
of pain 
BoNT/D VAMP I, II and 
III 
SP Stop the transmission 
of pain 
BoNT/E SNAP-25 CGRP Stop the transmission 
of pain 
BoNT/F VAMP I, II and 
III 
SP Stop the transmission 
of pain 
BoNT/G VAMP I, II and 
III 
SP Stop the transmission 
of pain 
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production of an immune response which is mediated by immune-related 
molecules, such as complement, immunoglobulins (Ig), interferons (IFNs), 
interleukins (IL), chemokines and cytokines (Table 1.4). 
 
Table 1.4 Cellular and molecular components of the immune system (this table 
is modified from Merk, 2012). 
 
Compound Type Main Source Major function 
Antigen-Presenting 
Cells (APCs) 
B cells; Monocytes; 
Macrophages; 
Dendritic cells 
Skin, lymph nodes, 
and tissues 
throughout the 
body 
Present antigen-derived 
peptides in conjunction 
with the major 
histocompatibility 
complex (MHC) 
molecules for T 
cell–dependent 
acquired immune 
responses. 
Polymorphonuclear 
(PMN) Leukocytes 
Neutrophils; 
Eosinophils; 
Basophils; Mast cells 
Whole blood Digest and kill 
pathogenic bacteria. 
Cytotoxic 
Leukocytes 
Natural killer (NK) 
cells; 
Lymphokine-activate
d killers (LAK) 
Peripheral blood Induce apoptosis, in 
infected or abnormal 
cells, killing a wide 
spectrum of tumor 
target cells and 
abnormal lymphocytes. 
Lymphocytes B cells (which 
mature in bone 
marrow); T cells 
(which mature in the 
thymus) 
Bone marrow and 
thymus 
Recognise specific 
antigen by 
antigen-specific surface 
receptors (i.e. 
antibodies) and clusters 
of differentiation. 
Antibodies IgM; IgG (Ig Y); Spleen, bone Recognise antigen on 
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IgA; IgD; IgE marrow, blood the surface of B cells 
and then responded to 
antigen. 
Acute Phase 
Reactants 
C-reactive protein 
and mannose-binding 
lectin (which fix 
complement and act 
as opsonins); the 
transport protein 
α1-acid glycoprotein, 
and serum amyloid P 
component 
Liver Limit tissue injury; 
enhance host resistance 
to infection, and 
promote tissue repair 
and resolution of 
inflammation. 
Cytokines TNFs (TNF-α, 
lymphotoxin-α, 
lymphotoxin-β); 
Interleukins; 
Chemokines; 
Transforming growth 
factors (TGFs); 
Hematopoietic 
colony-stimulating 
factors (CSFs) 
Immune cells Bridge innate and 
acquired immunity and 
generally influence the 
magnitude of 
inflammatory or 
immune responses. 
 
 
1.2.2 The genetics of recombinant antibody production 
 
Immunoglobulins (Ig), also known as antibodies are produced by B 
lymphocytes in response to foreign molecules. Antibody diversity and 
increased affinity is generated through a process known as somatic 
hypermutation. During this process different gene segments rearrange resulting 
in different combinations of heavy and light chains. All antibodies are 
composed of two heavy chains and two light chains which are connected 
through disulfide bridges (Fig. 1.1). The antibody light chain is encoded by 
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three gene segments: constant segment (C), variable segment (V), diversity 
segment (D) and joining segment (J); while the heavy chain is encoded by four 
gene segments: constant segment (C), variable segment (V), diversity segment 
(D) and joining segment (J). In humans, there are seven families of functional 
heavy chain germline sequences, thirty variable lambda (λ) and forty variable 
kappa (κ) light chain germline sequences, one constant lambda and multiple 
constant kappa light chain genes. The ratio of κ:λ is 3:2. For rabbits, there are 
more than twenty functional heavy chain germline genes, two constant kappa 
light chain genes and several variable lambda light chain genes. The κ:λ ratio is 
10-20:1. The chicken library is the most simple to create as it consists of only 
one variable heavy chain and one variable lambda light chain germline 
sequence (Barbas et al., 2001). 
 
1.2.3 Generation of an immune response 
 
The generation of the immune response involves the recognition of foreign 
antigens such as viruses, bacteria, fungi, parasites and self-reactive molecules 
by a host of immune receptors present both in and on immunocompetent cells.  
Following recognition, the immune cells are activated leading to the 
up-regulation of the immune system, cell proliferation, differentiation or 
apoptosis. The three main phases of an immune response are 
antigen-recognition, lymphocyte-activation and antigen-elimination.  
 
1.2.3.1 Innate immune response  
 
The innate immune response is a non-specific response and is the first line of 
defence in the immune system. The level of innate response can be very 
significant (i.e. on exposure to microbes), but does not lead to immunological 
memory (Hussain et al., 2006).  
There are four ways in which the immune system functions. Firstly, by 
inhibiting the invasion and reproduction of pathogens by the presence of 
immune barriers, for instance, hairs, skin, blood brain barrier, blood-embryo 
barrier and the blood-thymus barrier. Secondly, pathogens will be killed 
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directly by complement molecules and lysozymes which are induced by the 
inflammatory response. Thirdly, immune cells discriminate between pathogen 
and host molecules using specific germline-encoded receptors known as 
pattern recognition receptors (PRRs), causing enhanced phagocytosis by 
phagocytes and natural killer (NK) cells at inflammatory sites. The immune 
cells ingest and subsequently destroy the pathogen by means of the 
phagolysosome. These three reactions are very general and function against 
most pathogens. However, the fourth mechanism involves a specific response 
to a particular pathogen and leads to an adoptive response, which is a specific 
immune response by presenting antigen through dendritic cells to active T and 
B cells. 
 
1.2.3.2 Adaptive immune response  
 
1.2.3.2.1 Structure and function of major histocompatibility complex 
(MHC)  
 
The adaptive immune response generates specific defences against 
disease-associated pathogens or antigens (e.g. proteins) that can be invoked 
during subsequent infections. In adaptive immune responses, 
disease-associated proteins will be proteolytically digested by the cells (e.g. 
cytotoxic T cells, natural killer cells and macrophages) and then the 
disease-associated peptides will be transported to the cell surface and be bound 
by the major histocompatibility complex (MHC). MHC proteins, which found 
in all kinds of vertebrates, can transport internal or external antigens to the T 
cells for distinguishing self from non-self molecules. Without the transporting 
function of MHC, adoptive immune response cannot occur. 
The MHC is a large group of genes located on the short arm of chromosome 6. 
The MHC gene group consists of four million base pairs of DNA, 128 genes 
and 96 non-functional gene remnants (Spector, 2003). The MHC is divided 
into three regions, class I, II and III regions. These three regions are composed 
of a group of genes with specific functions which play vital roles in the 
immune system (Table 1.5). 
14 
 
MHC proteins expressed by MHC class I region (found on all nucleated cell 
surfaces) have the ability to present antigens to cytotoxic T lymphocytes 
(CTLs). MHC proteins expressed by MHC class II region (found only on B 
lymphocytes, macrophages, and other cells present antigens to T cells) present 
peptides which have been digested from external sources. This function is 
crucial to T-cell communication with B-cells and macrophages. 
 
Table 1.5 Function and location of proteins expressed by MHC class I, II and 
III regions. 
 
MHC region Function Location 
MHC class I 
region 
Present fragments of proteins that 
are synthesised inside cells. i.e. 
present antigens to cytotoxic T 
lymphocytes (Rodenko et al., 2009). 
On surfaces of all 
nucleated cells. 
MHC class II 
region 
Present peptides which are needed 
for T-cell communication with 
B-cells and macrophages (Kimura et 
al., 2005). 
B lymphocytes, 
macrophages, and 
other cells that 
present antigens to T 
cells. 
MHC class III 
region 
Encode several components, i.e. 
complement proteins which are 
involved in the antibody response; 
the inflammatory cytokines; tumor 
necrosis factor-α and -β (TNF-α and 
-β) and two heat shock proteins 
which help cells deal with heat, 
stress and viral infection (Milner and 
Campbell, 2001). 
Peripheral blood  
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1.2.3.2.2 Function of cluster of differentiation 4 and 8 (CD4 and CD8) 
 
Cluster of differentiation 4 (CD4) T cell is a glycoprotein which expressed on 
the surface of monocytes, T helper cells, dendritic cells and macrophages, and 
cluster of differentiation 8 (CD8) T cell is a transmembrane glycoprotein 
function as a co-receptor for the T cell receptor. Both CD4 and CD8 T cells 
mediate cell-mediated adoptive immune response. CD4 plays a role as a 
co-receptor helps the T cell receptor with an antigen-presenting cell for 
activation of the T cell. It is achieved by either amplifying the signal generated 
by the T cell receptor using its intracellular domain or interacting directly with 
the MHC class II molecules on the surface of the antigen-presenting cell using 
its extracellular domain (Wu, 2009). CD8 specifically binds to class I MHC 
protein which causes the T cell receptor of the cytotoxic T cell and its target 
cell to bind tightly together during antigen-specific activation (Devine et al., 
1999). 
 
1.2.3.2.3 Process of adaptive immune response 
 
The first exposure to pathogenic antigens leads to immunological memory 
which takes from two days to two weeks to establish, and an enhancement of 
the immune response will be achieved by future exposures. Immunological 
memory ensures quick and efficient immune response to later exposures. The 
adaptive immune response is also classified as humoral or cell-mediated 
immune responses. The humoral immune response is mediated through B cells 
by producing immunoglobulins which are specific to foreign antigens. There 
are five isotypes of immunoglobulins, IgM, IgD, IgE, IgA and IgG (which is 
called Ig Y in birds). The antigen-specific immunoglobulins then move from 
primary lymphoid organs (i.e. bone marrow, thymus and fetal liver) to 
secondary lymphoid organs, for instance, spleen, lymph nodes and small 
masses of lymph tissue.  
Mature circulating B cells secrete for one type of immunoglobulin on their 
surface. Upon a second or subsequent encounter with their specific antigen the 
B cell rapidly proliferates and transforms into antibody-secreting plasma cells. 
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Cell-mediated immune response is mediated by T cells. The body’s cells that 
are infected with bacteria, parasites or viruses are recognised by CD4 and CD8 
T cell. T cells proliferate and become activated T cells, which are also called 
effector T cells. Effector T cells kill antigen directly or through a synergistic 
killing effect with secreted cytokines when the same antigen is encountered in 
invade the body for a second time (Gao and Jakobsen, 2000; Hoebe et al., 
2004). 
 
1.2.4 Hosts for antibody production 
 
Rabbits, mice and chickens are three of the most common host animals chosen 
for the generation of human therapeutic antibodies. Both rabbits and chickens 
can generate large amounts of polyclonal antibodies with high specificity, and 
all animals may generate recombinant antibodies with good specificity and 
affinity. After animal immunisation, the antigen specific antibodies in a B-cell 
pool are enriched through clonal expansion and repeated exposure to antigen. 
Usually at least two animals per antigen is recommended, as in some cases 
there maybe little or no response to the target antigen. This often occurs as 
each animal has a unique immune system and therefore immune response is 
highly variable. Further comparisons between human, rabbit, mouse and 
chicken antibodies are shown in Table 1.6. 
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Table 1.6 Comparison of human, rabbit, mouse and chicken antibodies. 
 
Key characters Human Rabbit Mouse Chicken 
Structure IgM/G/A/D/
E 
IgM/G/A/D/
E 
IgM/G/A/D/E IgY/A/M 
Primarily used 
antibody 
IgG IgG IgG IgY 
Molecular 
weight 
~150 kDa ~150 kDa ~150 kDa ~180 kDa 
Main source and 
Concentration 
Serum (~10 
mg/mL) 
Serum (7-15 
mg/mL) 
Serum (7-10 
mg/mL) 
Egg yolk (15-25 
mg/mL); serum 
(~5 mg/mL) 
Generation -- Slow Moderate Fast 
Genetic diversity Light and 
heavy chain/ 
high 
Light chain/ 
high 
Light and 
heavy chain/ 
high 
Heavy 
chain/low 
Antibody avidity 
to human 
antigens 
-- Moderate Moderate High 
Cross reacting to 
human antigens 
-- Moderate Moderate Low 
 
 
The generation of antibodies using a rabbit as the host for immunisation offers 
a number of advantages. It is a medium sized animal and is easier and cheaper 
to maintain than large animals (e.g. goats, sheep and donkeys). A rabbit is able 
to produce a large amount of polyclonal antibodies in serum with an antibody 
concentration of 7-15 mg/mL (~5 mL serum per week). Young adult female 
rabbits are preferred because young rabbits have better antibody response than 
old ones, and female rabbits are more docile and less aggressive in social 
interaction than males (Hendriksen and Hau, 2003). However, there are more 
than twenty functional heavy chain germline genes in the rabbit immune 
system, two constant kappa light chain (Cκ) genes and multiple variable kappa 
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light chain (Vκ) genes. The κ:λ ratio is 10-20:1 (Barbas et al., 2001). 
Enormous diversity is generated by re-arrangement of the V (variable), D 
(diversity) and J (joining) gene segments. 
Bachmann et al. (1994) reported that in the mouse, approximately 1,000 to 
10,000 specific B-cells are produced in response to a complex antigen. In the 
murine immune system, there are 300 to 1,000 VH gene segments, 13 DH gene 
segments, four JH gene segments, nearly 300 Vκ gene segments, five Jκ gene 
segments, one Cκ gene segment, two Vλ gene segments, three Jλ gene 
segments and three Cλ gene segments (Early et al., 1980). Murine 
complementarity determining regions 1 and 2 (CDR1 and CDR2) of heavy and 
light chains of are determined by V gene segments, while CDR3 is produced 
by inaccurate joining of V, D and J gene segments ensuring great structural 
antibody diversity (Selsing et al., 1996).  
In general, the larger the phylogenetic distance between the immunised animal 
(e.g. chicken) and the antigen host (e.g. human), the greater the antibody 
response will be. Thus, chickens, which are phylogenetically more distant from 
humans than rabbits and mice, are more likely to achieve better immune 
responses to human proteins (Zhang et al., 2003). Female chickens (hens) are 
favoured for producing large amounts of IgY, which is the 180 kDa homolog 
of mammal IgG as this can be harvested from egg yolk. This process is more 
convenient than producing antibodies from blood and other organs, for instance, 
spleen and bone marrow. The immunoglobulin locus of chickens consists of 
only one functional copy of the V and J segment for both the heavy and light 
chains of the antibody (Ratcliffe, 2006). The production of an antibody 
repertoire in the chicken immune system is derived by re-arrangement of the V 
and J segments, which makes the diversity of antibodies extremely limited. 
However, this makes the generation of chicken recombinant antibody libraries 
easier (only two sets of primers for the amplification of variable chains are 
required) than generation of rabbit or mouse recombinant antibody libraries.  
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1.3 Production and amplification of antibodies 
 
1.3.1 The antibody: structure and function 
 
Antibodies, also known as immunoglobulins (Igs), possess antigen binding 
specificity. They are produced by B-cell-derived plasma cells. Antibodies 
mainly exist in serum, as well as in interstitial fluids and exocrine secretions. 
Antibodies can effectively identify, kill or neutralize invading bacteria, 
parasites, toxins, viruses and destroy other foreign compounds. 
 
1.3.2 Structure of mammalian antibody 
 
Mammalian antibodies are classified into five isotypes IgM, IgD, IgG, IgE and 
IgA based on five different heavy polypeptide chains µ, δ, γ, ε and α, 
respectively. The heavy polypeptide chains µ and ε consist of about 550 amino 
acids and about 450 amino acids comprise the heavy polypeptide chains α and 
γ (Janeway, 2001; Strome et al., 2007). 
There are two types of light chains for mammal antibodies, namely, lambda (λ) 
and kappa (κ). However, each antibody consists of only one of these. κ and λ 
light chains are about 211 to 217 amino acids in length (Diaz and Casali, 
2002). 
Both heavy and light chains contain two regions: namely, the variable (V) 
region at the N-terminal end and the constant (C) region at the C-terminal end. 
The amino acid sequence of the variable regions is responsible for the 
specificity of the antibody, and it is this region that is used for antigen-specific 
binding. For each isotype, the constant domain remains the same with the same 
amino acid consensus sequence. 
The synonymous “Y” shape associated with a basic immunoglobulin unit (Ig) 
monomer (or subunit) (Fig. 1.3) consists of two light and two heavy chains, 
which are connected by disulfide bonds (Woof and Burton, 2004). All five 
isotypes, IgM, IgD, IgG, IgE and IgA, are composed of this Ig monomer. IgD, 
IgE and IgG are monomers, while IgA is a dimer and IgM is a pentamer (Carey 
Hanly et al., 1973). 
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The single chain variable fragment (scFv) consists of variable (binding) regions 
of antibody heavy chain (VH) and light chain (VL), which are linked by a short 
peptide chain. The popularity achieved by the scFv fragment is due to its short 
generation time, capacity to be expressed in Escherichia coli (E. coli) and high 
antigen affinity and structural stability (Townsend et al., 2006). 
The fragment antigen-binding (Fab) region consists of the full antibody light 
chain, connected to a second antibody domain comprised of VH and CH1 
regions by disulphide bonding. Thus, each heavy and light chain has one 
constant and one variable domain. The two variable domains play a role in 
specific binding of defined antigens (Barbas et al., 2001).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.3 Structure of a basic IgG antibody. The basic antibody monomer 
consists of two light chains and two heavy chains which are connected by 
disulfide bonds. 
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1.3.3 Antibody types and production 
 
1.3.3.1 Polyclonal antibodies  
 
Antibodies that are derived from multiple B cell clones are called polyclonal 
antibodies and they recognise multiple epitopes. The production of polyclonal 
antibodies is usually conducted by carrying out several rounds of antigen 
immunisation into the host animal, for example, rabbits, mice, chicken, horses 
or goats. Specific antibodies are then generated by B lymphocytes. Finally, 
polyclonal antibodies are extracted from the serum of mammalian animals, 
whereas for chickens, polyclonal antibodies can also be extracted from egg 
yolks. Polyclonal serum offers the advantage of broad reactivity. However, 
polyclonal antibodies also display variability in specificity, avidity, relative 
percentage generated and are produced in limited quantities. It may also be 
difficult to reproduce these characteristics in new batches. 
 
1.3.3.2 Monoclonal antibodies 
 
Unlike polyclonal antibodies, monoclonal antibodies are generated from a 
single B cell and react with a single antigenic epitope. For monoclonal 
antibody production, antibody-generating spleen cells are initially fused to 
myeloma cells and the specific hybrids with the required antibody specificity 
selected. Compared to polyclonal antibodies, monoclonal antibodies are 
homogeneous in specificity, and unlimited quantities can be produced, but take 
more time to generate. 
 
1.3.3.3 Recombinant antibodies 
 
A recombinant antibody does not exist naturally but is assembled from 
recombinant DNA by combining antibody heavy chain and light chain gene 
sequences (Jeremy et al., 2007). First, the specific antibody genes are amplified 
using specifically designed primers and are assembled to form the recombinant 
antibody gene. These genes are cloned into a phage display vector (i.e. 
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pComb3H or pComb3X). The recombinant gene is then transformed into 
electrocompetent bacteria (i.e. XL1-Blue and ER2537) to produce the antibody 
phage library. Each bacterium from this library will express a single individual 
recombinant antibody on the surface of the phage particle. Finally, the 
extraction and selection of highly specific antibody is performed generally 
using phage display technology with several rounds of bio-panning. The most 
widely applied formats for recombinant antibodies are scFv and Fabs (Fig. 1.2 
A and B).  
Over the last twenty years, antibody genes have been cloned, genetically 
manipulated and expressed in E. coli to produce antigen binding proteins. 
Antibody expression in E. coli has several advantages i.e. large quantities, can 
be produced quickly and at low cost. Furthermore, recombinant antibody 
technology offers the possibility of production of anti-human antibodies with 
both high specificity and affinity for human disease diagnosis and therapy (de 
Lalla et al., 1996). Recombinant technology was proved to be a promising 
method for producing antibodies for diagnosis and therapy. 
 
1.4 Application of different types of recombinant antibodies 
 
Recombinant antibodies play a crucial role in biomedical research and are used 
as clinical therapeutic reagents. ScFv and Fab are the most popular 
recombinant antibody formats used for diagnosis and therapy. They are also 
important because of their high specificity for target antigens, their small size, 
and the lower negative response that they generate when exposed to the human 
immune system. Using molecular biological approaches it is possible to 
generate a recombinant chimeric antibody (a promising candidate in the 
treatment of many human diseases), which consists of mouse antibody variable 
region sequences with human antibody constant region sequences and then this 
chimeric gene can be largely expressed in either myeloma cells or E. coli. 
(Xiong et al., 2006). 
It is reported that over 151 recombinant therapeutics have been approved by 
the FDA or by the European Medicines Agency for different clinical 
indications (Huang et al., 2012). In addition to scFv and Fab, bispecific 
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antibodies [i.e. Fab-scFv fusion antibody, F(ab’)2 and ic scFvs] are also used as 
possible therapeutic agents for cancer treatment and have been developed since 
the mid-1980s because of their improved efficacy and stability (Table 1.7; Fig. 
1.4; Conroy et al., 2009; Thakur and Lum, 2010). 
 
Table 1.7 Types of recombinant antibodies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Types of 
recombinant 
antibodies 
Abbreviation Molecular 
mass 
scFv Single-chain variable 
fragment 
25 kDa 
Fab Fragment antigen-binding 
region 
50 kDa 
sc(Fv)2 Bivalant single-chain 
variable fragment 
50 kDa 
F(ab')2 Bivalant fragment 
antigen-binding region   
100 kDa 
Fab-scFv Single-chain variable 
fragment and fragment 
antigen-binding fusion 
75 kDa 
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Fig. 1.4 Structures of a scFv (A), a Fab fragment (B), a (scFv)2 (C), a F(ab')2 
(D) and a Fab-scFv (E). (A) The scFv fragment is composed of one variable 
region of a light chain (VL) and one variable region of a heavy chain (VH), with 
a flexible linker joining [i.e. (GGGGS)3 linker] the terminal ends of either the 
VH to VL (or VL to VH). (B) The Fab fragment is formed by one variable and 
one constant domain of both light and heavy chain linked with a disulphide 
bond. (C) A ic scFv, (scFv)2, is generated by linking two scFvs with a short 
amino acid (AA) linker. (D) F(ab')2 involves linking the two Fabs by 
disulphide bonds. F(ab')2 can also be produced by proteolytic cleavage of an 
IgG molecule. (E) A Fab-scFv can be generated by linking Fab and scFv via a 
short amino acid (AA) linker.  
F(ab')2 
A  
E D 
C B 
scFv Fab sc(Fv)2 
Fab-scFv 
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1.4.1 Single-chain variable fragment (scFv) 
 
The scFv (Fig. 1.4A) contains variable regions of antibody heavy (VH) and 
light chains (VL). In most cases, the scFv recombinant antibody fragment was 
used for targeted therapy through fusing to different proteins or genes. Chen et 
al. (2010) developed a stable anti-human CD44v6 scFv by selecting from a 
human phage-displayed scFv library. It can effectively and specifically target 
CD44v6-expressing cancer cells. Therefore, anti-CD44v6 scFvs may have 
significant value for cancer therapy. Ayyar et al. (2010) successfully generated 
anti- heart-type fatty acid binding protein (hFABP, a promising cardiac 
biomarker) scFv with high affinity and specificity and low limit of quantitation 
(1.9 ng/mL) for immunodiagnosis of cardiovascular diseases. He et al. (2010) 
reported that a prostate tumor-targeting scFv (UA20) internalizes in prostate 
tumor cells rapidly and specifically in vitro, and also accumulates in prostate 
tumor xenografts in vivo. It indicates the potential of UA20 for targeted therapy 
for prostate cancer. Furthermore, MacDonald et al. (2009) demonstrated that 
VB4-845, a scFv-Pseudomonas exotoxin A fusion construct that targets 
epithelial cell adhesion molecule (EpCAM), can provide a safe and feasible 
therapy for squamous cell carcinoma of the head and neck (SCCHN). 
 
1.4.2 Fragment antigen-binding (Fab) fragment 
 
The Fab fragment, which is double the size of the scFv, consists of the full 
antibody light chain, connected to a second antibody domain comprised of VH 
and CH1 regions by disulphide bonding (Fig. 1.4B). Recombinant antibody 
fragment Fabs have been used in therapy for various diseases (e.g. digitalis 
poisoning, human neuroblastoma, heart disease, severe preeclampsia, severe 
North American pit viper envenomation and heart disease). There are many 
medicines, which have been derived from Fabs and that are now approved by 
the FDA. For example, Abciximab (ReoPro), a monoclonal Fab (c7E3 Fab) for 
the treatment of cardiac ischemic complications, was approved by the FDA in 
1994 (Faulds and Sorkin, 1994). Ranibizumab (Lucentis), a monoclonal Fab 
with therapeutic efficacy of macular degeneration, was approved by the FDA 
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in 2006. ReoPro (Fab/chimeric) targeted to GpIIb/gpIIa for treatment of 
cardiovascular disease was approved by the FDA in 1994 (Holliger and 
Hudson, 2005).  
Recent research indicated more potential therapeutic applications of Fab. Mao 
et al. (2012) demonstrated that a novel Fab antibody fragment which targeted 
latent membrane protein 1 (a latent gene which was expressed when 
nasopharyngeal carcinoma occurs) has the ability to significantly inhibit 
nasopharyngeal carcinoma xenograft tumor growth in vivo (in nasopharyngeal 
carcinoma xenograft nude mice) after combining with mitomycin C. Hamatake 
et al. (2010) produced a CD4-reactive Fab of an IgM clone which limited the 
replication of HIV from a healthy HIV-seronegative individual. This Fab 
against CD4 may provide an efficacious therapy for HIV/AIDS.  
 
1.4.3 Bivalent and trivalent scFvs 
 
Bivalent or trivalent scFvs can be generated by linking two or three scFvs with 
a short amino acid linker (Fig. 1.4C). Heitner et al. (2006) selected a 
therapeutic ic scFv candidate (AT-19) using live cell (the human prostate 
carcinoma cell line PC-3) panning against native tomoregulin (a cell surface 
protein which provides potential prostate cancer target). Monomeric scFv can 
not bind the native receptor expressed by cells, while ic scFv AT-19 binds with 
nanomolar affinity. Wittel et al. (2005) reported that scFv dimer, sc(Fv)2, and 
tetramers, [(scFv)2]2, are stable in vivo and have significant potential for 
diagnostic and therapeutic applications. Pavlinkova et al. (1999) generated a 
stable noncovalent dimer of CC49 scFv by joining the VL and VH variable 
region genes together using a 25-amino acid helical linker (205C). The rapid 
clearance from the blood, higher tumor uptake and longer retention of the 
stable dimer CC49 scFv make it an important agent for potential imaging and 
therapeutic applications. Based on the variable regions of the monoclonal 
antibody (MAb) CC49, Beresford et al. (1999) generated a unique divalent 
single-chain Fv protein [sc(Fv)2]. This sc(Fv)2 is different from other ic 
single-chain fragments as a linker sequence (L) is inserted between the 
repeated VL and VH domains [VL-L-VH-L-VL-L-VH]. This soluble construct 
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was expressed in E. coli, followed by purification by ion-exchange and 
gel-filtration chromatography. This ic scFv of MAb CC49 was proved to be a 
competitive candidate for imaging and therapeutic applications. 
 
1.4.4 Fab dimer 
 
A F(ab')2 fragment contains two Fab fragments. It can be obtained by cleaving 
whole immunoglobulins using the enzyme pepsin below the hinge region (Fig. 
1.4D). A novel F(ab')2 fragment, 125I-F(ab')2, from the chimeric monoclonal 
antibody U36 (cMAb U36) recognizes the CD44v6 antigen (expressed by 
xenograft tumors) was proved by Sandström et al. (2012) to have better 
tumor-to-blood ratio and tumor penetration than cMAb U36 to the monovalent 
Fab fragment. This test was performed in nude mice with CD44v6-expressing 
xenograft tumors. Herrmann et al. (2008) constructed optimized bispecific 
antibodies, anti-CD3 F(ab')2 fragments, for selective activation of the death 
receptor CD95. Monoclonal anti-CD3 F(ab')2 fragments were generated by 
digestion with pepsin for 17 hr at 37°C in acetic acid, pH 4.0. The reaction was 
quenched with 2 M Tris and dialysed against PBS overnight at 2–8°C. F(ab')2 
fragments were finally purified by size-exclusion chromatography. 
Leavenworth et al. (2010) reported that anti-NKG2A F(ab')2 treatment in 
experimental autoimmune encephalomyelitis (EAE) induced mice had no 
detectable effect on the numbers or activity of T and B lymphocytes and NK 
cells in peripheral lymphoid tissues. This anti-NKG2A-based approach may 
offer a secure and efficient therapy for CNS disorders. Anti-NKG2A 20d5 
F(ab')2 antibodies were produced from a 20d5 rat IgG2a antibody using a F(ab')2 
preparation kit (Pierce). 
 
1.4.5 Fab-scFv fusion 
 
The Fab-scFv fusion antibody which is known as a kind of bispecific antibody 
(BsAb), has been proven to be an efficient approach in developing novel 
therapies for many diseases (Fig. 1.4E). Fab-scFv BsAb can be made by 
C-terminal fusion of scFv molecules to the light chain or heavy chain of a Fab. 
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This gave rise to disulphide stabilized Fab-scFv of intermediate molecular size 
(Schoonjans et al., 2000). Fab-scFv can bind to two different sites of the same 
or different antigens, e.g. one part of the BsAb targets a molecule or cell 
specifically for targeting; while the other part is directed towards an enzyme, 
toxin, virus or effector cell for therapy (Schoonjans et al., 2001; Lu et al., 
2002). 
Schoonooghe et al. (2009) developed an anti-MUC1 Fab-scFv antibody with 
better penetration in the tumor compared with a full-size monoclonal antibody 
for better anti-cancer therapeutics. MUC1 (a tumor-associated antigen on the 
surface of tumor cells) has been used as a specific antibody target for 
immunotherapy of human malignancies. Based on the anti-MUC1 PH1 Fab, 
they also developed bivalent PH1 bibodies and trivalent PH1 tribodies of 
intermediate molecular mass by addition of PH1 scFvs to the C-terminus of the 
Fab chains using flexible peptide linkers. 
 
1.5 Production and selection of recombinant antibodies 
 
1.5.1 Production and selection of recombinant antibodies through phage 
display 
 
Phage, a kind of virus that infects bacteria, can adopt foreign genes into its 
non-crucial regions of genome. In phage display technology, foreign DNA (i.e. 
gene of scFv or Fab), is inserted into phage gene III, the gene encodes one of 
the phage coat proteins, and is expressed as a fusion protein. After infecting 
gram-negative bacteria (i.e. Top-10, XL1-blue E. coli) the phage starts the 
replication of coat protein genes, including gene III and foreign DNA fusion. 
This fusion is then expressed as a fusion protein and is displayed on the surface 
of phage (Smith, 1985).  
The phage-expressed (i.e. M13, T4, T7 and λ phage) antibodies are then 
screened via biopanning for antibodies which are specific to the target 
molecule. Usually, several cycles of biopanning are needed for enrichment of 
specific antibodies, as more rounds of biopanning are more likely to result in 
higher enrichment of specific antibodies (McCafferty et al., 1990).  
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Each cycle of biopanning includes three basic steps. Firstly, selection of 
specific phage which bind to the target molecules. At this step, the prepared 
phage clones are added to a tube or mircrowell which is coated with a defined 
amount of the target antigen. The coating antigen concentration usually 
decreases with each round of biopanning. Secondly, removal of non-specific 
phage by washing 5-10 times using PBST and PBS. The unbound (non-specific) 
phage are washed away from the solid surface normally by washing several 
times with PBST followed by PBS. The number of washings is usually 
increased with each round of biopanning. Finally, specific phage are collected 
by eluting phage remaining bound to the antigen using freshly made trypsin. 
The eluted phage can be kept at 4°C for long-term storage (de Kruif et al., 
1996) and are analysed initially for specificity by polyclonal phage ELISA. If 
specific binding to the target antigen is detected, monoclonal phage ELISA will 
then be performed for selection of single colonies which express specific 
antibodies. However, if no specific binding is detected, the eluted phage will be 
infected into bacteria and the next round of biopanning is performed. The 
typical biopanning cycle is illustrated in figure 1.5. 
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Fig. 1.5 Illustration of biopanning cycle. A typical cycle of biopanning of 
specific phage binding. Removal of non-specific phage by washing and 
specific phage elution.  
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1.5.2 Production of soluble recombinant antibodies in E. coli 
 
The functional antibody fragments are transported to an oxidising environment 
to ensure that the required disulfide bonds are generated with attendant protein 
folding, by attaching the bacterial leader peptide sequences to the N terminus 
of the antibody (Rapoport, 1992). The antibody chains are usually transported 
to the periplasmic space which contains proteins (i.e. DsbA, PDI, DsbC, SKp 
and FkpA) that are crucial for the formation of disulfide bonds, folding and 
assembly of recombinant proteins (Bothmann and Pluckthun, 2000). However, 
the expression levels of functional antibodies are usually very low (Chen et al., 
2004). Therefore, cytoplasmic expression with higher protein expression level 
may be more productive. Intra-molecular disulfide bonds, which are crucial for 
antibody function, cannot be formed correctly in the cytoplasm, resulting in 
insoluble and inactive antibodies (Biocca et al., 1995).  
 
1.6 Aims of project 
 
The overall aim of this project was to generate single-chain antibody variable 
fragments (scFvs) which recognise extracellular domains of P2X3. The 
anti-P2X3 scFv will then be used as a targeting agent to deliver BoNT/A and 
BoNT/D to pain-signalling neurons for the treatment of inflammatory pain.  
There are four aims in this project: 
Firstly, generation of scFv libraries, using spleen and bone marrow cDNA from 
P2X3-BSA/KLH immunised animals, and selection of anti-P2X3 scFvs from 
scFv libraries using phage display. Various animals (rabbits, mice and chickens) 
will be immunised with two extracellular domains of P2X3 (P2X3-60 and 
P2X3-257). Large P2X3-specific scFv libraries will be constructed using these 
animal immune models. Phage display technology will be applied for screening 
for anti-P2X3 scFv recombinant antibodies, followed by polyclonal phage 
ELISA, monoclonal ELISA, cross reactivity analysis, competitive ELISA, 
Western blotting and immunofluorescence stain technologies, in order to select 
highly-specific anti-P2X3 scFvs. 
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Secondly, BoNT/A(or/D) and anti-P2X3 scFv fusion proteins will be expressed 
and purified. The neuron-acceptor binding domain gene in the long-acting 
BoNT/A or BoNT/D protease and the DNA sequence encoding the anti-P2X3 
scFv will be joined using a non-structural linker, (GGGGS)3. This resultant 
molecule will be inserted in a pET29a plasmid vector and expressed in E.coli, 
followed by IMAC affinity purification. 
Thirdly, the specificity of this new therapeutic will be investigated in vitro on 
DRGs (major sensory neurons). Their susceptibility to toxins will be 
investigated based on differential ability of the BoNT-scFv fusion protein to 
cleave specific SNAREs and inhibit release of pain transmitters. 
Finally, the specificity of this new therapeutic will be investigated in vivo in the 
rat. A capsaicin-induced or formalin-induced model for pain in rats will be 
used to investigate the anti-nociceptive behaviour of this new generation of 
therapeutics, and to elucidate how they perturb the propagation of pain signals. 
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Chapter 2 
 
Materials and Methods
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2.1 Materials and equipment 
 
2.1.1 Equipment 
 
This section describes equipment used and there relevant suppliers. 
 
Table 2.1 List of equipment 
 
Equipment Suppliers 
Biometra TGRADIENT PCR machine LABREPCO, 101 Witmer Road, Suite 
700, Horsham, PA19044, USA. 
Nanodrop™ ND-1000 NanoDrop Technologies, Inc., 3411 
Silverside Rd 100BC, Wilmington, 
DE19810-4803, USA. 
Gene Pulser Xcell ™ electroporation 
system 
Bio-Rad Laboratories, Inc., 2000 Alfred 
Nobel Drive, Hercules, California 94547, 
USA. 
Roller mixer SRT1 Sciencelab, Inc., 14025 Smith Rd., 
Houston, Texas 77396, USA. 
Safire 2 plate reader Tecan Group Ltd., Seestrasse 103, 
CH-8708 Männedorf, Switzerland. 
Vibra Cell™ sonicator Sonics and Materials Inc., 53 Church Hill 
Road, Newtown, CT 06470-1614, USA. 
UV-Vis Spectrophotometers (UV-160A) Shimadzu Scientific Instruments (SSI), 
7102 Riverwood Drive, Columbia, MD 
21046, USA. 
IX71 inverted microscope Olympus America Inc., 3500 Corporate 
Parkway, P.O. Box 610, Center Valley, 
PA 18034-0610. 
CO2 incubator (IG 150) Jouna, 10 Rue Duguay Trouin, 44807 
St-Herblain, France. 
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G:BOX Gel & Blot Imaging Series Syngene international Ltd, 5108 Pegasus 
Court Suite M. Frederick, MD. 21704, 
USA. 
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2.1.2 Consumables  
 
This section describes the disposable labware used and the associated 
suppliers. 
 
Table 2.2 List of consumables 
Consumables Suppliers 
Plastic labware, i.e. centrifuge tubes, 
pipettes tips, pipettes and tissue 
culture plates 
Sarstedt, Sinnottstown, Drinagh, Co. 
Wexford. 
Maxisorb 96-well plates Nunc, Kamstrup DK, Roskilde, 
Denmark. 
BIAcore CM5 sensor chips GE Healthcare Bio-Sciences AB, 
SE-751 84 Uppsala, Sweden. 
NuPAGE Bis-Tris Gel Invitrogen, 5791 Van Allen Way, 
Carlsbad, CA 92008, USA. 
Sealing membrane Sarstedt AG & Co., Sarstedtstraße, 
Postfach 1220, 51582 Nümbrecht, 
Germany. 
Filters Sarstedt AG & Co., Sarstedtstraße, 
Postfach 1220, 51582 Nümbrecht, 
Germany. 
Microscope slide Fisher Thermo Scientific, 47341 
Bayside Pkwy., Fremont, CA 94538, 
USA. 
Cover glass VWR International, LLC 1310 
Goshen Parkway, West Chester, PA 
19380, USA. 
10 × TAE buffer (#T9650) Sigma Aldrich, 3050 Spruce Street, St. 
Louis, MO 63103, USA. 
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2.1.3 Microbial cells and plasmids 
 
2.1.3.1 Bacterial cells for cloning and expression 
 
Table 2.3 List of bacterial cells 
 
Bacterial cells Genotypes 
E. coli TOP10 F Strain: {lacIq, Tn10(TetR)} mcrA 
(mrr-hsdRMS-mcrBC) 80lacZ M15 
lacX74 recA1 araD139 (ara-leu)7697 
galU galK rpsL (StrR) endA1 nupG 
E. coli XL1-Blue strain recA1 endA1 gyrA96 thi-1 hsdR17 
supE44 relA1 lac [F′ proAB lacIqZ∆M15 
Tn10 (TetR)] 
BL21(DE3) F– ompT hsdSB(rB–, mB–) gal dcm 
(DE3) 
Origami 2(DE3) ∆(ara-leu)7697 ∆lacX74 ∆phoA PvuII 
phoR araD139 ahpC galE galK rpsL 
F′[lac+ lacIq pro] (DE3) gor522::Tn10 
trxB (StrR, TetR) 
 
 
2.1.3.2 Plasmids used as expression vector  
 
A genetic map of the pComb3XSS vector used in the generation and expression 
of scFv antibodies is shown in Fig. 2.1a. ScFv expression is directed using a 
single lac promoter and an ompA leader sequence. The amber codon enables 
soluble expression, and the SfiI restriction sites enable directional insert cloning. 
Hemagglutinin (HA) and His tags make it is possible to detect and purify the 
scFv antibody (Berry et al., 2003). Thus, the pComb3XSS vector provides a 
good choice for soluble scFv expression, detection, purification and phage 
selection.  
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A map of the pET-29a (+) vector used in the generation and expression of 
BoNT-scFv fusion is shown in Fig. 2.1b. The pET-29a (+) vector contains an 
N-terminal thrombin restriction enzyme site which enables directional insert 
cloning and includes an ampicillin resistance marker for specific selection. The 
His-tag allows affinity purification by NTA–Ni affinity column and 
immunodetection using an anti-His tag antibody (Guo et al., 2006).  
 
 
 
 
 
 
 
 
 
 
 
 
pComb3Xss 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.1a PComb3Xss vector map (This vector map was sourced from GenBank 
with accession number AF268281). The vector map of pComb3XSS vector 
contains an amber codon, SfiI restriction sites, hemagglutinin (HA) and His tags. 
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Fig. 2.1b Plasmid map of pET-29a (This vector map was sourced from BVTech 
Plasmid, 2012). The pET-29a (+) vector contains an N-terminal thrombin 
restriction enzyme site, ampicillin resistance marker and His tag. 
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2.1.4 Composition of buffer and other solution  
 
Table 2.4 List of buffers 
 
Buffer Composition 
Phosphate buffered saline 
(PBS) 
150 mM NaCl 
2.5 mM KCl 
10 mM Na2HPO4 
18 mM KH2PO4, pH 7.4 
PBS-Tween 20 (0.05%, v/v) 
(PBST) 
0.15 M NaCl 
2.5 mM KCl 
10 mM Na2HPO4 
18 mM KH2PO4 
0.05% (v/v) Tween 20 
Ph 7.4 
PBST-milk (PBSTM) 0.15 M NaCl 
2.5 mM KCl 
10 mM Na2HPO4 
18 mM KH2PO4 
0.05% (v/v) Tween 20 
Specified % (w/v) milk marvel powder 
Ph 7.4 
Tris buffered saline (TBS) 20 mM Tris base 
135 mM NaCl 
pH 7.5 
TBS-Tween 20 (1% v/v) 
(TBST) 
20 mM Tris base 
135 mM NaCl 
0.1 % (v/v) Tween 20 
pH 7.5 
TBST-milk (TBSTM) 20 mM Tris base 
135 mM NaCl 
0.1 % (v/v) Tween 20 
Specified % (w/v) milk marvel powder, pH 7.5 
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10×electrophoresis buffer 500 mM MOPS 
500 mM Tris base 
1 % (w/v) SDS 
10 mM EDTA 
2.5×transfer buffer 125 mM Tris base 
192 mM Glycine 
20% (v/v) Methanol 
Coomassie stain dye 0.2% (w/v) Coomassie blue R-250 
45% (v/v) Methanol 
10% (v/v)Acetic acid 
Coomassie destain 25%(v/v) Acetic acid 
25% (v/v) Methanol 
FACS buffer 2% (w/v) FCS 
0.05% (w/v) NaN3 
1 x PBS 
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2.1.5 Commercial kits used in this research 
 
Table 2.5 List of commercial kits used in this research 
 
Commercial kits Catalog Number Suppliers 
Superscript III 
reverse 
transcriptase kit 
18080-051 Invitrogen Corporation, 5791 Van Allen 
Way, Carlsbad, CA 92008, USA. 
Plasmid 
Purification kit 
NZ74058850 Fisher Thermo Scientific, 47341 Bayside 
Pkwy., Fremont, CA 94538, USA. 
NucleoSpin® 
extract II 
NZ740609.50 Fisher Thermo Scientific, 47341 Bayside 
Pkwy., Fremont, CA 94538, USA. 
EZ-Link(R) 
Micro 
Sulfo-NHS-LC-
Biotinylation kit 
PN21935 Fisher Thermo Scientific, 47341 Bayside 
Pkwy., Fremont, CA 94538, USA. 
Biotin 
Quantification kit 
PN28005 Fisher Thermo Scientific, 47341 Bayside 
Pkwy., Fremont, CA 94538, USA. 
BCA kit PI-23252 Fisher Thermo Scientific, 47341 Bayside 
Pkwy., Fremont, CA 94538, USA. 
Rat CGRP EIA 
kit 
589001 Cayman Chemical Company, 1180 East 
Ellsworth Road, Ann Arbor, Michigan 
48108, USA 
Rat SP EIA kit 583751 Cayman Chemical Company, 1180 East 
Ellsworth Road, Ann Arbor, Michigan 
48108, USA 
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2.1.6 Antigens and antibodies  
 
2.1.6.1 Peptide-antigen selection and synthesis 
 
Frequently there are problems associated with the generation of antibodies 
against integral membrane proteins. This arises from difficulties in their 
isolation and the generation of specific antibodies to domains external to the 
membrane that can effectively be used for localisation, and eventually, targeting.  
The use of peptide-antigens derived from proteins is becoming more and more 
popular as they can be easily obtained with high purity and specificity for a 
particular region (e.g. an extracellular domain). Moreover, antibodies raised 
against whole proteins are more likely to predomainantly recognize only 
selected regions of the whole immunizing protein and it may sometimes be hard 
to identify the exact region to which they bind (Angeletti, 1999). Therefore, 
peptide-antigens, may result in the generation of antibodies with higher purity 
and specificity, and are ideal substitutes for whole natural proteins. 
There are four principles to follow for selection of peptides for immunisation: 
1) An anti-P2X3 scFv recombinant antibody will be used as the agent to deliver 
drugs to sensory neurons and, hence, the scFv should ideally bind to P2X3 
extracellular domains, e.g. Val60-Phe301 (Koshimizu et al., 2002). Thus, the 
immunised peptide region should be chosen from an extracellular domain of 
P2X3 (Fig. 2.2a). 
2) The ideal peptide lengths are from 10 to 20 amino acid residues. Peptides 
longer than 20 amino acids will be hard to synthesize, while less than 10 
residues may contain less epitope which may lead to less chance of the 
generation of a successful specific immune response (Brown et al., 2011). 
3) Ideally no cysteine should be present in peptides for immunisation, as it may 
lead to the formation of disulfide bonds and improper folding which may cause 
loss of epitope conformation (Kontermann and Dübel, 2010).  
4) N-terminal and C-terminal sequences of a protein are good choices for 
synthesis, as these sequences are often exposed to the solvent and mobile in 
protein crystallographic structures. Antibodies developed against these 
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sequences are suggested to be more likely to work well in immunoblot analysis 
(Angeletti, 1999). 
Human P2X3 protein consists of 397 amino acids, and the extracellular domain 
is Val60-Phe301. No extracellular P2X3 epitope has ever been published for 
antibody generation. Santa Cruz Biotechnology (U.S.A.) has two goat 
polyclonal antibodies against the P2X3 extracellular domain which are 
commercially available. The exact immunogens used to generate Santa Cruz’s 
peptide polyclonals are proprietary. They only provide peptides of 
approximately 50 amino acids range, i.e. 50-100 and 227-277 amino acids for 
these antibodies. After avoiding the Cys folding domain and taking into 
account N-terminal and C-terminal sequences, two extracellular domains, 
P2X3-60 and P2X3-257, were chosen for synthesis. P2X3-60 contributes the 
protein sequence from amino acids 60 to 79 and P2X3-257 is composed of the 
amino acid sequence from position 257 to 276. 
The amino acid sequence of 60-79 amino acids range (P2X3-60) is:  
Val-Val-Thr-Lys-Val-Lys-Gly-Ser-Gly-Leu-Tyr-Ala-Asn-Arg-Val-Met-Asp- 
Val-Ser-Asp (VVTKVKGSGLYANRVMDVSD). 
The amino acid sequence of 257-276 amino acids range (P2X3-257) is:  
Ile-Pro-Lys-Tyr-Ser-Phe-Thr-Arg-Leu-Asp-Ser-Val-Ser-Glu-Lys-Ser-Ser-Val- 
Ser-Pro (IPKYSFTRLDSVSEKSSVSP). 
 
 
 
 
 
 
 
 
 
 
Fig. 2.2a Schematic structure of human P2X3. The human P2X3 extracellular 
domain, starts at amino acid V60 and ends at F301 (Modified from human P2X3 
purinoceptor model of Sundukova et al., 2012). 
Human P2X3
F 301
NH2
V60
Extracellular domain
Intracellular domain
COOH
Cell membrane
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Rat was chosen to be both the in vitro and in vivo model system for analysis of 
anti-human P2X3 scFv antibody. The homology of human P2X3 with rat P2X3 
was analysed using Basic Local Alignment Search Tool (BLAST). A high 
identity of 94% was observed and that confirmed the rationality of using the rat 
as the selected appropriate pain model. The two human regions (P2X3-60 and 
P2X3-257) chosen for immunisation also showed high identity with their 
respective regions of rat P2X3. The identity of 60-79 amino acid sequence of the 
human showed a homoloty of 90% to rat, while for amino-acids 227-277 it was 
95% (Fig. 2.2b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.2b BLAST analysis of homology of human P2X3 and rat P2X3 amino 
acid sequences. The 20 amino acids region P2X3-60 is highlighted in red, and 
P2X3-257 is highlighted in blue. Identity of human P2X3 and rat P2X3 is 94%. 
 
The three-dimensional (3D) structure of human P2X3 was predicted by free 
online software, RaptorX, based on the 3D structure of another P2X family 
member, P2X4 (Kawate et al., 2009; Kallberg et al., 2012). This 3D structure 
showed that both P2X3-60 and P2X3-257 regions formed loops and were in the 
beta-sheet region which indicates that they are exposed on the surface for 
Human P2X3 MNCISDFFTYETTKSVVVKSWTIGIINRVVQLLIISYFVGWVFLHEKAYQVRDTAIESSV 60   
Rat P2X3 .   .  . . .  . . .  .  . .  .  .  .  . .  .  .  . .   .  . . .  . . .  . A .  . .  . . . . . .  .  .   .  .  . .  .  . .  .  .  .  .  .  .  .  . . . .  . .            60
HumanP2X3 VTKVKGSGLYANRVMDVSDYVTPPQGTSVFVIITKMIVTENQMQGFCPESEEKYRCVSDS      120
Rat P2X3 .  .  .  .  . .  F .R .  .  .  .  .   .  .  .  . .  .  . .  . .  .  .  .  . . .  .  .. .  .   .  . .  . .  .  .  .   .  .  . . .  . N . .  .  .  .  .  . .  .  .     120
Human P2X3 QCGPERLPGGGILTGRCVNYSSVLRTCEIQGWCPTEVDTVETPIMMEAENFTIFIKNSIR   180
Rat P2X3 .  .  .  .  . . F .  .  .  .  . .  . .  .  .  .  .  . . .  . .  .  .  .  . . .  .  .   . .  .  . .  .  .  .  . M..  .  .   .  .  .  . .  . . . . .  .  . . .        180
Human P2X3 FPLFNFEKGNLLPNLTARDMKTCRFHPDKDPFCPILRVGDVVKFAGQDFAKLARTGGVLG   240
Rat P2X3 . .  .  . .  . .  .  .  .  . .  .  . .  . DK .  I  . R .  . .  .  . E .A .  .  .  . . .  . .  .  .  .  .  .  .  .  .  . .  . .  . .  .  .  .  .  .  .  .  .   240
Human P2X3 IKIGWVCDLDKAWDQCIPKYSFTRLDSVSEKSSVSPGYNFRFAKYYKMENGSEYRTLLKA     300
Rat P2X3 . . .  .   .  .  .  .  .  .  .  .   . .   .  . . .  .  . . .  . .  . . G  . .  . .  . .  .  . .  .  .  . .  . .  .  .  . .  .   .   . .  .  . .  .  .  .  .  . .  .     300
HumanP2X3 FGIRFDVLVYGNAGKFNIIPTIISSVAAFTSVGVGTVLCDIILLNFLKGADQYKAKKFEE   360
Rat P2X3 .   . . .  . .  .  .  .  .  .  .  .  .  . .  .  . . . . .. .  . .  .  . .  . .  .  .  .  .  .  . .  .  . .. .  .  .  .  . .   .  .  . H .  .  . R . .  .  .            360
HumanP2X3 VNETTLKIAALTNPVYPSDQTTAEKQSTDSGAFSIGH   397
Rat P2X3 . T .  . .  . . GT . S .  . .  . FA . .  .  A .V . .  . .  .  . .  .  .Y . . .  .   397
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antibody binding (Fig. 2.2c). Thus regions of P2X3-60 and P2X3-257 should be 
promising choices for antibody generation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.2c Three-dimensional (3D) structure of human P2X3 was predicted using 
RaptorX software (Xu Group, Chicago). The red arrow indicates the loop of 
P2X3-60 and the black arrow the loop of P2X3-257. 
 
P2X3-60, P2X3-257 and all their BSA, KLH, bTg and biotin conjugates were 
then synthesized by Cambridge Bioscience Ltd. (Munro House, Trafalgar Way, 
Bar Hill, Cambridge, CB23 8SQ, United Kingdom). 
 
 
 
 
V74 
I257 
R264 
P276 
K65 
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2.1.6.2 Commercial antibodies used in this research 
 
Table 2.6 List of commercial antibodies used in this research 
 
Commercial antibodies Catalog 
Number 
Suppliers Dilution 
Used 
HRP-labelled mouse 
anti-M13 monoclonal 
antibody 
27-9421-01 GE Healthcare Bio-Sciences AB, 
SE-751 84 Uppsala, Sweden. 
1:1,000 
HRP-labelled mouse 
anti-hemagglutinin (HA) 
IgG1 
monoclonal antibody 
11988506001 Roche Diagnostics, 
Grenzacherstrasse 124, Basel 
4070, Switzerland. 
1:2,000 
HRP-labelled goat 
anti-rabbit 
polyclonal antibody 
A4914-1ML Sigma Aldrich, 3050 Spruce Street, 
St. Louis, MO 63103, USA. 
1:2,000 
HRP-labelled goat 
anti-mouse polyclonal 
antibody 
A8924 Sigma Aldrich, 3050 Spruce Street, 
St. Louis, MO 63103, USA. 
1:2,000 
HRP-labelled goat 
anti-chicken IgY 
polyclonal 
antibody 
A9046 Sigma Aldrich, 3050 Spruce Street, 
St. Louis, MO 63103, USA. 
1:2,000 
Rabbit anti-rat P2X3 
polyclonal antibody 
APR-016 Alomone labs Ltd., Har Hotzvim 
Hi-Tech Park, PO Box 4287, 
Jerusalem, 91042, Israel. 
1:50 for 
IF; 
1:300 for 
WB 
Goat anti-human P2X3 
polyclonal antibody 
sc-31494 Santa Cruz Biotechnology, Inc., 
2145 Delaware Avenue, Santa 
Cruz, CA. 95060, U.S.A. 
1:50 WB 
Fluorescein-labelled rat 
anti-HA monoclonal 
antibody (3F10) 
12013819001 Roche Diagnostics GmbH, 
Roche applied science, 68298 
Mannheim, Germany. 
2 µg/mL 
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HRP-labelled mouse 
anti-polyHistidine IgG2a 
monoclonal antibody 
A7058-1VL Sigma Aldrich, 3050 Spruce Street, 
St. Louis, MO 63103, USA. 
1:2,000 
Alexa Fluor-546-labelled 
goat anti-mouse IgG 
polyclonal 
antibody 
A11003 Invitrogen, 5791 Van Allen Way, 
Carlsbad, CA 92008, USA. 
1:200 
Mouse anti-neurofilament 
(NF) monoclonal antibody 
131300 Invitrogen, 5791 Van Allen Way, 
Carlsbad, CA 92008, USA. 
1:500 
Cy2-labelled goat 
anti-mouse IgM polyclonal 
antibody 
115-225-062 Jackson ImmunoResearch, Europe 
Ltd., Unit 7, Acorn Business 
Centre, Oaks Drive, Suffolk, UK. 
1:100 
Rabbit anti-rat calcitonin 
gene-related peptide 
(CGRP) 
Ig G polyclonal antibody 
ab47027 Abcam, 330 Cambridge Science 
Park Cambridge, CB4 0FL, UK. 
1:500 
Alexa Fluor-546-labelled 
goat anti-rabbit IgG 
polyclonal 
antibody 
A-11035 Invitrogen, 5791 Van Allen Way, 
Carlsbad, CA 92008, USA. 
1:200 
Mouse anti-SNAP25 IgG1 
monoclonal antibody 
(SMI-81) 
SMI-81R Sternberger monoclonals, Inc. 5210 
Eastern Avenue, Hopkins Bayview 
Research Campany, 
Baltimore, MD, USA. 
1:2,000 
Mouse anti-VAMP IgM 
monoclonal antibody (V2) 
ab90433 Abcam, 330 Cambridge Science 
Park, Cambridge, CB4 0FL, UK. 
1:2,000 
Mouse anti-syntaxin-1 IgG1 
monoclonal antibody 
(HPC-1) 
S0664-2ML Sigma Aldrich, 3050 Spruce Street, 
St. Louis, MO 63103, USA. 
1:2,000 
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2.1.7 Cell culture media 
 
Table 2.7 List of media 
 
Media Composition 
Super Broth (SB) Media 10 g/L MOPS 
20 g/L Yeast Extract 
30 g/L Tryptone 
Super Optimal Catabolite (SOC) Media 20 g/L Tryptone 
5 g/L Yeast Extract 
0.5 g/L NaCl 
2.5 mM KCl 
20 mM MgCl2 
20 mM Glucose 
LB agar 10 g/L Tryptone 
5 g/L Yeast Extract 
10 g/L NaCl 
15 g/L agar 
DMEM Culture medium 10% (v/v) FBS 
1% (v/v) P/S 
in DMEM 
ZY Media 10 g/L N-Z-Amime 
5 g/L Yeast Extract 
 
 
2.2 Methods 
 
2.2.1 Isolation and culture of dorsal root ganglion cells (DRGs) 
 
2.2.1.1 Animals, anesthesia and dissection 
 
Postnatal day 5 Sprague-Dawley rats, bred in the approved Bioresources Unit 
at Dublin City University (DCU), were deeply anesthetized by intraperitoneal 
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(i.p.) injection of euthatal (Merial Animal Health Ltd., 20% (w/v) 
pentobarbitone sodium, 25 µL/rat). The dissection of DRG was performed in 
an open-front laminar flow hood (Microflow, #H50548/1, Class I). The inner 
surface of the hood was sprayed with 70% (v/v) IMS. Tissue culture plates 
(12-wells or 24-wells) were coated with poly-L-lysine for one hour at room 
temperature (100 µL per well). Plates were washed three times with sterile H2O, 
and then dried in the hood for one hour (plates then can be stored at 4°C for a 
month). Laminin (20 µg/mL) was diluted with HBSS, and 100 µL was added 
per well, and incubated at room temperature for one hour, followed by washing 
three times with sterile 1 x PBS before culturing cells. 
 
2.2.1.2 Dissection, dissociation and culture of DRG cells 
 
Generally, 7-12 postnatal day 5 Sprague-Dawley rats were sacrificed for 
culturing 3-4 plates. Dorsal root ganglions (DRGs) were then collected in 
HBSS and placed on ice (Fig. 2.2.4.2). After dissection, DRGs were washed 
with ice-cold HBSS three times at 170 g for 1 min (HermLe Z233MK-2 
refrigerated centrifuge). Then HBSS was carefully removed. Twenty three mg 
dispase II and 5 mg collagenase in 10 mL HBSS were then added to the DRGs 
and incubated for 30 min in a 37°C water bath for dorsal root ganglion 
membrane digestion. The tube was shaken from time-to-time. The DRG 
preparation was centrifuged (HermLe Z233MK-2 refrigerated centrifuge) at 
170 g for 5 min, and then the pellet was washed with pre-warmed (37°C in a 
water bath) Dulbecco's Modified Eagle's Medium (DMEM) three times at 170 
g for 5 min. The DRG cells preparation was resuspended in 35-50 mL DMEM 
culture medium with 10% (v/v) fetal bovine serum (FBS), 100 U/mL penicillin 
and 100 µg/mL streptomycin and passed through a 100 µm cell strainer. Nerve 
growth factor (NGF) was added to final concentration of 50 ng/ mL. DRG cells 
were plated into each well and incubated at 37°C in 5% (v/v) CO2. Every two 
days the culture medium was replaced by fresh DMEM containing 10% (v/v) 
FBS, 100 U/mL penicillin, 100 µg/mL streptomycin, 50 ng/ mL NGF and 10 
µM Ara-c. The cell images were recorded using an Olympus IX71 microscope 
with a charge-coupled device (CCD) camera by phase contrast. 
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Fig. 2.3 Location of DRGs. DRG cells locate in the intervertebral foramen 
along the spinal column as indicated by the arrows. This picture is taken from 
Malin et al. (2007). 
 
2.2.1.3 Membrane protein enrichment 
 
To harvest P2X3, which is found on DRG membranes, a membrane protein 
enrichment was performed. After 4 days, medium was removed from each well 
of the DRG cell culture plate and 1 mL sterile of water containing 1:10 (v/v) 
protease inhibitor (Sigma, #P8849) was added per well. The cells were scraped 
from the wells of the cell culture plate. This action was followed by repeated 
pipetting and this served to break the cells’ membranes. The final suspension 
was collected in a 1 mL tube and centrifuged (Eppendorf centrifuge 5810R) at 
14,000 g for 1 min. The suspension was transferred to an ice-cold TL-100 
ultracentrifuge tube (stored in the cold room) and centrifuged at 480,000 g 
(Beckman TL 100 ultracentrifuge) for 20 min at 4°C. The supernatant was 
removed carefully from the tube. A 200 µL volume of LDS buffer was then 
added to resuspend the membrane pellet wherein the P2X3 protein should be 
found. The resuspended protein was heated to 80°C for 5min, and was 
subsequently loaded onto an SDS-PAGE gel. The protein was placed in 
long-term storage at -80°C, if not being used immediately. 
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2.2.1.4 Identification of DRGs by specific antibodies 
 
DRG cells were cultured in a 24-well tissue culture plate for 5-7 days. The 
DRGs were washed three times with Dulbecco’s phosphate buffer saline 
(D-PBS, lacking Mg2+ and Ca2+) and fixed using 3.7% (v/v) paraformaldehyde 
for 20 min at room temperature. The plate was washed three times with D-PBS, 
and then blocked with 1% (w/v) BSA in D-PBS for one hour at room 
temperature. The blocking solution was removed. Mouse anti-neurofilament 
(NF) monoclonal antibody (1:500 dilution) or rabbit anti-calcitonin 
gene-related peptide (CGRP) polyclonal antibody (1:500 dilution) was added, 
and incubated at room temperature for one hour. The plate was washed three 
times with D-PBS, followed by the addition of secondary antibody 
Cy2-labelled goat anti-mouse IgG (1:100 dilution) or Alexa Fluor-546-labelled 
goat anti-rabbit antibody (1:200 dilution). After washing three times by 
addition of 1 mL of D-PBS into each well, the cells were ready for imaging 
using an Olympus IX71 microscope or a inverted confocal microscope (Leica 
Dmire 2) with a CCD camera. Images were then analysed using the Image-Pro 
Plus 5.1 or Leica confocal software. A negative control was included with 
rabbit anti-goat IgG (1:1,000 dilution) as primary antibody, followed by 
secondary antibody Alexa Fluor-546-labelled goat anti-rabbit IgG (1: 200 
dilution). 
 
2.2.1.5 Analysis of P2X3 expression on DRG cells with commercial 
anti-P2X3 antibody 
 
Both Western blotting and immunofluorescence staining were performed to 
check for P2X3 expression on DRG cells using the protocol described in section 
2.2.3.17. With the exception that a commercial anti-P2X3 antibody (Alomone 
Labs Ltd.; 1:300 dilution for Western blotting and 1:50 dilution for 
immunofluorescence) was applied as the primary antibody. 
 
 
 
53 
 
2.2.1.6 Testing of DRGs sensitivity to botulinum neurotoxin (BoNT) 
 
Different concentrations of BoNT (0-1,000 nM) were added into rat DRGs 
cultures (P5, 6 DIV) and incubated for 24 hours at 37°C in 5% (v/v) CO2. After 
24 hours, the medium was removed from each well and the DRGs were 
harvested using Lithium dodecyl sulfate (LDS) buffer (60 µL per well). DRG 
cells were harvested at 3-5 days in vitro (DIV 3-5) by lysing the cells with 100 
µL 2 x LDS buffer.  
A 160 µg quantity of DRGs lysis protein sample (in a total volume of 20 µL) 
was added into each well of 4-12% precast Bis-Tris gel (Invitrogen). The gels 
were placed in an electrophoresis apparatus and submerged in electrophoresis 
buffer. The electrophoresis buffer was prepared using 50 mM MOPS, 50 mM 
Tris, pH 8.3, 1 mM ethylenediaminetetraacetic acid (EDTA) and 0.1% (w/v) 
SDS. The apparatus is attached to a power supply and a voltage of 200 V 
applied to the gel. The gels were allowed to run until the tracker dye had 
reached the bottom of the gel.  
Proteins were transferred from the gel to a PVDF membrane at 250 mA for 2.5 
hours. The membrane was blocked with 5% (w/v) TBSTM for one hour at 
room temperature. Mouse anti-SNAP-25 antibody (SMI-81, 1:1,000 dilution) 
was added at 4°C overnight. The membrane was washed three times with 1 x 
TBST for 5 min. HRP-labelled anti-mouse IgG (1:2,000 dilution) was added as 
secondary antibody and incubated at room temperature for one hour. The 
membrane was washed three times with 1 x TBST for 5 min and TMB (0.4 g/L) 
was added for visualisation. When the bands appeared, the membrane was 
washed with ddH2O to stop the reaction. A picture was taken using the G:BOX 
Gel & Blot Imaging Series. 
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2.2.2 Immunisation protocols 
 
2.2.2.1 Immunisation of rabbits using P2X3-60/257-BSA and 
P2X3-60/257-KLH 
 
Two New Zealand white rabbits (designated CKPH and DARP) were 
immunised by subcutaneous injections, using 200 µg P2X3-60-KLH (in 700 µL 
PBS) and 200 µg P2X3-257-BSA (in 700 µL PBS) in µL complete Freund's 
adjuvant (Sigma), and subsequently boosted four times with 100 µg 
P2X3-60-KLH (in 400 µL PBS) and 100 µg P2X3-257-BSA (in 400 µL PBS) 
in 400 µL incomplete Freund's adjuvant (Sigma), each given on day 21 after 
the former injection. Approximately 5 mL peripheral blood was removed from 
the ear vein on day seven following each boost; this was carried out to assess 
the serum antibody titre. Rabbits were sacrificed on day seven after the final 
boost. The RNA was extracted from the spleen and bone marrow, followed by 
cDNA synthesis and scFv library building.  
 
2.2.2.2 Immunisation of mice with P2X3-60-BSA and P2X3-257-BSA 
 
Six BALB/c mice were immunised by intraperitoneal injections. Three mice 
were immunised with 50 µg P2X3-60-BSA (in 200 µL PBS) and the other three 
with 50 µg P2X3-257-BSA (in 200 µL PBS) in 200 µL complete Freund's 
adjuvant (Sigma), and subsequently boosted four times with 25 µg 
P2X3-60-BSA (in 100 µL PBS) and 25 µg P2X3-257-BSA (in 100 µL PBS) in 
100 µL incomplete Freund's adjuvant (Sigma) respectively, each given on days 
14 after the previous injection except the fourth boost, which was given on day 
67 after the previous injection. Approximately 200 µL blood was removed 
from the cheek 7 days after each boost, to check the serum antibody titre. Mice 
were sacrificed on day seven after the final boost. The RNA was extracted 
from the spleen, followed by cDNA synthesis and scFv library building.  
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2.2.2.3 Immunisation of chickens with P2X3-60-KLH and P2X3-257-BSA 
 
Three chickens were immunised by subcutaneous injections. One was 
immunised with 200 µg P2X3-60-KLH (in 600 µL PBS) and the remaining two 
were immunised with 200 µg P2X3-257-BSA (in 600 µL PBS), in 600 µL 
complete Freund's adjuvant (Sigma), and subsequently boosted four times with 
100 µg P2X3-60-KLH (in 300 µL PBS) and 25 µg P2X3-257-BSA (in 300 µL 
PBS), respectively, in 300 µL incomplete Freund's adjuvant (Sigma), each 
given on day 21 after the former injection. Approximately 5 mL blood was 
removed from the wing vein on day seven after each boost, to check for serum 
antibody titre. One chicken died before any injection and another three 
chickens gave little response after the third boost. No RNA was extracted from 
chickens after they were sacrificed.  
 
2.2.2.4 Serum screening and antibody titre 
 
Sera from the immunised animals were analysed for the presence of antibodies 
to P2X3. After each boost, an enzyme-linked immunosorbent assay (ELISA) 
was carried out. Maxisorb 96-well plates were coated with 100 µL per well 
neutravidin (2.5 µg/µL) at 37°C for one hour. This was followed by addition of 
100 µL per well of 5 µg/µL P2X3-257/60-biotin conjugates coated at 4°C 
overnight. Plates were then blocked with 5% (w/v) PBSTM (200 µL per well) 
at 37°C for one hour. The serum was made up in a range of dilutions 
(1:100-1:400,000) in 3% (w/v) PBSTM and incubated at 37°C for one hour. 
Then, HRP-labelled antibody (1:1,000 dilution, 100 µL per well) directed 
against each of the species (i.e. HRP-labelled anti-rabbit IgG, HRP-labelled 
anti-mouse IgG and HRP-labelled anti-chicken IgG) was added and incubated 
at 37°C for one hour. TMB (0.4 g/L, 100 µL per well) was added and 
incubated at room temperature for 10 min. After stopping the reaction by 
addition of1 M HCl (50 µL per well), the absorbances were read at 450 nm 
using a Safire 2 plate reader.  
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2.2.2.5 Competitive enzyme-linked immunosorbent assay (ELISA) 
 
Maxisorb 96-well plates were coated with 100 µL per well of 2.5 µg/µL 
neutravidin for one hour at 37°C. This was followed by addition of 100 µL per 
well of 5 µg/µL P2X3-257/60-biotin conjugates overnight at 4°C. Plates were 
blocked with 200 µL per well 5% (w/v) PBSTM for one hour at 37°C. A range 
of concentrations of P2X3-257/60 free peptide (0-2 µg/mL) were prepared and 
mixed with a fixed concentration of serum. This mixture (100 µL per well) was 
incubated for one hour at 37°C. Then 100 µL per well of anti-IgG antibody 
(whole molecule) labelled with HRP was applied as the secondary antibody for 
one hour at 37°C. TMB (0.4 g/L) was then added (100 µL per well) and 
incubated at room temperature for 10 min. The reaction was stopped by 
addition of 50 µL per well of 1 M HCl. The absorbances of the wells were read 
at 450 nm using a Safire 2 plate reader.  
 
2.2.3 Production of anti-P2X3 polyclonal antibody 
 
2.2.3.1 Protein A purification of polyclonal IgG antibody from rabbit 
serum 
 
Two mL of Protein A-Sepharose® 4B (Sigma, #P9424-5ML) was added to a 20 
mL column (VWR). The column was washed five times with 2 mL of PBS. A 
cap was placed on the base of the column. Debris in the serum was removed by 
centrifugation at 3,220 g for 10 min at 4°C before addition of to the column. 
Five mL of serum was added to the resin and mixed gently on a roller overnight 
at 4°C before addition of to the column. The flow-through was reapplied to the 
column. This process was repeated four times. The column was washed five 
times with 10 mL 1 x PBS (pH 7.5). The antibody was eluted with 10 mL of 100 
mM glycine-HCl buffer (pH 2.5). Individual 1 mL fractions were collected in 
tubes containing 100 µL of 1 M Tris-HCl, pH 8.0, for pH neutralization. The 
column was washed with 20 mL of PBS (pH 7.5) and was stored at 4°C with 
20% (v/v) ethanol. The eluted fractions were analysed by determining the 
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absorbances at 280 nm. The fractions which contained the eluted antibodies 
were then combined, washed and concentrated through buffer exchange against 
filtered 20 mL of PBS (pH 7.5) using 10,000 MWCO Viva spin columns 
(Sartorius, #VS0601). Protein concentration was determined by the BCA assay. 
The purified polyclonal antibody (1 mL, 39.27 mg/mL) was divided into 100 µL 
aliquots and stored at -20°C. 
 
2.2.3.2 Purification of anti-P2X3 polyclonal antibody using 
streptavidin-agarose  
 
P2X3-257-biotin (138 µg) was mixed with 90 mg purified rabbit IgG antibody in 
a volume of 300 µL (from section 2.2.2.1) on a roller overnight at 4°C. Two mL 
of high capacity streptavidin-agarose resin (Fisher, #PN20359) was added to a 
20 mL column (VWR). The resin was washed five times with 2 mL of PBS. A 
cap was placed on the base of the column. The serum and P2X3-257-biotin 
mixture, was incubated overnight, and then applied to the column. This was 
mixed on a roller at room temperature for one hour. The flow-through was 
reapplied to the column four times. A total of 30 mL of wash buffer 
(sterile-filtered PBS) was passed through the column and, subsequently, the 
retained protein was eluted with 100 mM glycine-HCl buffer (pH 2.5). 
Fractions of eluate were collected in micro-centrifuge tubes containing 150 µL 
of neutralisation buffer (2 M Tris-HCl, pH 8.5). This served to rapidly 
neutralise the highly acidic environment of the elution buffer, thereby, 
preventing denaturation of the eluted IgG fraction. Each of the fractions was 
quantified using the NanoDrop™ ND-1000 using the pre-programmed ‘IgG’ 
option (mass extinction coefficient of 13.7 at 280 nm). The fractions containing 
high concentrations of IgG were pooled, desalted on a 10,000 MWCO Viva 
spin column (Sartorius, #VS0601) against PBS and stored at -20°C until 
required for further use.  
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2.2.3.3 Determination of anti-P2X3 polyclonal antibody concentration using 
the bicinchoninic acid (BCA) protein assay 
 
A range of BSA concentrations (0-2,000 µg/µL) were prepared, based on the 
BCA kit protocol, for the protein standard curve. Four dilutions (1/5, 1/10, 1/20, 
1/40) were made for unknown samples. Twenty five µL of BSA standards and 
unknown sample dilutions (in duplicate) were added into ELISA plate wells. 
Two hundred µL of Reagent A and Reagent B mixture (50:1) from the BCA kit 
was added into the wells and mixed gently on a plate shaker for 30 seconds. 
The plate was covered with tinfoil and incubated at 37°C for 30 min. The plate 
was placed on a bench to cool it to room temperature. The absorbances of the 
wells were measured at 562 nm using a Safire 2 plate reader. Protein 
concentrations of unknown samples were then calculated from the linear range 
of the standard curve. 
 
2.2.3.4 SDS-PAGE analysis of anti-P2X3 antibody purity 
 
Purified polyclonal antibody (15 µL in PBS; 0.1 mg) was mixed with 5 µL of 4 
x lithium dodecyl sulfate (LDS) loading buffer and was added into each well of 
a 4-12% (w/v) NuPAGE Bis-Tris gel. The gel was resolved at 170 volts until 
the blue tracker dye reached the bottom of gel (took approximately 1.5 hours). 
The gel was removed and stained with Coomassie Blue for one hour. Finally, 
the stained gels were destained overnight using Coomassie destain solution.  
 
2.2.3.5 Western blotting (WB) and Immunofluorescent (IF) stain analysis 
of polyclonal anti-P2X3 antibody specificity for P2X3 expressed on root 
ganglion cells (DRGs) 
 
2.2.3.5.1 Western blotting 
 
After grown 3-5 days in 24-well tissue plate, DRG cells were harvested after 
grown and membrane proteins were enriched as described in section 2.2.4.3. A 
160 µg quantity of DRGs membrane protein sample (in a total volume of 20 
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µL) was added into each well of 4-12% precast Bis-Tris gel (Invitrogen). The 
gel was resolved at 170 volts for about one hour until the blue tracker dye 
reached the bottom of the gel. The proteins on the gel were transferred to a 
PVDF membrane at 250 mA for 2.5 hours. The membrane was blocked in 5% 
(w/v) TBSTM for one hour at room temperature. Purified polyclonal anti-P2X3 
antibody was used as the primary antibody and incubated overnight at 4°C. The 
membrane was washed three times with TBST for 5 min. HRP-labelled 
anti-rabbit IgG antibody (1:2,000 dilution) was added as secondary antibody 
and incubated at room temperature for 1 hour. The PVDF membrane was 
washed three times with TBST for 5 min and then developed by addition of 1 
mL of TMB (0.4 g/L) to the membrane until the bands appeared. The 
membrane was washed with ddH2O to stop the reaction. An image was taken 
using the G:BOX Gel & Blot Imaging Series. 
 
2.2.3.5.2 Immunofluorescent staining 
 
DRG cells were cultured in a 24-well tissue plate for 5-7 days. They were then 
washed three times with Dulbecco’s phosphate buffer saline (D-PBS, lacking 
Mg2+ and Ca2+) and fixed using 3.7% (v/v) paraformaldehyde for 20 min at 
room temperature. The plate was washed three times with D-PBS, and then 
blocked with 1% (w/v) BSA in D-PBS for one hour at room temperature. The 
blocking solution was removed. Polyclonal anti-P2X3 antibody was added as 
primary antibody and incubated at room temperature for one hour. The plate 
was washed three times with D-PBS, followed by addition of the secondary 
antibody which was Alexa Fluor-488-labelled goat anti-rabbit IgG (1: 200 
dilution). After washing three times with D-PBS, the cells were imaged using 
an Olympus IX71 microscope or a inverted confocal microscope (Leica Dmire 
2) with a CCD camera. The images were then analysed using the Image-Pro 
Plus 5.1 or Leica confocal software. A negative control was included which 
contained rabbit anti-goat IgG (1:1,000 dilution) as primary antibody, followed 
by secondary antibody Alexa Fluor-488-labelled goat anti-rabbit IgG (1: 200 
dilution). 
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2.2.4 Generation of anti-P2X3 scFv library 
 
2.2.4.1 Extraction and isolation of total RNA from immunised animals 
 
The inner surface of a Gelaire BSB 4 laminar flow hood was sprayed with both 
70% (v/v) IMS and RNaseZAP (Sigma, #R2020) to prevent RNA degradation 
by RNase. The spleens and bone marrow from rabbits, and the spleens from 
mice were removed and transferred into a 50 mL ‘RNase-free’ tube containing 
10 mL TRIzol ™ reagent. A homogenizer, previously autoclaved and baked 
overnight at 60°C, was used to homogenize the spleen/bone marrow. The 
homogenized tissue was transferred to a 85 mL polypropylene Oakridge 
‘RNase-free’ tube and incubated for 5 min at room temperature, to allow 
complete dissociation of nucleoprotein complexes. Chloroform (2 mL) was 
then added to the tube. The tube was shaken vigorously for 15 seconds and 
then incubated for 15 min at room temperature. After centrifugation 
(Eppendorf centrifuge 5810R) at 19,000 g for 20 min at 4°C, the suspension 
was separated into 3 distinct layers. The top aqueous and transparent layer 
which contains RNA, was carefully transferred into a new 85 mL 
polycarbonate Oakridge ‘RNase-free’ tube and precipitated by addition of 5 
mL of isopropanol. This tube was incubated for 10 min at room temperature, 
and then centrifuged (Eppendorf centrifuge 5810R) at 19,000 g for 25 min at 
4°C. The supernatant was carefully removed and the white RNA pellet was 
washed with 30 mL 75% (v/v) ethanol by centrifugation at 19,000 g for 10 min 
at 4°C. The RNA pellet was air-dried in the laminar hood and then resuspended 
in 800 µL of molecular grade water. RNA concentrations were measured with 
the NanoDropTM spectrophotometer ND-1000 (Thermo Fisher Scientific, 
USA). 
 
2.2.4.2 Reverse transcription of total RNA to cDNA 
 
Total RNA was reverse transcribed into cDNA using Superscript III Reverse 
Transcriptase kit (Invitrogen, USA). A ‘20 X mixture 1’ was set up on ice and 
then 20 X 10 µL aliquots were made in sterile PCR tubes. Mixture 1 was 
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incubated at 65°C on Biometra TGRADIENT PCR machine (Labrepco, USA) for 5 
min. At the same time, a ‘20 x mixture 2’ was set up. Mixture 1 was placed on 
ice. Ten µL of mixture 2 was added to 10 µL aliquots of mixture 1 and 
incubated at 50°C for 50 min, and then 85°C for 5 min. Five µL of RNase ™ H 
was added into each of the 20 µL reactions and incubated at 37°C for 20 min. 
The cDNA samples were stored at -20°C for subsequent light chain and heavy 
chain amplification. 
 
The following components were used for mixture 1: 
Mixture 1 Component 10 µL Volume Conc. In 10 µL reaction 
Total RNA x µL 5 µg/reaction 
Oligo (dT) primer 1 µL 0.5 µg/reaction 
dNTP mix 1 µL 1 mM 
Molecular grade H2O (8-x) µL N/A 
 
 
The following components were used for mixture 2: 
Mixture 2 Component 10 µL Volume Conc. In 10 µL reaction 
10xRT Buffer 2 µL 2x 
MgCl2 4 µL 2.5 mM 
DTT 2 µL 20 mM 
RNase Out 1 µL 1 U/µL 
Superscript Ш enzyme 1 µL 200 U/µL 
 
 
2.2.4.3 PCR primers for the amplification of anti-P2X3 scFv (pComb series) 
 
2.2.4.3.1 PCR primers for amplification of rabbit anti-P2X3 scFv 
 
All primers listed below were synthesized by Eurofins-MWG-Operon (318 
Worple Road, Raynes Park, London, SW20 8QU). 
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Vκ 5′ Sense Primers 
RSCVK1 
 
5′ GGG CCC AGG CGG CCG AGC TCG TGM TGA CCC AGA CTC 
CA 3′ 
RSCVK2 
 
5′ GGG CCC AGG CGG CCG AGC TCG ATM TGA CCC AGA CTC 
CA 3′ 
RSCVK3 5′ GGG CCC AGG CGG CCG AGC TCG TGA TGA CCC AGA CTG 
AA 3′ 
 
Vκ 3′ Reverse Primers, long linker  
(linker amino acid sequence: SSGGGGSGGGGGGSSRSS) 
RKB9J1o-BL 
 
5′ GGA AGA TCT AGA GGA ACC ACC CCC ACC ACC GCC 
CGA GCC ACC GCC ACC AGA GGA TAG GAT CTC CAG CTC 
GGT CCC 3′ 
RKB9Jo-BL 
 
5′ GGA AGA TCT AGA GGA ACC ACC CCC ACC ACC GCC 
CGA GCC ACC GCC ACC AGA GGA TAG GAT CTC CAG CTC 
GGT CCC 3′ 
RKB42Jo-BL 
 
5′ GGA AGA TCT AGA GGA ACC ACC CCC ACC ACC GCC 
CGA GCC ACC GCC ACC AGA GGA TTT GAC SAC CAC CTC 
GGT CCC 3′ 
 
 
VH 5′ Sense Primers 
RSCVH1 
 
5′ GGT GGT TCC TCT AGA TCT TCC CAG TCG GTG GAG GAG 
TCC RGG 3′ 
RSCVH2 
 
5′ GGT GGT TCC TCT AGA TCT TCC CAG TCG GTG AAG GAG 
TCC GAG 3′ 
RSCVH3 
 
5′ GGT GGT TCC TCT AGA TCT TCC CAG TCG YTG GAG GAG 
TCC GGG 3′ 
RSCVH4 
 
5′ GGT GGT TCC TCT AGA TCT TCC CAG SAG CAG CTG RTG 
GAG TCC GG 3′ 
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VH 3′ reverse primers 
RSCG-B 
 
5′ CCT GGC CGG CCT GGC CAC TAG TGA CTG AYG GAG CCT 
TAG GTT GCC C 3′ 
 
Overlap extension primers 
RSC-F 
(sense) 
5′ GAG GAG GAG GAG GAG GAG GCG GGG CCC AGG CGG 
CCG AGC TC 3′ 
RSC-B 
(reverse) 
5′ GAG GAG GAG GAG GAG GAG CCT GGC CGG CCT GGC 
CAC TAG TG 3′ 
 
pComb rabbit anti-P2X3 scFv primer combinations 
Variable Heavy chain combinations 
Heavy chain Forward Reverse 
VH1 RSCVH1 RSCG-B 
VH2 RSCVH2 RSCG-B 
VH3 RSCVH3 RSCG-B 
VH4 RSCVH4 RSCG-B 
 
Variable kappa light chain combinations 
Light chain Forward Reverse 
VK1 RSCVK1 RKB9J10-BL 
VK2 RSCVK1 RKB9J0-BL 
VK3 RSCVK1 RKB42J0-BL 
VK4 RSCVK2 RKB9J10-BL 
VK5 RSCVK2 RKB9J0-BL 
VK6 RSCVK2 RKB42J0-BL 
VK7 RSCVK3 RKB9J10-BL 
VK8 RSCVK3 RKB9J0-BL 
VK9 RSCVK3 RKB42J0-BL 
 
 
 
 
64 
 
 
2.2.4.3.2 PCR primers for amplification of mouse anti-P2X3 scFv 
 
All primers listed below were synthesized by Eurofins-MWG-Operon (318 
Worple Road, Raynes Park, London, SW20 8QU). 
 
VH 5′ Sense Primers 
MSCVH1 5′ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTR MAG 
CTT CAG GAG TC 3′ 
MSCVH2 5′ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTB CAG 
CTB CAG CAG TC 3′ 
MSCVH3 5′ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG CAG 
CTG AAG SAS TC 3′ 
MSCVH4 5′ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTC CAR 
CTG CAA CAR TC 3′ 
MSCVH5 5′ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTY CAG 
CTB CAG CAR TC 3′ 
MSCVH6 5′ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTY CAR 
CTG CAG CAG TC 3′ 
MSCVH7 5′ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTC CAC 
GTG AAG CAG TC 3′ 
MSCVH8 5′ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG AAS 
STG GTG GAA TC 3′ 
MSCVH9 5′ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG AWG 
YTG GTG GAG TC 3′ 
MSCVH10 5′ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG CAG 
SKG GTG GAG TC 3′ 
MSCVH11 5′ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG CAM 
CTG GTG GAG TC 3′ 
MSCVH12 5′ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG AAG 
CTG ATG GAR TC 3′ 
MSCVH13 5′ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG CAR 
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CTT GTT GAG TC 3′ 
MSCVH14 5′ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTR AAG 
CTT CTC GAG TC 3′ 
MSCVH15 5′ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG AAR 
STT GAG GAG TC 3′ 
MSCVH16 5′ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTT ACT 
CTR AAA GWG TST G 3′ 
MSCVH17 5′ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTC CAA 
CTV CAG CAR CC 3′ 
MSCVH18 5′ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG AAC 
TTG GAA GTG TC 3′ 
MSCVH19 5′ GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG AAG 
GTC ATC GAG TC 3′ 
MSCJL-B 5′ GGA AGA TCT AGA GGA ACC ACC GCC TAG GAC AGT 
CAG TTT GG 3′ 
 
 
VH 3′ Reverse Primers 
MSCM-B 5′ CCT GGC CGG CCT GGC CAC TAG TGA CAT TTG GGA 
AGG ACT GAC TCT C 3′ 
MSCG3-B 5′ CCT GGC CGG CCT GGC CAC TAG TGA CAG ATG GGG 
CTG TTG TTG T 3′ 
MSCG1ab-B 5′ CTG GCC GGC CTG GCC ACT AGT GAC AGA TGG GGS 
TGT YGT TTT GGC 3′ 
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Vκ light chain 5′ sense primers 
MSCVK-1 5′ GGG CCC AGG CGG CCG AGC TCG AYA TCC AGC TGA 
CTC AGC C 3′ 
MSCVK-2 5′ GGG CCC AGG CGG CCG AGC TCG AYA TTG TTC TCW 
CCC AGT C 3′ 
MSCVK-3 5′ GGG CCC AGG CGG CCG AGC TCG AYA TTG TGM TMA 
CTC AGT C 3′ 
MSCVK-4 5′ GGG CCC AGG CGG CCG AGC TCG AYA TTG TGY TRA 
CAC AGT C 3′ 
MSCVK-5 5′ GGG CCC AGG CGG CCG AGC TCG AYA TTG TRA TGA 
CMC AGT C 3′ 
MSCVK-6 5′ GGG CCC AGG CGG CCG AGC TCG AYA TTM AGA TRA 
MCC AGT C 3′ 
MSCVK-7 5′ GGG CCC AGG CGG CCG AGC TCG AYA TTC AGA TGA 
YDC AGT C 3′ 
MSCVK-8 5′ GGG CCC AGG CGG CCG AGC TCG AYA TYC AGA TGA 
CAC AGA C 3′ 
MSCVK-9 5′ GGG CCC AGG CGG CCG AGC TCG AYA TTG TTC TCA 
WCC AGT C 3′ 
MSCVK-10 5′ GGG CCC AGG CGG CCG AGC TCG AYA TTG WGC TSA 
CCC AAT C 3′ 
MSCVK-11 5′ GGG CCC AGG CGG CCG AGC TCG AYA TTS TRA TGA 
CCC ART C 3′ 
MSCVK-12 5′ GGG CCC AGG CGG CCG AGC TCG AYR TTK TGA TGA 
CCC ARA C 3′ 
MSCVK-13 5′ GGG CCC AGG CGG CCG AGC TCG AYA TTG TGA TGA 
CBC AGK C 3′ 
MSCVK-14 5′ GGG CCC AGG CGG CCG AGC TCG AYA TTG TGA TAA 
CYC AGG A 3′ 
MSCVK-15 5′ GGG CCC AGG CGG CCG AGC TCG AYA TTG TGA TGA 
CCC AGW T 3′ 
MSCVK-16 5′ GGG CCC AGG CGG CCG AGC TCG AYA TTG TGA TGA 
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CAC AAC C 3′ 
MSCVK-17 5′ GGG CCC AGG CGG CCG AGC TCG AYA TTT TGC TGA 
CTC AGT C 3′ 
 
 
Vκ light chain 3′ reverse primers, long linker 
MSCJK12-BL 5′ GGA AGA TCT AGA GGA ACC ACC CCC ACC ACC GCC 
CGA GCC ACC GCC ACC AGA GGA TTT KAT TTC CAG YTT 
GGT CCC 3′ 
MSCJK4-BL 5′ GGA AGA TCT AGA GGA ACC ACC CCC ACC ACC GCC 
CGA GCC ACC GCC ACC AGA GGA TTT TAT TTC CAA CTT 
TGT CCC 3′ 
MSCJK5-BL 5′ GGA AGA TCT AGA GGA ACC ACC CCC ACC ACC GCC 
CGA GCC ACC GCC ACC AGA GGA TTT CAG CTC CAG CTT 
GGT CCC 3′ 
 
 
Vκ light chain 3′ reverse primers 
MSCJK5-B 5′ GGA AGA TCT AGA GGA ACC ACC TTT CAG CTC CAG 
CTT GGT CCC 3′ 
MSCJK4-B 5′ GGA AGA TCT AGA GGA ACC ACC TTT TAT TTC CAA CTT 
TGT CCC 3′ 
MSCJK12-B 5′ GGA AGA TCT AGA GGA ACC ACC TTT KAT TTC CAG 
YTT GGT CCC 3′ 
 
 
λ light chain 5′ sense primers 
MSCVL-1 5′ GGG CCC AGG CGG CCG AGC TCG ATG CTG TTG TGA 
CTC AGG AAT C 3′ 
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λ light chain 3′ back reverse primers 
MSCJL-BL 5′ GGA AGA TCT AGA GGA ACC ACC CCC ACC ACC GCC 
CGA GCC ACC GCC ACC AGA GGA GCC TAG GAC AGT CAG 
TTT GG 3′ 
 
 
Overlap Extension Primers 
RSC-F 
(sense) 
5′ GAG GAG GAG GAG GAG GAG GCG GGG CCC AGG CGG 
CCG AGC TC 3′ 
RSC-B 
(reverse) 
5′ GAG GAG GAG GAG GAG GAG CCT GGC CGG CCT GGC 
CAC TAG TG 3′ 
 
 
2.2.4.4 Amplification of antibody variable domain genes using pComb3X 
series primers 
 
The components for a 1x reaction with 50 µL total volume were as follows: 
Component 50 µL Volume Conc. in 50 µL 
GoTaq Buffer (5 x) 10.0 µL 1 x 
VL/VH sense Primer 0.5 µL 60 pM 
VH/VL reverse Primer 0.5 µL 60 pM 
MgCl2 3.0 µL 1.5 mM 
cDNA 1.0 µL 0.5 µg 
dNTP 1.0 µL 0.2 mM 
H2O 33.75 µL N/A 
GoTaq ™ Polymerase 0.25 µL 5 U/µL 
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The PCR for the amplification was performed using a Biometra TGRADIENT PCR 
machine with the following conditions: 
Stage Temperature (°C) Time (seconds) 
1 (1 cycle) 94 120 
2 (25 cycles) 94 
56 
72 
15 
30 
90 
3 (1 cycle) 72 
4 
600 
Pause 
 
 
2.2.4.5 Purification of VH and VL variable gene fragments using a 
NucleoSpin
®
 Extract II kit 
 
After each VH and VL variable gene fragment was obtained via PCR, VH and 
VL amplifications were ethanol-precipitated with 10% (w/v) 3 M sodium 
acetate (pH 5.5) and twice the total sample volume of 100% ethanol. The 
solution was then incubated overnight at -20°C and subsequently centrifuged 
(Eppendorf centrifuge 5810R) at 13,220 g for 15 min at 4°C. The ethanol 
supernatant was discarded and the pellet was washed by addition of 750 µL of 
70% (v/v) ice cold ethanol. It was then centrifuged (Eppendorf centrifuge 
5810R) at 13,220 g for 4 min at 4°C. The pellet was then allowed to air-dry 
(but not over dry) before dissolving in 20 µL of molecular grade H2O.  
VH and VL amplifications were loaded on a 1% (w/v) agarose gel and run at 60 
volts using 1 × TAE buffer until single bands at 386-440 bp (VH chain) and 
375-402 bp (VL chain) were observed and had separated clearly from 
non-specific bands. Both VH and VL bands were then separated using sterile 
scalpels and transferred into a new sterile 1.5 mL micro-centrifuge tubes. For 
each 100 mg agarose gel, 200 µL buffer NT was added. The mixture was 
incubated at 50°C for approximately 10 min until the gel had completely 
dissolved. The mixture was then transferred to a NucleoSpin® extract column 
which was placed into a clean collection tube and was then centrifuged 
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(Eppendorf centrifuge 5810R) at 13,220 g for 1 min to remove residual buffer. 
The ‘flow-through’ was discarded and the column was washed with 700 µL of 
‘buffer NT3’ by centrifugation at 13,220 g for 1 min. After discarding the 
‘flow-through’ the column was centrifuged (Eppendorf centrifuge 5810R) at 
13,220 g for 2 min to remove residual buffer NT3. Finally, DNA was eluted 
from the column using 30 µL molecular grade H2O. The concentration of 
purified DNA was measured using the Nanodrop™ ND-1000. 
 
2.2.4.6 Splice by Overlap extension (SOE) polymerase chain reaction 
(PCR) 
 
The VH and VL purified fragments were joined by SOE-PCR via a long 
glycine-serine linker (Gly4Ser)3 to produce a fragment of approximately 800 bp.  
 
The following components were used for SOE-PCR: 
RSC-F 
(sense) 
GAG GAG GAG GAG GAG GAG GCG GGG CCC AGG CGG 
CCG AGC TC 
RSC-B 
(reverse) 
GAG GAG GAG GAG GAG GAG CCT GGC CGG CCT GGC CAC 
TAG TG 
 
Component 50 µL Volume Conc. in 50 µL reaction 
GoTaq Buffer (5 x) 10 µL 1 x 
RSC-F 0.5 µL 60 Pm 
RSC-B 0.5 µL 60 pM 
VH chain 2.5 µL 100 ng/reaction 
VL chain 2.5 µL 100 ng/reaction 
dNTP 1 µL 0.2 mM 
MgSO4 2 µL 2 mM 
H2O 30.75 µL N/A 
Go ™ Taq 0.25 µL 5 U/ µL 
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The SOE-PCR was performed using Biometra TGRADIENT PCR machine under 
the following conditions: 
 
 
 
 
 
 
 
 
 
 
2.2.4.7 SfiΙ restriction digestion of purified SOE-PCR fragment and 
ligation into pComb3XSS vector 
 
The SOE product and pComb3XSS vector were digested using the SfiΙ 
restriction enzyme which enables the unidirectional cloning of the scFv 
fragment into the pComb3XSS phage display vector. SfiΙ recognises 8 bases 
which are interrupted by 5 non-recognised nucleotides (5′ggccnnnnnggcc3′). 
The SfiΙ sites on both forward and reverse SOE primers are different and 
similar to that of the SfiΙ sites on the pComb3XSS phage display vector, thus 
allowing unidirectional cloning of the scFv gene into phagemid vector. 
Digestion was carried out for 5 hours at 50°C on a heating block. 
 
Components of SOE product SfiΙ digestion: 
Component Volume 
SOE product (10 µg) 60 µL 
10 x buffer 2 15 µL 
100 x BSA 1.5 µL 
H2O 58.5 µL 
SfiΙ 15 µL 
Total volume 150 µL 
        
Stage Temperature (°C) Time (seconds) 
1 (1 cycle) 94 300 
2 (25 cycles) 94 
56 
72 
15 
15 
120 
2 (1 cycle) 72 
4 
600 
Pause 
72 
 
Components of pComb3XSS vector SfiΙ digestion: 
Component Volume 
pComb3XSS vector (40 µg) 44 µL 
10 x Buffer 2 20 µL 
100 x BSA 2 µL 
H20 114 µL 
SfiΙ 20 µL 
Total volume 200µL 
 
After 5 hours incubation at 50°C, the SfiΙ digested pComb3XSS (~ 3,400 bp) 
and SOE products (800 bp) were ethanol-precipitated and gel-purified 
following the protocol in section 2.2.3.5. The restriction digested scFv gene 
was then ligated into the pComb3XSS vector with the following conditions and 
incubated on a bench at room temperature overnight. 
 
Components of SfiΙ digested SOE and pComb3XSS vector ligation: 
Component Volume 
5 x Ligase buffer 20 µL 
Digested pComb3X vector (1.4 µg) 12 µL 
Digested scFv gene (700 ng) 4 µL 
H2O 54 µL 
T4 DNA ligase 10 µL 
Total Volume 100 µL 
 
The ligated samples were ethanol-precipitated and gel-purified following the 
protocol in section 2.2.3.5. For scFv library construction, 30 µL of the ligation 
mixture was used.  
 
2.2.4.8 Electro-transformation of scFv-containing plasmid into XL-1 Blue 
E. coli cells 
 
The ligated products were transformed into electrocompetent XL-1 Blue cells 
by Gene Pulser Xcell ™ electroporation at 25 µF, 1.25 kV and 200 Ω for the 
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gene pulse controller. The 30 µL ligation for each library was split into three 
aliquots of 10 µL. After thawing on ice, 100 µL of the competent cells was 
quickly added to each of the ice cold ligated product aliquots, mixed by 
pipetting up and down once gently and incubated on ice for 30 seconds. The 
mixture was then transferred to a chilled 0.2 cm electroporation cuvette and 
placed in the ‘ShockPod’. After pulsing the cuvette, the transformant was 
immediately flushed with 1 mL of 37°C pre-warmed SOC medium, using a 
sterile tip. A further 2 mL of SOC media were added to flush the cuvette. The 
processes between applying the pulse and transferring the cells to growth 
media must be as rapid as possible to allow for better recovery of XL-1 Blue 
cells. The rescued ligations for both libraries (spleen and bone marrow) were 
then incubated for 1 hour at 250 rpm at 37°C. Following incubation, the 
rescued transformants were centrifuged (HermLe Z233MK-2 refrigerated 
centrifuge) down for 10 min at 3,220 g at 4°C. The pellets from each library 
were resuspended in 1 mL of SB medium which were then plated out on LB 
agar plates containing 100 µg/mL carbenicillin. A negative control was also 
provided by plating the XL-1 Blue cells containing no plasmid onto a LB agar 
plate with 100 µg/mL carbenicillin. All agar plates were incubated overnight at 
37°C and then scraped into SB medium containing 20% (v/v) glycerol at -80°C 
for long-term storage. 
 
2.2.4.9 Rescue of anti-P2X3 scFv-displaying phage 
 
The scraped library (200 µL) (section 2.2.3.8) was inoculated into 200 mL of 
SB medium (50 µg/mL carbenicillin and 10 µg/mL tetracycline) for both of the 
rabbit scFv libraries (spleen and born marrow). The culture was left to grow by 
shaking at 37°C for one hour at 220 rpm. More carbenicillin was then added to 
a final concentration of 100 µg/mL. When the OD reached 0.6, 200 µL of 
commercial M13K07 helper phage (ISIS, # N0315S) was added to each of the 
libraries, and left static at 37°C for 20 min. The culture was then grown in a 
rotating incubator at 37°C for two hours at 220 rpm. Kanamycin was then 
added to a final concentration of 70 µg/mL. The culture was then left to grow 
overnight at 37°C at 250 rpm.  
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2.2.4.10 Enrichment of the phage library via biopanning against 
immobilised antigens 
 
2.2.4.10.1 Immunotube-based biopanning 
 
2.2.4.10.1.1 Phage preparation 
 
A Nunc-immunotube was coated overnight at 4°C with 500 µL of dilution of 
P2X3-biotin in PBS solution (Table 2.2.3.10.1), and blocked with 3% (w/v) 
BSA-PBS. This was left for 2 hours at 37°C. Meanwhile, the overnight-rescued 
phage-induced libraries were pelleted by centrifuging (HermLe Z233MK-2 
refrigerated centrifuge) at 15,000 g for 20 min with the ‘brake-on’ option. The 
phage supernatants were decanted into 85 mL sterile polycarbonate Oakridge 
tubes, to which 4 g of PEG and 3 g of NaCl were added for every 100 mL of 
phage supernatants. The tubes were placed in a 37°C shaking incubator for 
5-10 min at 220 rpm to ensure all the PEG and NaCl was dissolved. The tubes 
were placed on ice and left in a cold room for 45 min. Subsequently, the 
PEG-precipitated phage were harvested by centrifugation (HermLe Z233MK-2 
refrigerated centrifuge) at 19,000 g for 20 min with the ‘brake-off’ option and 
the supernatant was decanted carefully. The phage pellets were thoroughly 
resuspended in 1 mL of 1% (w/v) BSA-PBS and 0.1% (w/v) KLH-PBS, and 
transferred into 2 mL centrifuge tubes. They were centrifuged (Eppendorf 
centrifuge 5810R) at 13,220 g for 5 min at 4°C to pellet excess bacterial cells 
and the phage supernatants were transferred into clean 1.5 mL micro-centrifuge 
tubes kept on ice.  
 
2.2.4.10.1.2 Biopanning using immunotubes 
 
The process was continued using blocked immunotubes (Table 2.8). The 
blocking solution was decanted out of the immunotube and 150 µL input phage 
incubated at 37°C for two hours. The phage solution was decanted out, the 
immunotube washed five times with PBST (4 mL) and then five times with 
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PBS (4 mL). To elute the bound phage, freshly prepared 10 mg/ml trypsin was 
added into the washed immunotube at 500 µL volume and incubated at 37°C 
for 30min. The trypsin was vigorously pipetted up and down for 10 times. The 
trypsin eluted phage were then infected to 5mL XLI-Blue (OD 600nm of 
0.4-0.6) and incubated for 15 min at room temperature. Subsequently, 5 mL SB 
media was added containing 2 µL of 100 mg/mL carbenicillin and 12 µL of 5 
mg/mL tertracycline. Ten mL of phage infected XLI-Blue culture were 
incubated in the rotating incubator at 220 rpm for 1.5 hours at 37°C followed 
by centrifugation (HermLe Z233MK-2 refrigerated centrifuge) at 3,220 g for 
10min at 4°C. The supernatant was discarded and 500 µL SB was added to 
resuspend the pellet. Finally, five LB agar plates (containing 100 µg/mL 
carbenicillin) with 100 µL of the phage-infected XLI-Blue suspension were 
plated out and incubated at 37°C overnight. 
 
Table 2.8 Culture volumes, concentration of coating antigen and competitive 
peptide, and wash times for each round of immunotube-based panning of the 
rabbit anti-P2X3 scFv library. 
 
Round 
number 
Culture 
volume (mL) 
[P2X3-257- 
biotin] nM 
Helper 
phage (µL) 
Washing 
1 200 400 400 PBSTx5, 
PBSx5 
2 100 200 200 PBSTx5, 
PBSx5 
3 100 40 200 PBSTx10, 
PBSx10 
4 100 20 200 PBSTx10, 
PBSx10 
 
* Phage was dissolved in sterile 1% (w/v) BSA and 0.1% (w/v) KLH to 
‘deplete’ potential cross reacting scFvs. 
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2.2.4.10.1.3 Output and input titres 
 
To determine the output titre, 2 µL of phage-infected bacteria were diluted 
[sample after infecting into XLI-Blue (OD600 nm of ~0.5) and addition of 
5mL SB media] in 400 µL SB media to make the 1/100 dilution. Two LB agar 
plates (containing 100 µg/mL carbenicillin) were plated with 100 uL of the 1 in 
100 dilution of the culture. Two further LB agar plates (containing 100 µg/mL 
carbenicillin) were plated with 10 µL of the 1:100 dilution of the culture. Plates 
were labelled “output titre” and incubated stationary at 37°C overnight. 
To determine the input titre, phage were diluted to 1:1,000,000, 1:10,000,000 
and 1:100,000,000, and 1 µL of each dilution was infected into 50 µL 
XLI-Blue cells (OD 600 nm of 0.4-0.6) and incubated at room temperature for 
15 min. Each dilution (in duplicate) was plated onto LB agar plates (containing 
100 µg/mL carbenicillin) and incubated at 37°C overnight. 
 
2.2.4.10.2 Biopanning using streptavidin-labelled magnetic beads  
 
2.2.4.10.2.1 Phage preparation 
 
Streptavidin-labelled magnetic beads (BioLabs; 2 x 20 µL) were blocked in 1.5 
mL tubes by filling with 5 % (w/v) PBSM and incubated overnight at 4°C. The 
following day, the overnight-rescued phage-induced libraries were pelleted by 
centrifuging (HermLe Z233MK-2 refrigerated centrifuge) at 15,000 g for 20 
min (brake-on). The phage supernatants were decanted into 85 mL sterile 
polycarbonate Oakridge tubes, to which, 4 g of PEG and 3 g of NaCl were 
added for every 100 mL of phage supernatant. The polycarbonate Oakridge 
tubes were placed in a 37°C shaking incubator for 5-10 min at 220 rpm to 
ensure all the PEG and NaCl has dissolved. The tubes were placed in ice and 
left in the cold room for 45 min. Then the PEG-precipitated phage were 
harvested by centrifugation (HermLe Z233MK-2 refrigerated centrifuge) at 
19,000 g in for 20 min using the ‘brake-off’ option and the supernatant was 
decanted carefully. The phage pellets were thoroughly resuspended in 1 mL of 
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1% (w/v) BSA-PBS and 0.1% (w/v) KLH-PBS to ‘deplete’ potential cross 
reacting phage, and transferred into 2 mL centrifuge tubes. They were then 
centrifuged (Eppendorf centrifuge 5810R) at 13,220 g for 5 min at 4°C to 
pellet excess bacterial cells. The supernatant was transferred into a sterile 1.5 
mL tube on ice.  
 
2.2.4.10.2.2 Streptavidin-labelled magnetic bead-based biopanning  
 
The blocked beads were washed three times with 1 x PBST, followed by three 
times with 1 x PBS. Input phage (180 µL) were incubated in one tube with 
washed beads at 37°C for 15 min to deplete the non-specific binding phage. 
The beads were then pelleted using a Magnetic Separation Rack (New England 
Biolabs Ltd.), and 150 µL depleted phage solution was taken out and incubated 
with 50 µL of a serial dilution of P2X3-biotin (Table 2.9) at 37°C for 45 min. 
The phage and P2X3-biotin mixture were than added into 1.5 mL tube with 
blocked beads and incubated at 37°C for 15 min. The beads were washed five 
or ten times (Table 2.9) with PBST, followed by PBS. To elute the bound 
phage, the beads were resuspended in 500 µL freshly prepared trypsin (10 
mg/ml) and incubated for 30 min at 37°C. The beads were pelleted and the 
phage solution was taken out, infected into 5 mL XLI-Blue (OD 600 nm of 
0.4-0.6) and incubated at room temperature for 15 min. Following this, 5 mL 
SB media containing 2 µL 100 mg/mL carbenicillin and 12 µL 5 mg/mL 
tertracycline was added. A 10 mL culture was shaken at 220 rpm for 1.5 hours 
at 37°C followed by centrifugation at 3,220 g for 10 min at 4°C. The 
supernatant was discarded and 500 µL of SB was added to resuspend the pellet. 
Finally, five LB agar plates with 100 µL suspension of phage-infected 
XLI-Blue, were incubated at 37°C overnight. 
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Table 2.9 Culture volumes, concentration of coating antigen and wash times 
for each round of magnetic bead-based panning of the rabbit anti-P2X3 scFv 
library. 
 
Round 
number 
Culture 
volume (mL) 
[P2X3-257- 
biotin] nM 
Helper 
phage (µL) 
Washing 
1 200 400 400 PBSTx5, 
PBSx5 
2 100 200 200 PBSTx5, 
PBSx5 
3 100 40 200 PBSTx10, 
PBSx10 
4 100 20 200 PBSTx10, 
PBSx10 
 
* Phage was dissolved in sterile 1% (w/v) BSA and 0.1% (w/v) KLH to 
‘deplete’ potential cross reacting scFvs. 
 
2.2.4.10.1.3 Output and input titres 
 
To determine the output titre, 2 µL of phage infected bacteria was diluted 
[sample after infecting into XLI-Blue (OD600 nm of ~0.5) and addition of 
5mL SB media] in 400 µL SB media to make the 1/100 dilution. Two LB agar 
plates (containing 100 µg/mL carbenicillin) were plated with 100ul of the 1 in 
100 dilution of the culture. Two further LB agar plates (containing 100 µg/mL 
carbenicillin) were plated with 10 µL of the 1/100 dilution of the culture. Plates 
were labelled pan output titre plates and incubated stationary at 37°C O/N. 
To determine the input titre, phage were diluted to 1:1,000,000, 1:10,000,000 
and 1:100,000,000, and 1 µL of each dilution was infected into 50 µL 
XLI-Blue (OD 600 nm of 0.4-0.6) and incubated at room temperature for 15 
min. Each dilution (in duplicate) was plated onto LB agar plates (containing 
100 µg/mL carbenicillin) and incubated at 37°C overnight. 
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2.2.4.11 Polyclonal phage ELISA  
 
A 96-well plate (Maxisorp™, Nunc) was coated with 2 µg/mL P2X3-biotin, 
P2X3-BSA, P2X3-BTG, neutravidin, BSA, BTG and KLH, incubated overnight 
at 4°C. The coating solution was decanted and the plate was blocked with 5% 
(w/v) PBSM for one hour at 37°C. The phage inputs for each round of panning 
were diluted 1:1 with 3% (w/v) PBSTM. Then 100 µL of each diluted phage 
was added to a designated well of the ELISA plate and incubated for one hour 
at 37°C. M13K07 helper phage and 3% (w/v) PBSTM were also diluted and 
added to certain wells as negative controls to identify any background binding. 
After washing the plate three times with PBST and three times with PBS, 100 
µL of 1:2,000 dilution of a HRP-conjugated anti-M13 antibody (GE Healthcare 
Life Sciences) in PBST was added to each well as secondary antibody and 
incubated for one hour at 37°C. After washing the plate three times with PBST 
and three times with PBS, 100 µL of TMB substrate (0.4 g/L) was added and 
the colour was allowed to develop for 15 min at room temperature. Finally, the 
reaction was stopped by applying 50 µL of 1 M HCl. The absorbances of the 
wells were read at 450 nm using a Safire 2 plate reader. 
 
2.2.4.12 Infection of the eluted phage output into E. coli Top 10 F′ 
(non-suppressor strain) for soluble expression 
 
A 5 µL aliquot of output phage, from the last round of panning, was infected 
into 5 mL of Top 10 F′ cells (OD 600 nm of ~0.5) containing 12 µg/mL 
tetracycline and incubated for 15 min at room temperature. Subsequently, 
1:1,000,000, 1:10,000,000 and 1:100,000,000 dilutions were prepared for 
obtaining single colonies for further analysis. Each dilution (in duplicate) was 
plated on LB agar plates (containing 100 µg/mL carbenicillin) and incubated at 
37°C overnight. 
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2.2.4.13 Direct and inhibition ELISA of solubly expressed scFv fragments 
 
Single colonies of scFv fragments were picked from overnight plates, as 
described in section 2.2.3.12, and inoculated into 96-well plates containing 100 
µL SB media per well (containing 50 µg/mL of carbenicillin) and were grown 
overnight at 220 rpm at 37°C (stock plates). The 96-well stock plates were then 
subcultured into fresh SB media (150 µL) containing 1 x 505 [0.5% (v/v) 
glycerol, 0.05% (w/v) glucose, sterile-filtered], 1mM MgSO4 and 100 µg/mL 
carbenicillin (subcultured plates). For the stock plates, glycerol was added to a 
final concentration of 20% (v/v) and kept at -80°C for long-term storage. The 
subcultured plates were incubated at 37°C and rotated at 200 rpm until the cells 
appeared to be cloudy (OD 600 nm of 0.4-0.6). Expression was then induced 
by addition of 1 mM IPTG overnight at 30°C (220 rpm). For each plate of 
colonies, a 96-well plate (Maxisorp™, Nunc) was coated with 1 µg/mL 
neutravidin (100 µL per well) incubated for one hour at 37°C, and washed with 
1 × PBS twice. Two µg/mL P2X3-biotin (100 µL per well) was then added and 
incubated overnight at 4°C, followed by blocking with a 5% (w/v) PBSM (200 
µL per well) for 1 hour at 37°C. The overnight expression plates were frozen 
(-80°C) and thawed (37°C) three times to break open the cells to produce a 
scFv-containing lysate. The plates were centrifuged (HermLe Z233MK-2 
refrigerated centrifuge) at 3,220 g for 10 min at 4°C, and the lysate supernatant 
was added (100 µL per well) to its corresponding coated/blocked well and 
incubated at 37°C for one hour. For the inhibition ELISA, at this step, the 
lysate was pre-incubated with several concentrations of the free P2X3-257/60 
and then added to the corresponding coated/blocked well and incubated at 
37°C for 1 hour. After washing the plates three times with 1 x PBST and three 
times with 1 x PBS to remove any unbound scFv, the scFv-bound P2X3 
complex was detected using HRP-labelled anti-HA secondary monoclonal 
antibody (1:2,000 dilution, 100 µL per well). After incubating for one hour at 
37°C, TMB (0.4 g/L) was added (100 µL per well) and incubated for 15 min at 
37°C. The reaction was stopped by the addition of 10% (v/v) HCl (100 µL per 
well), and absorbances of the wells was read at 450 nm using a Safire 2 plate 
reader. 
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2.2.4.14 ‘Colony-pick’ PCR and restriction enzyme digestion of scFv 
 
Individual colonies were picked with a sterile 200 µL pipette tip and added to 
an SOE-PCR reaction mixture containing the following components: 
 
Component 50 µL Volume Conc. in 50 µL reaction 
GoTaq buffer (5x) 10 µL 1x 
MgCl2 3.0 µL 1.5 mM 
RSC-F 0.5 µL 60 pM 
RSC-B 0.5 µL 60 pM 
dNTP 1.0 µL 0.2 mM 
H2O 34.75 µL N/A 
GoTaq ™ Polymerase 0.25 µL 5 U/µL 
 
 
The mixture above was placed into PX2 thermal cycler (Thermo Electron 
Corporation) and proceed reactions under the following conditions: 
 
Stage Temperature (°C) Time (seconds) 
1 (1 cycle) 94 300 
2 (26 cycles) 94 
56 
72 
45 
60 
150 
3 (1 cycle) 72 
4 
600 
Pause 
 
 
 
 
 
 
 
82 
 
Following by analysis of PCR reactions using 1% (w/v) agarose gel 
electrophoresis. The successfully amplified products were restriction digested 
by AluI (New England Biolabs) under the following conditions: 
 
 
 
 
 
 
 
 
 
 
The AluI digestion was carried out for two hours at 37°C. Then the digested 
samples were run on a 3% (w/v) agarose gel for analysis. 
 
2.2.4.15 ScFv purification by immobilised metal affinity chromatography 
(IMAC) 
 
A 3 mL aliquot of Ni+-NTA agarose resin (QIAgen) was added to a 20 mL 
column and equilibrated with 20 mL of running buffer (1 x PBS, 0.5 M NaCl, 20 
mM imidazole and 1% (v/v) Tween-20). The filtered lysate was then applied to 
the equilibrated column and the ‘flow-through’ collected in a 50 mL tube. The 
column was washed with 30 mL of running buffer to remove any loosely bound 
non-specific proteins, again collecting the ‘flow-through’ in a 50 mL tube. The 
scFv fraction was eluted using 100 mM NaAc (pH 4.4) and collected in 24 x 400 
µL aliquots in 1.5 mL micro-centrifuge tubes containing 100 µL of filtered 
neutralisation buffer (50 µL 100 mM NaOH and 50 µL of 10 x PBS). The 
neutralised scFv (12 mL) was then thoroughly buffer exchanged against filtered 
1 x PBS using a 5 kDa ‘cut-off’ Vivaspin™ 6 column (AGB, VS0611). The 
buffer-exchanged scFv was then quantified using the Nanodrop™ ND-1000 and 
aliquoted into clean PCR tubes and stored at -20°C. 
 
scFv gene AluI digest 
Component 24 µL Volume 
SOE product 8 µL 
10 x buffer 2 2.4 µL 
100 x BSA 0.24 µL 
H2O 12.86 µL 
AluI 0.5 µL 
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2.2.4.16 ScFv titre and competitive ELISA 
 
Maxisorb 96-well plates were coated with 100 µL per well 2.5 µg per µL 
neutravidin at 37°C for one hour. Then the plates were washed once with 1 × 
PBS, followed by the addition of 100 µL per well 5 µg/µL P2X3-257/60-biotin 
conjugates overnight at 37°C. Plates were blocked with 200 µL per well 5 % 
(w/v) PBSTM at 37°C for one hour. A range of dilutions of purified scFv in 
3% (w/v) PBSTM (1:2-1:1,000 dilution; 100 µL per well) was applied as 
primary antibody at 37 ℃ for one hour. To carry out the competitive ELISA, a 
range of concentrations of P2X3-257/60 peptide (0-2 µg/mL) were prepared 
and mixed with a fixed concentration of purified scFv. One hundred µL per 
well of this mixture was incubated at 37°C for one hour. Then HRP-labeled 
HA antibody (100 µL per well) was added as secondary antibody and 
incubated at 37°C for one hour. TMB (0.4 g/L, 100 µL per well) was added 
and incubated at room temperature for 10 min. The reaction was stopped by 
addition of 50 µL of 1 M HCl per well. The absorbances of the wells were read 
at 450 nm using Safire 2 plate reader.  
 
2.2.4.17 SDS-PAGE, Western blotting (WB) and Immunofluorescent (IF) 
staining analysis of rabbit anti-P2X3 scFv specificity to rat root ganglion 
cells (DRGs) expressing P2X3. 
 
2.2.4.17.1 SDS-PAGE and Western blotting 
 
DRG cells were harvested at 3-5 days in vitro (DIV 3-5) by lysing the cells 
with 100 µL 2 x LDS buffer. A 160 µg quantity of DRGs lysis protein sample 
(in a total volume of 20 µL) was added into each well of 4-12% precast 
Bis-Tris gel (Invitrogen). The gels were placed in an electrophoresis apparatus 
and submerged in electrophoresis buffer. The electrophoresis buffer was 
prepared using 50 mM MOPS, 50 mM Tris, pH 8.3, 1 mM 
ethylenediaminetetraacetic acid (EDTA) and 0.1% (w/v) SDS. The apparatus is 
attached to a power supply and a voltage of 200 V is applied to the gel. The 
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gels were allowed to run until the tracker dye had reached the bottom of the gel. 
The gels were taken out and stained using Coomassie stain [0.2% (w/v) 
Coomassie blue R-25, 45% (v/v) methanol, 45% water, 10% (v/v) acetic acid] 
for 1-2 hours. Finally, the stained gels were destained overnight using 
Coomassie blue destain [10% (v/v) acetic acid, 25% (v/v) methanol, 65% (v/v) 
water], changing the destain several times.  
For Western blotting, proteins were transferred from the gel to a PVDF 
membrane at 250 mA for 2.5 hours. The membrane was blocked with 5% (w/v) 
TBSTM for one hour at room temperature. Purified scFv antibody (prepared in 
section 2.2.3.15) was added overnight at 4°C. The membrane was washed three 
times with 1 x TBST for 5 min. HRP-labelled anti-HA (1:2,000 dilution) 
secondary antibody was added and incubated at room temperature for one hour. 
The membrane was washed three times with 1 x TBST for 5 min, and TMB 
(0.4 g/L) was added for visualisation. When the bands appeared, the membrane 
was washed with ddH2O to stop the reaction. A picture was then taken using 
the G:BOX Gel & Blot Imaging Series. 
 
2.2.4.17.2 Immunofluorescent staining 
 
A 24-well tissue culture plate with DRG cells cultured for 5-7 day were 
washed three times with Dulbecco’s phosphate buffer saline (D-PBS, lacking 
Mg2+ and Ca2+) and fixed using 3.7% (v/v) paraformaldehyde for 20 min at 
room temperature. The plate was washed three times with D-PBS, and then 
blocked with 1% (w/v) BSA in D-PBS for one hour at room temperature. The 
blocking solution was removed, purified anti-P2X3-scFv was added as primary 
antibody and the cells were incubated at room temperature for one hour. The 
plate was washed three times with D-PBS, followed by addition of 
fluorescein-labelled rat anti-HA monoclonal antibody (2 µg/mL, 200 µL). 
After washing three times with D-PBS, the cells were ready to image using an 
Olympus IX71 microscope or inverted confocal microscope (Leica Dmire 2) 
with a CCD camera. Images were then analysed using the Image-Pro Plus 5.1 
or Leica confocal software. A negative control was included with rabbit 
anti-goat-IgG (1:1,000 dilution) as primary antibody instead of purified 
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anti-P2X3-scFv, followed by secondary antibody Alexa Fluor-488-labelled goat 
anti-rabbit IgG (1: 200 dilution). 
 
2.2.4.18 Determination of rabbit anti-P2X3 scFv stability in solution 
 
Purified rabbit scFv was stored in autoclaved glycerol or sterile filtered BSA or 
in a protease inhibitor cocktail (PIC) according to conditions shown in table 
2.10. The scFv titre was measured on days 1, 6, 12, 19, 30, 60 and 90. The 
scFv titre determination was described in section 2.2.3.16. 
 
Table 2.10 Different storage conditions with different additions for rabbit 
anti-P2X3 scFv. 
 
Component added Storage temperature  
1:1 (v/v) glycerol 4°C 
10 mg/mL BSA 4°C 
1:10 (v/v) PIC 4°C 
10 mg/mL BSA + 1:10 (v/v) PIC 4°C 
10 mg/mL BSA -80°C 
 
 
2.2.4.19 ScFv mutation of Cys80 to Ala 
 
Cys80 mutation Primers 
Mutation sense primer 5′ CGG ACG ATG CTG CCA CTT ACT ACT G 3′ 
Mutation reverse primer 5′ CCT GCA CGT CGC TGA TGG TGA GAG 3′ 
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The components for a 1 x reverse PCR reaction with 50 µL total volume were 
as follows: 
 
Component 50 µL Volume Conc. in 50 µL 
Accu Pfx Buffer (10x) 5.0 µL 1x 
Mutation sense primer 1 µL 60 pM 
Mutation reverse primer 1 µL 60 pM 
ScFv plasmid (H7C; 500 ng) 5.0 µL 0.5 µg 
H2O 37.2 µL N/A 
Accu Pfx 0.8 µL 5 U/µL 
 
 
The PCR for the amplification was performed using a Biometra TGRADIENT PCR 
machine with the following conditions: 
 
Stage Temperature 
(°C) 
Time (seconds) 
1 (1 cycle) 94 120 
2 (15 cycles) 94 
55 
68 
30 
53 
285 
3 (1 cycle) 68 
4 
600 
Pause 
 
The reverse PCR mutated samples were ethanol-precipitated and gel-purified 
following the protocol in section 2.2.3.5, followed by transformation into Top 
10 electrocompetent E.coli, as described in section 2.2.3.8. Six single colonies 
were picked and plasmids were extracted as described in section 2.2.3.8, and 
then sfiI restriction digestion was performed for selection of positive colony 
(section 2.2.3.7). 
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2.2.4.20 Fluorescence-activated cell sorting (FACS) analysis of rat DRG 
expressed-P2X3 staining  
 
Fluorescence-activated cell sorter (FACS), an instrument based on flow 
cytometry, is effectively used for detecting antibody specific binding on 
antigen expressed by cells (Geuijen et al., 2005). The principle of FACS 
analysis is a fluorescence-labelled suspension containing individual cells 
passes a focused laser-beam, and then the fluorescence-labels are stimulated by 
the laser light. The emitted flurescent light from the flurophores (correspond to 
the number of antibody) and the scattered-light (correspond to size of cell) are 
detected separately (Nunez, 2001). Thus, FACS enables quantification of 
specific-binded antibodies which can not be achieved by merely 
immunofluorescent staining and observed using microscope. 
Rat DRG cells cultured for 4 days were fixed and stained as described in 
section 2.2.4.17.2. After proper wash with D-PBS, 0.5 mL per well D-PBS was 
added and DRG cells were scraped from the wells of the cell culture plate. 
DRG cells were then transferred to labelled FACs tubes (Becton Dickson, 
U.S.A.). Samples were acquired immediately or left overnight at 4°C in the 
dark. 10,000 events were acquired per sample using a 4-colour FACS Calibur 
(fluorescence activated cell sorter) Becton Dickson. Data was analysed using 
FlowJo software. For negative control, the primary antibody was omitted and 
only applied with secondary antibody. For positive control, commercial rabbit 
anti-P2X3 polyclonal antibody was added instead of scFv antibody. 
 
2.2.4.21 Immunohistochemical analysis of specificity of anti-P2X3 antibody 
 
Sections of 4 µm thickness were cut from the whole section blocks for the 
purpose of immunohistochemistry. Sections were immunostained with rabbit 
anti-P2X3-257 scFv antibody (50 µM) or rabbit anti-P2X3-257 polyclonal 
antibody (50 µM) after antigen heat retrieval on an automated platform (Bond 
system-Leica Microsystems, Bannockburn, IL, U.S.A.) in Beaumont Hospital. 
Briefly, cut sections were subjected to on-board dewaxing and the following 
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conditions were applied: P2X3 antigen retrieval in tri-sodium citrate buffer 
(Bond Epitope Retrieval 1 solution) for 20 mins. Detection of the 
antibody–antigen complex was achieved using a polymer-based kit (Bond 
Refine) with DAB as the chromogen. All sections were counterstained with 
haematoxylin. Negative controls were included for all sections by omitting the 
primary antibody; competition controls were performed by preincubating 
antibodies with P2X3 peptides (1 µg peptide per 1 µg antibody); positive 
controls included rat DRG sections stained by commercial rabbit anti-P2X3 
polyclonal antibody (50 µM). 
 
2.2.5 Expression and purification of LC-HN/A-core streptavidin (CS5)  
 
2.2.5.1 Expression and purification of LC-HN/A-core streptavidin (CS5) 
 
The principle of P2X3 delivering BoNT for treating inflammatory pain was 
proved by LC-HN/A-anti-P2X3 pAb conjugates (BoNT/E light chain and heavy 
chain translocation domain and anti-P2X3 polyclonal antibody conjugates), 
which were obtained by conjugating biotinylated rabbit polyclonal anti-P2X3 
antibody and LC-HN/A-core streptavidin (CS5) via the high affinity 
biotin-streptavidin bond. A description of how LC-HN/A-core streptavidin 
(CS5) was expressed and purified follows. 
One clone of LC-HN/A-core streptavidin was picked and added into 5 mL LB 
medium and incubated overnight at 220 rpm and 37°C. LC-HN/A-core 
streptavidin overnight culture (0.5 mL) was inoculated into 500 mL of ZY 
medium in 2 L flask and the culture was shaken at 220 rpm and 37°C. After 
five hours, the temperature was changed from 37°C to 22°C for self-induction 
of LC-HN/A-core streptavidin expression and it was incubated overnight with 
shaking at 220 rpm. The culture was centrifuged (Beckman J2-HS centrifuge) 
at 8,500 g for 20 min at 4°C. The pellet was resuspend in 25 mL of lysis buffer 
(25 mM HEPES, 500 mM NaCl and 10% (v/v) glycerol, pH 7.8) containing 
150 µL protease inhibitor (CalBiochem, #539134), 20 µL benzonase (Novagen, 
#70746-3) and 45 mg lysozyme (Sigma, #L6876-10G). The sample was mixed 
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gently on a roller for 40 min at room temperature, then frozen (-80°C) and 
thawed (37°C) three times to break open the bacterial cells to release expressed 
LC-HN/A-core streptavidin. The sample was either kept at -80°C for long-term 
storage or purification steps undertaken.  
For purification, 1 mL of metal affinity resin (Talon superflow, # 635507) was 
equilibrated twice with 10 mL lysis buffer, and then the freeze-thawed sample 
was centrifuged (Beckman J2-HS centrifuge) at 18,000 g for 20 min. A 2 mL 
volume of supernatant was added to the column and mixed resin with 
supernatant for one hour at 4°C. The mixture was transferred to the column and 
incubated for 10 min to allow the solution pass through the column. The 
column was washed twice with 6 mL wash buffer (25 mM HEPES, 500 mM 
NaCl, 10% (v/v) glycerol and 5 mM imidazole, pH 7.8). The LC-HN/A-core 
streptavidin was then eluted with 6 mL elution buffer (25 Mm HEPES, 500 
mM NaCl, 10% (v/v) glycerol and 500 mM imidazole, pH 7.8). The eluate was 
collected in 6 x 1.5 mL tubes and the protein concentration was then measured 
with a BCA kit (section 2.2.2.3).  
Subsequently, the eluted fractions were desalted using a Zeba Desalt Spin 
Column (Pierce, # 89893). The desalting column was equilibrated with running 
buffer (20 mM HEPES, 145 mM NaCl, pH 7.4). Eluted fractions from the last 
step were added to the column, the ‘flow-through’ discarded, and the 
LC-HN/A-core streptavidin was eluted with 3.5 mL nicking buffer (25 mM 
HEPES, 145 mM NaCl, 2 mM CaCl2, pH 7.8). Eluted desalted LC-HN/A-core 
streptavidin was added to a 50,000 MWCO Vivaspin, and centrifuged (HermLe 
Z233MK-2 refrigerated centrifuge) at 2,465 g for 5-10 min at 4°C until 1 mL 
of solution was left. The concentrated sample was transferred to a 1.5 mL tube, 
and centrifuged (Eppendorf centrifuge 5810R) at 18,000 g for 10 min at 4°C to 
remove debris.  
At this stage, the purified LC-HN/A-core streptavidin protein was in single 
chain (SC) form, which is inactive, and needed to be nicked to the di-chain 
(DC) active form by thrombin (1:250 dilution) treatment at 27°C for 40 mins. 
Then a thrombin inhibitor, APMSF (250 µM), was added to the solution to 
inactive the thrombin. The concentration of LC-HN/A-core streptavidin was 
measured with a BCA protein determinationkit (section 2.2.2.3). 
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2.2.5.2 Analysis of expression and purity of LC-HN/A-core streptavidin 
(CS5) via SDS-PAGE 
 
For SDS-PAGE analysis, 0.1 mg of purified LC-HN/A-core streptavidin (CS5, 
in a total volume of 20 µL) was loaded into each well of 4-12% (w/v) 
NuPAGE Bis-Tris Gel. The gels were placed in an electrophoresis apparatus 
and submerged in electrophoresis buffer. The electrophoresis buffer was 
prepared using 50 mM MOPS, 50 mM Tris, pH 8.3, 1 mM EDTA and 0.1% 
(w/v) SDS. The apparatus was attached to a power supply and a voltage of 170 
V applied to the gel. The gels were allowed to run until the tracker dye had 
reached the bottom of the gel, taking approximately 45-60 minutes. The gel 
was taken out and stained using Coomassie stain [0.2% (w/v) Coomassie blue 
R-25, 45% (v/v) methanol, 45% water, 10% (v/v) acetic acid] for 1 hour. 
Finally, the stained gels were destained for 2 hours using Coomassie destain 
[10% (v/v) acetic acid, 25% (v/v) methanol, 65% (v/v) water], changing the 
destain twice.  
 
2.2.5.3 Biotin-binding capacity of LC-HN/A-core streptavidin (CS5) 
 
A Maxisorb 96-well plate was coated with a range of concentrations (0.004, 
0.01, 0.02, 0.04, 0.1, 0.2, 0.4, 1, 2 and 4 nM) of LC-HN/A-core streptavidin 
(100 µL per well) overnight at 4°C. The plate was blocked with 200 µL/well 5 
% (w/v) PBSTM at 37°C for one hour. One hundred µL per well of 
HRP-labelled biotin was added as secondary antibody and the plate was 
incubated at 37°C for one hour. Subsquently, 100 µL per well TMB (0.4 g/L) 
was added and incubated at room temperature for 15 min. The reaction was 
stopped by addition of 50 µL per well of 1 M HCl, and the absorbances of the 
wells read at 450 nm using a Safire 2 plate reader.  
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2.2.5.4 Activity determination of purified LC-HN/A-core streptavidin (CS5) 
 
Different amounts of LC-HN/A-core streptavidin (0, 0.013, 0.13, 1.3, 13 µg) 
were added into rat DRGs cultures (P5, 6 DIV) and incubated for 16 hours at 
37°C in 5% (v/v) CO2. Culture medium was carefully removed and DRG cells 
were lysed using LDS buffer (60 µL per well). Western blotting was performed 
for checking P2X3 expression on DRG cells using the protocol described in 
section 2.2.3.17, with mouse anti-SNAP-25 antibody (SMI-81, 1:1,000 dilution) 
applied as the primary antibody, and followed by HRP-labelled anti-mouse IgG 
secondary antibody. 
 
2.2.6 Anti-P2X3 polyclonal antibody-LC-HN/A-core streptavidin 
conjugates 
 
2.2.6.1 Biotinylation of rabbit anti-P2X3 polyclonal antibody and 
quantitation 
 
An EZ-Link(R) Micro Sulfo-NHS-LC-biotinylation kit (Fisher Thermo 
Scientific, #PN21935) was used for labeling antibody with biotin. Polyclonal 
antibody was prepared in 1 x PBS to a final concentration of 1-10 mg. One vial 
of Sulfo-NHS-LC-biotin, stored at -20°C, was placed at room temperature for 
equilibration. Ultrapure water (180 µL) was added to the 1 mg microtube to 
give a 10 mM biotin reagent solution. An appropriate volume of 10 mM biotin 
reagent solution was added to the polyclonal antibody solution based on the 
following formulae (from the EZ-Link(R) Micro sulfo-NHS-LC-biotinylation 
kit protocol): 
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1) Caculation of millimoles of sulfo-NHS-LC-biotin to add to the reaction to 
give a 20-fold molar excess: 
mL (protein) X 
(protein) mL
(protein) mg
 X 
(protein) mg
 (protein) mol
 X 
(protein) mmol
(biotin) mmol 20
= mmol 
biotin 
20 = Recommemded molar fold excess of biotin per 1-10 mg/mL protein 
sample 
 
2) Calculation of microliters of 10 mM Sulfo-NHS-LC-biotin to add to the 
reaction: 
 mmol biotin  X 
(biotin) mmol
mg 557
 X 
(biotin) mmol
 = µL biotin colution 
577 = Molecular weight of Sulfo-NHS-LC-biotin 
400 = Microliters of water in which 2.2 mg of Sulfo-NHS-LC-biotin is 
dissolved to make a 10 mM solution 
 
The biotin reagent and antibody mixture were placed on ice and incubated for 
two hours. The biotinylated polyclonal antibody was desalted and concentrated 
using 10,000 MWCO viva spin (Sartorius, #VS0601) by applying 3 times 1 X 
PBS (pH 7.5). The concentration was determined by the BCA assay. The 
biotinylated polyclonal antibody sample was dispensed into 50 µL volumes and 
stored at -20°C for future use.  
A kit (Fisher Thermo Scientific, # PN28005) was used for biotin quantitation. 
One microtube of HABA/Avidin Premix was removed from the kit at -20°C 
and left at room temperature for equilibration. Ultrapure water (100 µL) was 
added and mixed by pipetting up and down. PBS (160 µL) was added into each 
Maxisorb plate well, followed by 20 µL of the HABA/Avidin Premix solution. 
Mixing was achieved by manually shaking the plate on the bench 10 times. The 
absorbances of the wells were read at 500 nm using a Safire 2 plate reader and 
the values recorded as A500 H\A. Twenty µL biotinylated sample or 
biotinylated-HRP (positive control) was added as secondary antibody and 
mixed by manually shaking the plate on the bench 10 times. The plate was read 
at 500 nm and the value was recorded as A500 H\A\B sample. Finally, the moles 
400 µL 
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of biotin conjugated per mole of protein was calculated based on the following 
formulae (from the Biotin Quantification Kit protocol):  
 
1) Calculation No. 1 is for the concentration of biotinylated protein in 
mmol/mL (before any dilution for the assay procedure) 
 
                                            
 
MW = Molecular weight 
Calc No. 1 = Calculation number 1 
 
2) Calculation No. 2 is for the change in absorbance at 500nm: 
Cuvette: 
△A500= (0.9 x A500 H\A)-(A500 H\A\B) = Calc No. 2 
Microplate: 
△A500= (A500 H\A)-(A500 H\A\B) = Calc No. 2 
 
A500 H\A = Absorbance at 500nm for PBS 
A500 H\A\B = Absorbance at 500nm for biotinylated sample 
Calc No. 2 = Calculation number 2 
 
 
 
 
 
 
 
3) Calculation No. 3 is for the concentration of biotin in mmol per mL of 
reaction mixture: 
 
 
 
Calc No. 3 = Calculation number 3 
Note: The cuvette format requires the 0.9 correction factor to 
adjust for dilution of the H/A mixture by the biotinylated 
protein sample. The microplate format does not require this 
correction factor because the dilution effect is exactly offset 
by the increased height and light path length of solution in the 
well. 
Protein concentration (mg/mL) 
MW protein (mg/mmol) 
= Calc No.1 mmol protein per Ml = 
mmol biotin          ∆A500        Calc. No.2 
mL reaction mixture     (34,000 x b)      (34,000 x b) 
= = Calc. No.3 
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4) Calculation No. 4 is for the mmol of biotin per mmol of protein: 
 
 
 
 
 
 
 
 
 
Calc No. 4 = Calculation number 4 
 
 
 
 
 
 
 
 
 
2.2.6.2 Avidin-binding capacity of biotinylated rabbit anti-P2X3 polyclonal 
antibody 
 
A Maxisorb 96-well plate was coated overnight at 4°C with 100 µL per well of 
2.5 µg/µL neutravidin. The plate was blocked with 200 µL per well 5 % (w/v) 
PBSTM at 37°C for one hour. A range of concentrations (2, 4, 10, 20, 40, 100, 
Note: The original biotinylated protein sample was diluted 
10-fold in the reaction mixture. Therefore, a multiplier of 10 is 
used in this step to convert the biotin concentration in the 
original sample. If the original sample was diluted before 
performing the assay, then the dilution factor must be used as 
well. Calculation No. 4 yields the biotin: protein molar ratio 
(average number of biotin molecules per protein molecule). 
Note: b is the light path length (cm) of the sample. Use b = 1 with 
cuvette format. Use b = 0.5 with the microplate format when 
using a standard 96-well plate and the volumes specified in the 
procedure. The exact path length is the height of the solution 
through which the plate reader measures the absorbance. 
= 
= 
= 
mmol biotin in original sample 
mmol protein in original sample 
(mmol per mL biotin in reaction mixture) (10) (dilution factor) 
mmol per mL protein in original sample 
(Calc No.3) x 10 x dilution factor 
Calc No.1 
Calc No.4 = 
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200, 400, 1,000 and 2,000 ng) of biotinylated rabbit anti-P2X3 polyclonal 
antibody was prepared and added into separate wells (100 µL per well), and 
incubated at 37°C for one hour, followed by the secondary antibody 
HRP-labelled anti-rabbit antibody (100 µL per well) and incubated for one 
hour at 37°C. Then, 100 µL per well TMB (0.4 g/L) was added and incubated 
at room temperature for 15 min. The reaction was stopped by addition of 50 µL 
per well 1 M HCl, and the absorbances of the wells were read at 450 nm using 
a Safire 2 plate reader.  
 
2.2.6.3 Western blotting and immunofluorescent staining analysis of 
biotinylated rabbit anti-P2X3 polyclonal antibody and its specificity to 
P2X3 expressed on rat DRG cells 
 
The same protocol was followed, as described in section 2.2.2.5, with 20 µg (in 
250 µL) biotinylated rabbit anti-P2X3 polyclonal antibody as the primary 
antibody. 
 
2.2.6.4 The conjugation of biotinylated rabbit anti-P2X3 polyclonal 
antibody to purified LC-HN/A-core streptavidin (CS5) 
 
Biotin-streptavidin bond is known to be the strongest noncovalent biological 
interaction (Holmberg et al., 2005), and one molecule of core streptavidin 
binds to one molecules of biotin. Therefore, LC-HN/A-core streptavidin and 
biotinylated polyclonal antibody were mixed at a molecular ratio of 2:1 to 
ensure sufficient binding occurred. The mixture was incubated at 4°C on a 
roller for two hours to maximum binding.  
 
2.2.6.5 SDS-PAGE and Western blotting (WB) analysis of successful 
conjugation of rabbit anti-P2X3 pAb and LC-HN/A-core streptavidin (CS5) 
 
A 160 µg quantity of rabbit anti-P2X3 pAb-LC-HN/A-core streptavidin (CS5) 
conjugates (in a total volume of 20 µL) in 1 x LDS loading buffer was added 
into each well of 4-12% (v/v) precast Bis-Tris gel (Invitrogen). The gels were 
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placed in an electrophoresis apparatus and submerged in electrophoresis buffer. 
The electrophoresis buffer was prepared using 50 mM MOPS, 50 mM Tris, pH 
8.3, 1 mM ethylenediaminetetraacetic acid (EDTA) and 0.1% (w/v) SDS. The 
apparatus is attached to a power supply and a voltage of 200 V applied to the 
gel. The gels were allowed to run until the tracker dye had reached the bottom 
of the gel. The gels were taken out and stained using Coomassie stain [0.2% 
(w/v) Coomassie blue R-25, 45% (v/v) methanol, 45% (v/v) water, 10% (v/v) 
acetic acid] for 1-2 hours. Finally, the stained gels were destained overnight 
using Coomassie blue destain [10% (v/v) acetic acid, 25% (v/v) methanol, 65% 
(v/v) water], changing the destain several times.  
For Western blotting, proteins were transferred from the gel to a PVDF 
membrane at 250 mA for 2.5 hours. The membrane was blocked with 5% (w/v) 
TBSTM for one hour at room temperature. HRP-labelled anti-rabbit IgG 
(1:2,000 dilution) was added as secondary antibody and incubated at room 
temperature for one hour. The membrane was washed three times with 1 x 
TBST for 5 min, and TMB (0.4 g/L) was added for visualisation. When the 
bands appeared, the membrane was washed with ddH2O to stop the reaction. A 
picture was taken using the G:BOX Gel & Blot Imaging Series. 
 
2.2.6.6 Immunofluorescent (IF) staining analysis of rabbit anti-P2X3 
pAb-CS5 specificity to rat root ganglion cells (DRGs) expressing P2X3 
 
A 24-well tissue culture plate with DRG cells cultured 5-7 days in vitro were 
washed three times with Dulbecco’s phosphate buffer saline (D-PBS, lacking 
Mg2+ and Ca2+) and fixed using 3.7% (v/v) paraformaldehyde for 20 min at 
room temperature. The plate was washed three times with D-PBS, and then 
blocked with 1% (w/v) BSA in D-PBS for one hour at room temperature. The 
blocking solution was removed, rabbit anti-P2X3 pAb-CS5 was added as 
primary antibody and the cells were incubated at room temperature for one 
hour. The plate was washed three times with D-PBS, followed by addition of 
secondary antibody Alexa Fluor-546-labelled goat anti-rabbit polyclonal 
antibody. After washing three times with D-PBS, the cells were ready to image 
using an Olympus IX71 microscope or inverted confocal microscope (Leica 
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Dmire 2) with a CCD camera. Images were then analysed using the Image-Pro 
Plus 5.1 or Leica confocal software. A negative control was included with 
contained anti-goat IgG (1:1,000 dilution) as primary antibody, followed by 
secondary antibody Alexa Fluor-488-labelled goat anti-rabbit IgG (1: 200 
dilution). 
 
2.2.6.7 Endopeptidase activity of Rabbit anti-P2X3 polyclonal antibody-CS 
conjugates 
 
Different concentrations of anti-P2X3 pAb-CS5 (0, 0.013, 0.13, 1.3, 13 µg in a 
total volume of 200 µL) in DMEM culture medium were added into rat DRGs 
cultures (P5, 6 DIV) and incubated for 16 hours at 37°C in 5% (v/v) CO2. The 
medium was removed, and DRGs were harvested by lysing with 2 x LDS buffer 
(60 µL per well). Western blotting was performed to check P2X3 expression on 
DRG cells using the protocol described in section 2.2.3.17, with anti-SNAP-25 
antibody (SMI-81, 1:1,000 dilution) applied as the primary antibody. 
 
2.2.7 P2X3 scFv-BoNT genetic fusion 
 
2.2.7.1 Generation, expression and purification of BoNT-rabbit anti-P2X3 
scFv fusion 
 
These processes were carried out by Dr. Jiafu Wang in the International Centre 
for Neurotherapeutics (ICNT), Dublin City University (DCU). BoNT-scFv 
fusions [joined with an (GGGGS)3 linker] with C-terminal His-tag (for 
BoNT-scFv fusion detection and purification), with or without a linker, and 
with or without the C-terminal banding domain, were designed and generated, 
followed by primer design, and amplification of fusions via PCR. BoNT-scFv 
fusions were then ligated onto the pET-29a plasmid vector and transferred to 
BC21(DE3) or Origami 2(DE3) competitive E.coli cells for expression. Finally, 
the BoNT-scFv fusions were purified by both IMAC and ion exchange 
chromatography (Fig. 2.4). 
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Fig. 2.4 Structure of BoNT-scFv fusion. LC = light chain; HN = heavy chain 
translocation domain; HCN = heavy chain C-terminal binding domain; LC/A = 
light chain of BoNT/A; HN/A= heavy chain translocation domain of BoNT/A; 
HCN/A= heavy chain C-terminal binding domain of BoNT/A; LC/D = light 
chain of BoNT/D; HN/D= heavy chain translocation domain of BoNT/D; 
HCN/D= heavy chain C-terminal binding domain of BoNT/D; L = linker, S-S = 
disulfide bond; scFv = single-chain variable fragment; His6 = histidine tag. 
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2.2.7.2 Analysis of expression and purity of BoNT/A(or/D)-rabbit anti-P2X3 
scFv fusion via SDS-PAGE and Western blotting 
 
A 160 µg quantity of BoNT/A(or/D)-rabbit anti-P2X3 scFv fusion (in a total 
volume of 20 µL) in 1 x LDS loading buffer was added into each well of 
4-12% (v/v) precast Bis-Tris gel (Invitrogen). The gels were placed in an 
electrophoresis apparatus and submerged in electrophoresis buffer. The 
electrophoresis buffer was prepared using 50 mM MOPS, 50 mM Tris, pH 8.3, 
1 mM ethylenediaminetetraacetic acid (EDTA) and 0.1% (w/v) SDS. The 
apparatus is attached to a power supply and a voltage of 200 V applied to the 
gel. The gels were allowed to run until the tracker dye had reached the bottom 
of the gel. The gels were taken out and stained using Coomassie stain [0.2% 
(w/v) Coomassie blue R-25, 45% (v/v) methanol, 45% (v/v) water, 10% (v/v) 
acetic acid] for 1-2 hours. Finally, the stained gels were destained overnight 
using Coomassie blue destain [10% (v/v) acetic acid, 25% (v/v) methanol, 65% 
(v/v) water], changing the destain several times.  
For Western blotting, proteins were transferred from the gel to a PVDF 
membrane at 250 mA for 2.5 hours. The membrane was blocked with 5% (w/v) 
TBSTM for one hour at room temperature. As His-tag was located in the 
C-terminal of BoNT/A(or/D)-rabbit anti-P2X3 scFv fusion (Fig. 2.4), complete 
His-tag expression may indicate successful and complete expression of the 
fusion. Therefore, HRP-labelled anti-His antibody (1:500 dilution) was added 
as secondary antibody (detect BoNT/A(or/D)-rabbit anti-P2X3 scFv fusion) and 
incubated at room temperature for one hour. The membrane was washed three 
times with 1 x TBST for 5 min, and TMB (0.4 g/L) was added for visualisation. 
When the bands appeared, the membrane was washed with ddH2O to stop the 
reaction. A picture was taken using the G:BOX Gel & Blot Imaging Series. 
 
2.2.7.3 Western blot analysis of BoNT/A(or/D)-rabbit anti-P2X3 scFv 
specificity to rat DRG-expressed P2X3 
 
After DRG cells were grown in 24 wells plate for 4 days, the membrane 
proteins were enriched, as described in section 2.2.4.3. A 160 µg quantity of 
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DRG membrane protein (in a total volume of 20 µL) was added into each well 
of a 4-12% precast Bis-Tris gel (Invitrogen). The gel was resolved at 170 volts 
for about one hour until the blue tracker dye reached the bottom of the gel. The 
proteins on the gel were transferred to a PVDF membrane at 250 mA for 2.5 
hours. The membrane was blocked in 5% (w/v) TBSTM for one hour at room 
temperature. Purified BoNT/A(or/D)-rabbit anti-P2X3 scFv was used as the 
primary antibody and incubated overnight at 4°C. The membrane was washed 
three times with TBST for 5 min. The His-tag was located in the C-terminal of 
BoNT/A(or/D)-rabbit anti-P2X3 scFv fusion (Fig. 2.4), hence, complete 
His-tag expression may indicate successful and complete expression of the 
fusion. Therefore, HRP-labelled anti-His antibody (1:500 dilution) was added 
as secondary antibody (detect BoNT/A(or/D)-rabbit anti-P2X3 scFv fusion) and 
incubated at room temperature for 1 hour. The PVDF membrane was washed 
three times with TBST for 5 min and then developed by addition of 1 mL of 
TMB (0.4 g/L) to the membrane until the bands appeared. The membrane was 
washed with ddH2O to stop the reaction. An image was taken using the G:BOX 
Gel & Blot Imaging Series. 
 
2.2.7.4 Activity of BoNT/A(or/D)-rabbit anti-P2X3 scFv fusion 
 
2.2.7.4.1 Analysis of BoNT/A(or/D)-rabbit anti-P2X3 scFv fusion inhibition 
K
+
-evoked release of CGRP and SP from rat cultured DRG neurons 
 
After DRGs were cultured 7 days in vitro, medium was gently aspirated from 
DRG cell cultures. Different concentrations of anti-P2X3 scFv antibody-BoNT 
fusion (1.6, 8, 40 200 and 1000 nM) were added to the rat DRG cultures and 
incubated for 24 hours at 37°C in 5% (v/v) CO2. The cells were washed three 
times with 0.5 mL/well basal release (low K+) buffer [22.5 mM HEPES, 135 
mM NaCl, 3.5 mM KCl, 1 mM MgCl2, 2.5 mM CaCl2, 3.3 mM glucose, BSA 
(0.1%, w/v), pH 7.4] and incubated in 0.5 mL of basal release buffer at 37°C in 
5% (v/v) CO2 for 5 min to get the basal release samples. The basal release 
samples were then collected into sterile 1.5 mL EP tubes, followed by added 
0.5 mL of high K+ buffer [22.5 mM HEPES, 76 mM NaCl, 60 mM KCl, 1 mM 
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MgCl2, 2.5 mM CaCl2, 3.3 mM glucose, BSA (0.1%, w/v), pH 7.4] into each 
well and incubated at 37°C in 5% (v/v) CO2 for 5 min to stimulate K
+-evoked 
(Ca2+-dependent) release. The stimulated release samples were collected into 
sterile 1.5 mL EP tubes. 
 
2.2.7.4.2 Enzyme immuno-assay (EIA) of calcitonin gene-related peptide 
(CGRP) 
 
This enzyme immuno-assay (EIA) was based on a double-antibody sandwich 
technique that permits measurement of calcitonin gene-related peptide (CGRP) 
within the range of 1-500 pg/mL. The wells of the plates supplied with the kits 
were coated with a monoclonal antibody specific for CGRP. This monoclonal 
antibody binds CGRP (100 µL per well) added in the wells (samples and 
standards supplied with the kits). This was followed by addition of an 
acetylcholinesterase (AChE)-Fab conjugate (anti-CGRP AChE tracer) (100 µL 
per well) which binds to an epitope on the CGRP molecule This allowed the 
two antibodies to form a sandwich by binding of different epitopes of the 
CGRP molecule, which remained immobilised on the plate. The excess 
reagents were then removed by washing five times with wash buffer (300 µL 
per well) supplied in the kit. The concentration of CGRP was then determined 
by measuring the enzymatic acitivity of the AChE using Ellman’s reagent, 
which contains acetylthiocholine as substrate. The final product of the 
enzymatic reaction, 5-thio-2-nitrobenzoic acid, is bright yellow and its 
absorbance can be determined at 405-420 nm. The intensity of the yellow 
colour, determined spectrophotometrically, is proportional to the amount of the 
CGRP present in the well. 
For determining the amount of released CGRP, 0.1 mL of sample or standard 
was added to the plate (supplied with kit) followed by 0.1 mL of CGRP-tracer 
solution and incubated at 4°C overnight. After the plate was washed five times 
with wash buffer (300 µL per well) supplied in the kit, Ellman’s reagent (200 
µL per well) was added and incubated in dark at room temperature for 30 min. 
The absorbances of the wells were read at 405 nm using a Safire 2 plate reader. 
For data analysis, a standard curve was generated for each assay and the 
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best-fit line through the points drawn using Excel software. Concentrations of 
released CGRP were then calculated from the linear range of the standard 
curve. 
 
2.2.7.4.3 Analysis of SNAP-25 and VAMP2 cleavage in cultured DRGs for 
BoNT/A-anti-P2X3-scFv and BoNT/D-anti-P2X3-scFv 
 
After being exposed to different concentrations of anti-P2X3 scFv 
antibody-BoNT fusion (1.6, 8, 40 200 and 1000 nM) and being treated with 
basal and stimulated release buffers in section 2.2.7.4.1, DRGs (same DRGs is in 
section 2.2.7.4.1) were harvested by scraping from the wells of cell culture plate 
using LDS buffer (60 µL per well). 
Western blot analysis was performed to check SNAP-25 and VAMP2 using the 
protocol described in section 2.2.3.17, with mouse anti-SNAP-25 antibody 
(SMI-81; 1:1,000 dilution) or mouse anti-VAMP IgM monoclonal antibody (V2; 
1:1,000 dilution) as the primary antibody followed by HRP-labelled goat 
anti-mouse secondary antibody (1:1,000 dilution).  
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Chapter 3 
 
Isolation and Culturing of Rat 
Dorsal Root Ganglion Cells 
(DRGs) 
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3.1 Introduction  
 
In this chapter, a description is given of culturing dorsal root ganglion cells 
(DRGs), including their expression of sensory neuron markers and P2X 
purinoceptor 3 (P2X3), and their susceptibility to botulinum neurotoxin type A 
and type D BoNT/A and BoNT/D. Successful establishment of rat DRG cell 
cultures was demonstrated by their expression of peptidergic sensory neuron 
markers and targeting was achieved by use of an anti-P2X3 receptor antibody.  
DRGs are among the most common and major sensory neurons in vertebrata 
(Bessac et al., 2008). It was reported that inflammation can activate multiple 
intracellular signalling pathways in DRGs. During persistent inflammatory 
pain, DRGs were found to be sensitized by a majority of identified signalling 
cascades (Kallenborn and Schmidtko, 2011).  
BoNT/A and BoNT/D are two different types of BoNT. BoNT/A was shown to 
be a promising means of treating inflammatory pain (Mahowald et al., 2009). 
BoNT/D inhibits inflammatory pain peptide calcitonin gene-related peptide 
(CGRP) release in cultured sensory neurons (Meng et al., 2007).  
P2X3, one of purinergic receptors, plays a crucial role in signalling that leads to 
chronic inflammatory pain. Anti-P2X3 antibody can be used as a targeting 
agent to deliver BoNT to pain-signalling neurons.  
Rat neurons are sensitive to BoNT (Foran et al., 2003; Meng et al., 2007). Rat 
animal pain models are stable (Kim et al., 1997), easily dissected and readily 
cultured with sufficient dorsal root ganglions (60 pairs) with large size 
(20-51µm). A high percentage of rat DRGs express P2X3 receptor on postnatal 
day seven (P7) and 72.6 ± 3.4% of DRGs were identified as P2X3 
receptor-positive cells (Ruan et al., 2004). Thus, rat DRGs were chosen for 
analysis of the antibody specificity and targeting ability to P2X3, and for the 
capacity of delivering BoNT endopeptidase and the resultant inhibition of 
transmitter release in vitro. 
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3.2 Results 
 
3.2.1 Images for morphology of cultured rat DRGs using 
immunofluorescent staining and microscopic examination  
 
3.2.1.1 Phase contrast microscopy of rat DRGs 
 
Using the phase contrast mode of the Olympus IX71 microscope, DRGs 
isolated from postnatal day 5 (P5) rats and cultured in DMEM medium, as 
described in section 2.2.4.1 and 2.2.4.2, were easily recognised by the presence 
of large, opaque and round cell bodies with fine neuritis (Fig. 3.1, 1DIV). After 
seven days in vitro (7 DIV), cells were pure and mature compared with DRGs 
of earlier stages, with less satellite cells and astrocytes, but with extensive 
neuritis, which can be observed using the Olympus IX71 inverted microscope 
(Fig. 3.1, 7 DIV). 
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Fig. 3.1 Visualization of the DRG cell culture process after plating for periods 
of 4 hours to 7 days in 24-well cell culture plates. DRGs were isolated from P5 
rats and cultured from four hours to 7 DIV. Original magnification x 20; scale 
bars are 50 µm. 
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3.2.1.2 Identification of DRGs by specific antibodies for neuron and 
nociceptive markers 
 
3.2.1.2.1 DRGs display neuron-specific proteins 
 
In order to prove that the cultured cells were enriched with nerve cells, the cells 
were stained using anti-neurofilament (NF) heavy chain antibody, which is 
specific to neurons, as described in section 2.2.4.4. The high majority of all 
cultured cells were successfully stained by anti-NF antibody (Fig. 3.2) 
indicating that the cultured cells were neuronal in origin. 
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Fig. 3.2 Demonstration of the presence of neurofilament (NF) in rat DRG 
culture by immunofluorescent staining. Images were viewed in an Olympus 
IX71 inverted microscope by both phase contrast (B, D) and in epifluorescence 
mode (A, C). Rat DRGs grown in 24 wells plate for 6 days in vivo (6 DIV) 
were fixed, permeabilised and then stained by mouse anti-NF antibody (1:500 
dilution), followed by Cy2-labelled goat anti-mouse IgG (1:100 dilution) (A). 
For control, rabbit anti-goat IgG (1:1,000 dilution) was added instead of NF 
antibody, followed by secondary antibody Alexa Fluor-546-labelled goat 
anti-rabbit polyclonal antibody (1: 200 dilution) (C). Original magnification x 
20; scale bars are 50µm. 
 
3.2.1.2.2 DRGs display sensory neuron specific proteins 
 
To demonstrate that the cultured cells were sensory nerve cells, the cells were 
stained with anti-calcitonin gene-related peptide (CGRP) antibody, which is 
A B 
C D 
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specific to sensory nerve cell, as described in section 2.2.4.4. Fig. 3.3 showed 
that the cells were successfully stained by anti-CGRP antibody, and thus 
indicated that the cultured cells were sensory nerve cells in origin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.3 Demonstration of the presence of anti-calcitonin gene-related peptide 
(CGRP) in rat DRG culture (P5, 5 DIV) by immunofluorescent staining. 
Images were viewed in an Olympus IX71 inverted microscope by both phase 
contrast (B, D) and in epifluorescence mode (A, C). Rat DRGs grown in 24 
wells plate for 6 days in vivo (6 DIV) were fixed, permeabilised and then 
stained by rabbit anti-CGRP antibody (1:500 dilution), followed by Alexa 
Fluor-488-labelled goat anti-rabbit IgG (1:200 dilution) (A). For control, rabbit 
anti-goat IgG (1:1,000 dilution) was added instead of CGRP antibody, 
followed by secondary antibody Alexa Fluor-488-labelled goat anti-rabbit IgG 
(1:200 dilution) (C). Original magnification x 20; scale bars are 50 µm. 
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3.2.2 Demonstration of P2X3 expression in cultured rat DRGs using 
commercial anti-P2X3 antibody 
 
3.2.2.1 P2X3 expression on cultured rat DRGs  
 
Cultured DRGs (P7, 7 DIV) were fixed, permeabilized and blocked, as 
described in section 2.2.4.5. Then rabbit anti-rat P2X3 polyclonal antibody 
(1:50 dilution) was applied, followed by secondary antibody Alexa 
Fluor-546-labelled goat anti-rabbit polyclonal antibody (1:200 dilution). Strong 
and punctate red fluorescence signal was shown on cell bodies and their 
extensive neurites (Fig. 3.4), as reported by Kaan et al. (2010), demonstrating 
that P2X3 is expressed in these DRGs. 
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Fig. 3.4 Immunofluorescent staining of cultured DRG by P2X3 antibody. 
Samples were viewed in an Olympus IX71 inverted microscope by both phase 
contrast (B, D) and in fluorescence mode (A, C). Rat DRGs, grown in 24 wells 
plate for 7 days in vivo (7 DIV), were fixed and stained by rabbit anti-rat P2X3 
polyclonal antibody (1:50 dilution), followed by secondary antibody Alexa 
Fluor-546-labelled goat anti-rabbit polyclonal antibody (1: 200 dilution). For 
control, rabbit anti-goat IgG (1:1,000 dilution) was added instead of anti-P2X3 
antibody, followed by secondary antibody Alexa Fluor-546-labelled goat 
anti-rabbit polyclonal antibody (1: 200 dilution) (C, D). Original magnification 
x 20; scale bars are 50 µm. 
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3.2.2.2 P2X3 expression on DRGs culture detected using immunoblot 
analysis 
 
Cultured DRGs (P7, 7 DIV) were harvested and lysed, as described in section 
2.2.4.3. Lysed samples were loaded and run on a SDS-PAGE gel, and the 
proteins transferred to a PVDF membrane, as described in section 2.2.3.17.1, 
for Western blotting. Rabbit anti rat-P2X3 polyclonal antibody (1:300 dilution) 
was applied to the membrane, followed by HRP-labelled anti-rabbit secondary 
antibody (1:2,000 dilution). A strong band at the expected size of P2X3 (50-55 
kDa) is shown indicating that P2X3 was expressed by cultured DRGs (Fig. 3.5; 
A and B). 
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Fig. 3.5 Western blot analysis of DRGs for P2X3 (50-55 kDa) expression. 
DRGs were isolated from postnatal day 5 rats and cultured for 2 or 5 days in 
vitro before harvesting in SDS sample buffer and analysis by SDS-PAGE and 
Western blotting (400 µg protein lysate per lane). After Western blotting, the 
membranes were stained by rabbit anti rat-P2X3 polyclonal antibody (1:300 
dilution), followed by HRP-labelled anti-rabbit secondary antibody (1:2,000 
dilution) (Fig. 3.5 A). For the negative control, rabbit anti-goat IgG (1:1,000 
dilution) was added instead of anti-P2X3 antibody, followed by followed by 
HRP-labelled anti-rabbit secondary antibody (1:2,000 dilution) (Fig. 3.5 B). 
DIV = days in vitro and MW = molecular weight markers. 
 
3.2.3 Sensitivity of DRGs to BoNT 
 
3.2.3.1 Demonstration that cultured DRGs are sensitive to BoNT/A 
 
Different concentrations of BoNT/A (0, 10, 100 and 1,000 nM) were added 
into rat DRGs cultures (P5, 6 DIV) and incubated for 24 hours at 37°C in 5% 
(v/v) CO2, as described in section 2.2.4.6. Initially, the sensitivity of DRGs to 
BoNT/A was observed by cleavage of its intracellular substrate, SNAP-25, 
P2X3
(50-55 kDa)
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using anti-SNAP-25 antibody (SMI-81) which detects both cleaved SNAP-25 
(~ 25 kDa) and full length SNAP-25 (~ 27 kDa) (Morris et al., 2002). Another 
SNARE protein, syntaxin 1 (~ 35 kDa) was simultaneously detected by mouse 
anti-syntaxin-1 antibody (HPC-1) and was used as an internal control due to 
the lack of cleavage. The generation of the cleaved form of SNAP-25 
demonstrated that cultured DRGs were sensitive to BoNT/A (Fig. 3.6).  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.6 Western blot analysis of cleavage of SNAP-25 by BoNT/A in cultured 
rat DRGs. After Western blotting, the membrane was stained by mouse 
anti-SNAP-25 antibody (SMI-81; 1:1,000 dilution) and mouse anti-syntaxin-1 
antibody (HPC-1; 1:1,000 dilution), then followed by addition of alkaline 
phosphatase-conjugated anti-mouse IgG (1:5,000 dilution) secondary antibody. 
Syntaxin 1 was used as an internal control. The SNAP-25 cleaved form (~ 24 
kDa; lower band) was enhanced with increasing concentration of BoNT/A-2T 
from 0 to 1,000 nm. MW = molecular weight markers. 
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3.2.3.2 Sensitivity of cultured DRGs to BoNT/D 
 
Rat DRGs, cultured for 5 days in vivo, were incubated with BoNT/D for 24 
hours to cleave vesicle-associated membrane protein (VAMP2), a pain-related 
protein. Cells were then solubilized in 2 x LDS sample buffer and subjected to 
SDS-PAGE and Western blotting, as described in section 2.2.4.6. The 
sensitivity of the DRG to BoNT/D was also successfully observed by the 
presence of VAMP2 (~ 18 kDa) cleavage detected using mouse anti-VAMP2 
antibody (V2). Another SNARE protein, syntaxin 1 (~ 35 kDa) was 
simultaneously detected by mouse anti-syntaxin-1 (HPC-1) used as an internal 
control due to the lack of cleavage. Fig 3.7 shows the absence of VAMP2 
following exposure to 1000 nM BoNT/D and a significant reduction when 
treated with 100 nM BoNT/D compared to 10 nM and 0 of BoNT/D, indicating 
that VAMP2 is cleaved by BoNT/D.  
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Fig. 3.7 Western blot analysis of cleavage of VAMP2 by BoNT/D-2T in 
cultured rat DRGs. After Western blotting, the membrane was stained by 
mouse anti-VAMP2 (V2; 1:10,000 dilution) and mouse anti-syntaxin-1 
antibody (HPC-1; 1:1,000 dilution), followed by addition of alkaline 
phosphatase-conjugated anti-mouse IgG (1:5,000 dilution) secondary antibody. 
VAMP2 levels were reduced with increased concentrations of BoNT/D-2T (0 
to 1,000 nM). MW = molecular weight markers. 
 
3.3 Discussion 
 
The dissection, isolation and culturing of rat DRGs was difficult with several 
attempts required before success was achieved. It was also important to choose 
rat pups of the correct age. Postnatal days five to seven was found to be the 
optimal age range since pups which were less than postnatal day five had 
DRGs of tiny size and nearly transparent colour, making them difficult to see 
and, therefore, to dissect. However, pups more than postnatal day seven 
expressed less P2X3 in their DRGs with the percentage of P2X3- 
immunopositive DRG cell bodies decreasing from 72.6 ± 3.4 to 44.3 ± 3.5 
(Ruan, 2004).  
The cultured cells from rat dorsal root ganglions were shown to successfully 
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express sensory neuron markers and the P2X purinoceptor 3 (P2X3), which 
indicated that the cultured cells are DRGs. Over 70% of the cells stained 
positively for P2X3, which is consistent with the reported value of 72.6 ± 3.4% 
(Ruan, 2004).  
Cultured DRGs have been proven to be an ideal in vitro pain model through 
evaluation of cleavage of SNAP-25 or VAMP2 (Morenilla-Palao et al., 2004; 
Meng et al., 2007). The cultured DRGs showed sensitivity to BoNT/A and 
BoNT/D, by cleavage of pain-related proteins SNAP-25 and VAMP2, which 
implies that the cultured rat DRGs may be suitable as an in vitro model for 
investigating the specificity and effect of this new targeted therapeutic (i.e. use 
of anti-P2X3 antibody as a targeting agent to deliver BoNT/A/D to 
pain-signalling neurons for inhibiting inflammatory pain peptides).  
For further applications, for instance, analysis of anti-P2X3 antibody specificity, 
the polyclonal anti-P2X3 antibody and recombinant anti-P2X3 scFv antibodies 
can be applied to cultured rat DRGs to prove their specificity to P2X3 (expressed 
in rat DRGs) via Western blotting and immunofluorescence (Sokolova et al., 
2004; Liu et al., 2011); for evaluation of BoNT-antibody efficacy, 
BoNT-polyclonal anti-P2X3 antibody conjugates and the BoNT-anti-P2X3 scFv 
fusion will be applied to cultured rat DRGs for analysis of cleavage of 
pain-related proteins SNAP-25 and VAMP2 via Western blotting, as described 
by Meng (2009). The availability and use of cultured DRGs makes the further 
analysis of novel treatment of pain possible.
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Chapter 4 
 
Generation of Anti-P2X3 
Antibodies
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4.1 Introduction 
 
P2X3, a member of the family of purinoceptors for ATP, is involved in 
inflammatory pain signalling. Cockayne and colleagues found that after an 
intraplantar injection of formalin into P2X3-knock-out mice reduced pain 
behaviour, such as hind paw licking and lifting, was displayed (Cockayne et al., 
2000). It was subsequently suggested that P2X3 may provide a promising 
delivery target for inflammatory pain treatment (North, 2003). P2X3 is a 
transmembrane protein and hence, anti-P2X3 antibodies required for 
inflammatory pain therapy should be against the P2X3 extracellular domain 
(Val60-Phe301) in order to target P2X3 on neuron cell bodies. Therefore, 
anti-P2X3 antibody and the associated drug complex could enter into the pain 
signalling pathway as a treatment strategy (Koshimizu et al., 2002).  
This chapter describes the generation of polyclonal and recombinant antibodies 
to the extracellular domain of P2X3 in rabbits, mice and chickens following 
immunization with P2X3. 
Two human extracellular P2X3 peptides (P2X3-60: Val60-Asp79 and P2X3-257: 
Ile257-Pro276) were identified (section 2.1.6.1) and then subsequently 
conjugated to bovine serum albumin (BSA), keyhole limpet hemocyanin 
(KLH), biotin and bovine thyroglobulin (bTg). Both P2X3-257-BSA and 
P2X3-60-BSA conjugates were used to immunise two rabbits (CKPH and 
DARP) and high serum titres were achieved (Table 3.1). In addition, 
P2X3-257-BSA and P2X3-60-BSA conjugates were used to immunise a group 
of three mice per conjugate. After the final boost, each mouse had shown a 
sufficient immune response with high serum titres (Table 3.1). These mice 
were then sacrificed and RNA was extracted from the spleens. This genetic 
material was used to generate a mouse scFv library. 
Four chickens were also immunised with P2X3-257-BSA or P2X3-60-KLH 
conjugates, but failed to provide an adequate immune response. 
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Table 4.1 Antibody titre of rabbits, mice and chickens immunised with 
P2X3-257/60. 
 
 
 
 
Immunised animal Serum titre to 
P2X3-257-biotin  
Serum titre to 
P2X3-60-biotin  
Rabbit-CKPH (immunised with 
both P2X3-257/60) 
1:20,000 1:10,000 
Rabbit-DARP (immunised with 
both P2X3-257/60) 
1:20,000 1:4,000 
Mouse number 1 (immunised 
with P2X3-60) 
--- 1:20,000 
Mouse number 2 (immunised 
with P2X3-60) 
--- 1:40,000 
Mouse number 3 (immunised 
with P2X3-60) 
--- 1:40,000 
Mouse number 4 (immunised 
with P2X3-257) 
1:200,000 --- 
Mouse number 5 (immunised 
with P2X3-257) 
1:200,000 --- 
Mouse number 6 (immunised 
with P2X3-257) 
--- --- 
Chicken number 1 (died before 
any injection) 
--- --- 
Chicken number 2 (immunised 
with P2X3-60) 
--- --- 
Chicken number 3 (immunised 
with P2X3-257) 
--- --- 
Chicken number 4 (immunised 
with P2X3-257) 
--- --- 
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RNA was extracted from both the spleen and bone marrow of rabbits, cDNA 
synthesis performed, and it was used to generate scFv libraries. These were 
then screened for scFvs specific to P2X3 using phage display. Five rounds of 
iterative bio-panning were performed and up to 52% of positive colonies were 
screened with P2X3-257-biotin. Some P2X3-positive colonies without cross 
reactivity to neither carrier protein (BSA and KLH) or ELISA-test protein 
(neutravidin) were picked for DNA sequencing. ELISA, Western blotting and 
immunofluorescence-based staining were performed to choose positive 
colonies with high antibody titres, IC50 and high specificity to P2X3.  
 
4.2 Results 
 
4.2.1 Production of rabbit polyclonal antibodies 
 
4.2.1.1 Titres and competitive ELISA of sera from New Zealand white 
rabbits (designated DARP and CKPH) 
 
The rabbit immunisation procedure was followed, as described in section 
2.2.1.1. Rabbit bleeds were taken seven days after the final boost and the serum 
anti-P2X3 titre was performed using a direct ELISA format to detect IgG 
antibodies against the two P2X3 extracellular domains, P2X3-257 and P2X3-60 
(section 2.1.6.1). Serum antibody titres were determined (the serum dilutions 
required to produce an absorbance three times greater than the background 
signals of pre-bleed serum, neutravidin, KLH and BSA). For rabbit-CKPH, the 
serum titre against P2X3-60 was 1:10,000 (Fig. 4.1a) and 1:20,000 against 
P2X3-257. For rabbit-DARP, the titre against P2X3-60 was 1:4,000 and against 
P2X3-257 was 1:20,000 (Fig. 4.1b).  
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Fig. 4.1a Rabbit anti-P2X3-60/257 antibody for titre after the fourth boost 
(P2X3-60/257-biotin was applied for screening). An ELISA plate was coated 
with 5 µg/mL P2X3-257-biotin conjugate. For competition, various dilutions of 
rabbit sera were added, followed by HRP-labelled anti-rabbit secondary 
antibody. Sera were diluted in 1% (w/v) BSA and 0.1% (w/v) KLH to ‘deplete’ 
potential cross reacting antibodies. The titre was 1:10,000 against P2X3-60 and 
1:20,000 against P2X3-257.  
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Fig. 4.1b Anibody titre to P2X3-257 for rabbit-DARP after the fifth boost 
(P2X3-60/257-biotin was applied for screening). An ELISA plate was coated 
with 5 µg/mL P2X3-257-biotin conjugate. For competition, various dilutions of 
rabbit sera were added, followed by HRP-labelled anti-rabbit secondary 
antibody. Sera were diluted in 1% (w/v) BSA and 0.1% (w/v) KLH to ‘deplete’ 
potential cross reacting antibodies. The titre was 1:4,000 against P2X3-60, and 
1:20,000 against P2X3-257. 
 
To verify that the rabbit polyclonal antibody response for the injected P2X3 
(P2X3-257) was also competitive, competitive ELISA with free P2X3-257 and 
P2X3-60 peptides was performed using the polyclonal sera (section 2.2.1.5). 
ELISA analysis revealed that the rabbit antibodies were competitive, which 
was shown by major reduction in signal in the presence of free competing 
peptide (Fig. 4.1c).  
All of the titres and competitive ELISA results indicated a high level of 
specific mRNA for the creation of a recombinant anti-P2X3-257 antibody 
library. However, there was a very low level titre against P2X3-60. Thus, 
P2X3-257 was chosen as the target for further experiments.  
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Fig. 4.1c Competitive ELISA analysis of rabbit sera specificity to P2X3-60/257 
after the fourth boost for CKPH and after the fifth boost for DARP. An ELISA 
plate was coated with 5 µg/mL P2X3-257-biotin conjugate. For competition, 
the P2X3-257/60 free peptide (25 µg/mL) was added to a fixed dilution (the 
dilution of P2X3-257 was 1:20,000; the dilution of P2X3-60 was 1:5,000) of 
sera. Sera were dissolved in 1% (w/v) BSA and 0.1% (w/v) KLH. HRP-labeled 
anti-rabbit IgG was applied as secondary antibody. Rabbit sera were shown to 
have antibody specific to P2X3-60/257, which was demonstrated by a large 
decrease in signal response in the presence of free competing peptide. The 
results are the mean ± standard deviation (S.D.), where n = 3. 
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4.2.1.2 Purification and analysis of rabbit anti-P2X3 polyclonal antibodies 
 
Rabbit serum was purified using both Protein A and streptavidin-agarose (used 
to bind P2X3-257/60-biotin to make a P2X3-257/60 specific column), 
polyclonal IgG antibodies (pAbs) (section 2.2.2.1-2) and fractions containing 
protein were analysed using SDS-PAGE and Western blotting. SDS-PAGE 
indicated a high level of IgG purity after purification by the presence of two 
single bands, i.e. the light chain (~25 kDa) and heavy chain (~50 kDa) (Fig. 
4.2a). Western blotting showed the purified IgG was specific to P2X3 indicated 
by a P2X3 specific band (Fig. 4.2b). In total, 8.67 mg of purified rabbit 
anti-P2X3 IgG (1.7 mg/mL) were obtained. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.2a SDS-PAGE analysis of rabbit (DARP) serum purified by protein 
A-sepharose followed by streptavidin-agarose resins. After purification, a high 
level of IgG purity was indicated by the presence of two single bands; the light 
chain (~25 kDa) and the heavy chain (~50 kDa). MW = molecular weight 
markers. 
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Fig. 4.2b Western blot analysis of polyclonal anti-P2X3 antibodies specificity 
by applying rat DRG-expressed P2X3. DRG samples were harvested from 2 
days in vitro (2 DIV) culture. After Western blotting, the membranes were 
stained by purified anti-P2X3 Ab (1:200 dilution), followed by HRP-labelled 
anti-rabbit secondary antibody (1:2,000 dilution). For the positive control, 
commercial anti-P2X3 antibody was applied. For the negative control, rabbit 
anti-goat IgG (1:1,000 dilution) was added as the primary antibody instead of 
the anti-P2X3 antibody. MW = molecular weight markers. 
 
4.2.1.3 Examination of purified rabbit anti-P2X3 polyclonal antibody 
specificity to rat DRG-expressed P2X3 
 
In order to analyze the specificity of rabbit anti-P2X3 polyclonal antibodies to 
P2X3 on rat DRG cells, DRG cultures grown in 24 wells plate for 5 days were 
fixed and incubated with rabbit anti-P2X3 polyclonal antibodies, followed by 
addition of Alexa Fluor-488-labelled goat anti-rabbit secondary antibody 
(section 2.2.2.5.2). Samples were then viewed in an inverted microscope under 
both phase contrast and fluorescence modes using an Olympus IX71 
microscope. Immunofluorescence staining further indicated purified IgG was 
specific to P2X3 on DRG cultures by green fluorescence evident on DRG cell 
bodies. A similar result was shown with commercial rabbit anti-P2X3 
polyclonal antibody-stained DRG cells (Fig. 4.3). For the negative control, 
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anti-goat IgG was added as primary antibody instead of anti-P2X3 antibody, 
and no DRG cells were stained as no green florescence was observed. 
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Fig. 4.3 Immunofluorescence-based microscopic analysis of anti-P2X3 
antibody binding in rat DRG culture cells (P4, 5 DIV). Samples were viewed in 
an inverted microscope by phase contrast (B, D and F) and in fluorescence 
modes (A, C and E). Rat DRG cells grown in 24 wells plate for 5 days were 
fixed, permeabilised and then stained by purified anti-P2X3 pAbs (3.2 µg/well), 
followed by Alexa Fluor-488-labelled goat anti-rabbit secondary antibody 
(1:200 dilution) (E and F). For the negative control (A and B), anti-goat IgG 
(1:1,000 dilution) was added as primary antibody instead of anti-P2X3 antibody 
(A and B). For positive control, commercial rabbit anti-P2X3 Ab (1:50 dilution) 
was added instead of polyclonal anti-P2X3 antibody (C and D). Original 
magnification x 20; scale bars are 50 µm. 
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4.2.1.4 Competitive ELISA analysis to determine the half-maximal 
inhibitory concentration (IC50) of anti-P2X3 polyclonal antibodies 
 
In order to compare the binding of anti-P2X3-257 IgG (after purification) with 
recombinant anti-P2X3-257-scFv (which will be generated later), the 
half-maximal inhibitory concentration (IC50) was measured by competing 
immobilised P2X3-257-biotin with solution-phase P2X3-257.  
Anti-P2X3-257 IgG was purified and the concentration of anti-P2X3-257 IgG 
with an absorbance of approximately 1.00 was chosen as the primaryantibody 
(anti-P2X3-257 IgG) concentration for competitive ELISA. The binding 
activity was evaluated by the IC50: the concentration at which half-maximal 
inhibition of antibody-antigen interactions by competing antigen is achieved. 
With indirect competition ELISA, the value of IC50 for anti-P2X3-257 Ig was 
approximately 20,000 ng/mL (Fig. 4.4). 
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Fig. 4.4 Competitive ELISA analysis of IC50 of purified anti-P2X3 polyclonal 
antibody. An ELISA plate was coated with 5 µg/mL P2X3-257-biotin 
conjugate. The plate was blocked with 5% (w/v) milk in PBST. The P2X3-257 
free peptide was added at varying concentrations to a fixed concentration (400 
µg/mL) of purified anti-P2X3-257 Ig. This mixture (100 µL per well) was 
incubated for one hour at 37°C, followed by addition of HRP-labelled 
anti-rabbit secondary antibody (1:1,000 dilution). The IC50 for anti-P2X3-257 
Ig was approximately 20,000 ng/mL (8.70 nM). The results are the mean ± 
standard deviation (S.D.), for n=3. 
 
4.2.1.5 Biotinylated anti-P2X3 polyclonal antibodies specific to rat DRGs 
expressed P2X3 
 
Conjugation of rabbit anti-P2X3 polyclonal antibodies to BoNT (which is 
conjugated with streptavidin) was necessary for proof of principle studies 
before fusion of anti-P2X3-scFv with BoNT. The rabbit anti-P2X3 polyclonal 
antibodies had first to be biotinylated. After biotinylation of anti-P2X3 
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polyclonal antibodies with EZ-Link(R) micro Sulfo-NHS-LC-biotinylation kit 
(section 2.2.6.1), the specificity of biotinylated IgG to rat DRG-expressed P2X3 
was demonstrated by both Western blotting (Fig. 4.5a). Confocal microscopic 
studies were also applied to demonstrate biotinylated anti-P2X3 
antibody-specific binding to P2X3, which is a transmembrane membrane 
protein as shown, by the striking red staining which outlined the surface of the 
DRG cells (Fig. 4.5b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.5a Western blot analysis of biotinylated polyclonal anti-P2X3 Ab 
specificity on rat DRG-expressed P2X3. P2X3 was harvested from 2 days in 
vitro (2 DIV) cultures and 160 µg of protein applied per lane. After Western 
blotting, the membranes were stained by biotinylated rabbit anti-P2X3 
antibody (20 µg) and mouse anti-SNAP-25 monoclonal antibody (1:1000 
dilution), followed by HRP-labelled anti-rabbit secondary antibody (1:1,000 
dilution) and HRP-labelled anti-mouse secondary antibody (1:1,000 dilution). 
For the positive control, commercial anti-P2X3 antibody (1:300 dilution) was 
applied. For the negative control, anti-goat IgG (1:1,000 dilution) was added as 
primary antibody instead of anti-P2X3 antibody. MW = molecular weight 
markers. 
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Fig. 4.5b Confocal micrograph analysis of biotinylated anti-P2X3 antibody 
specific binding to P2X3. Rat DRG cultures grown in 24 wells plate for 5 days 
were fixed and stained by biotinylated anti-P2X3 antibody (3.2 µg/well), 
followed by Alexa Fluor-546-labelled goat anti-rabbit secondary antibody 
(1:200 dilution). Binding of the biotinylated anti-P2X3 antibody specific to rat 
DRG-expressed P2X3 (a membrane protein) was demonstrated by the striking 
red staining which clearly outlined the surface of the DRG cell body. Original 
magnification x 60.  
 
4.2.1.6 Avidin-binding activity of biotinylated rabbit anti-P2X3 polyclonal 
antibody 
 
In order to demonstrate that biotinylated rabbit anti-P2X3 polyclonal antibodies 
can bind BoNT-core streptavidin correctly, the avidin-binding activity was 
analyzed using direct ELISA. As described in section 2.2.6.2, ELISA plate was 
coated with neutravidin. A range of concentrations of biotinylated rabbit 
anti-P2X3 polyclonal antibody or commercial biotinylated chicken anti-human 
IgG was prepared and added into separate wells, followed by the HRP-labelled 
anti-rabbit secondary antibody or HRP-labelled anti-chicken antibody. For the 
negative control, rabbit anti-P2X3 polyclonal antibodies were added instead of 
biotinylated antibodies. 
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The biotinylated anti-P2X3 polyclonal antibody limit of detection (LOD, three 
times greater than negative control) for neutravidin was 0.04 nM, which was 
very similar to the LOD of the commercial biotinylated anti-human antibody 
(Fig. 4.6). The avidin-binding activity of biotinylated rabbit anti-P2X3 
polyclonal antibody was then proved to be as good as the commercial source. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.6 Avidin-binding activity of biotinylated rabbit anti-P2X3 polyclonal 
antibody. A 96-well ELISA plate was coated with neutravidin (2.5 µg/mL) and 
blocked with 5 % (w/v) PBSTM. A range of concentrations (20-10,000 ng/mL) 
of biotinylated rabbit anti-P2X3 polyclonal antibody or commercial 
biotinylated chicken anti-human IgG was prepared and added into separate 
wells, followed by the HRP-labelled anti-rabbit secondary antibody (1:1,000 
dilution) or HRP-labelled anti-chicken antibody (for positive control, 1:1,000 
dilution). Both biotinylated rabbit anti-P2X3 IgG and commercial biotinylated 
anti-human IgG gave similar binding profiles demonstrating that biotinylation 
of the rabbit anti-P2X3 antibody was successfully achieved. 
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4.2.2 Generation of rabbit recombinant scFv antibodies 
 
Due to the impressive performance of the purified rabbit anti-P2X3 polyclonal 
antibody, it was decided to construct scFv recombinant libraries from the 
previously harvested bone marrow and spleen cDNA from both 
P2X3-BSA/KLH immunised rabbits (CKPH and DARP).  
In rabbit, very few antibody gene segments are rearranged and accessed during 
immune responses, which greatly reduces the number of PCR primers required 
for cloning of the entire immune repertoire (section 2.2.3.3.1). Consequently, 
each primer combination for the heavy and light chains was individually 
optimised and then combined in equimolar ratios for the SOE-PCR, which may 
lead to the overall library diversity being considerably enhanced. 
 
4.2.2.1 Rabbit variable heavy and light chain amplification optimization 
 
For rabbit CKPH, 4.8 mg spleen RNA and 1.6 mg bone marrow RNA were 
produced, and stored at -80°C. Spleen cDNA (600 µg) and bone marrow 
cDNA (445 µg) were generated and stored at -20°C. For DARP, 4.0 mg spleen 
RNA and 1.8 mg bone marrow RNA were produced and stored at -80°C. Six 
hundred µg spleen cDNA and 600 µg bone marrow cDNA was synthesized, 
and stored at -20°C. Before sacrifice, 50 mL serum was collected. 
Subsequently, the amplification of the variable heavy (VH) and variable light 
(VL) genes used rabbit spleen and bone marrow cDNA as template (Fig. 4.7). 
The VH and VL amplifications were resolved on a 1% (w/v) agarose gel and 
single bands at 386-440 bp (VH chain) and 375-402 bp (VL chain) were 
observed (Fig.4.7a and Fig.4.7b). A large-scale PCR amplification was then 
performed, using the conditions described in section 2.2.3.4, for each of the 
variable chains in their respective buffers. Following purification of the VH 
and VL chains (see section 2.2.3.5), a SOE-PCR (section 2.2.3.6) was 
employed to fuse the two chains via a serine-glycine linker (Gly4Ser)4 resulting 
in the formation of the scFv fragment.  
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Fig. 4.7a PCR amplifications for the four variable heavy chains for both rabbit 
spleen and bone marrow libraries. Lanes VH1-4 = heavy chains 1-4. 
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Fig. 4.7b Optimization of variable light (kappa) chains for both rabbit spleen 
and bone marrow. There are nine different primer combinations for rabbit 
spleen and bone marrow, respectively. Here one primer combination 
(Vκ3+42JoB) for each of rabbit spleen and bone marrow variable light (kappa) 
chain is shown. For spleen Vκ3+42JoB primer combination, 1.5 mM, 3 mM 
and 4 mM MgCl2 was tested. A concentration of 3 mM MgCl2 was selected for 
large-scale amplification as high amount of ligh chain product was already 
amplified with 3 mM MgCl2, no higher concentration of MgCl2 was needed. 
For the bone marrow Vκ3+42JoB primer combination, 0, 6% (v/v), 8% (v/v) 
and 12% (v/v) DMSO concentrations were tested. A concentration of 6% (v/v) 
DMSO was selected for large-scale amplification.  
 
4.2.2.2 SOE-PCR of variable heavy and light chains for rabbit library 
 
Purified VH and VL fragments were linked with a glycine-serine linker 
(Gly4Ser)4 by SOE primers RSC-F and RSC-B (section 2.2.3.6) via PCR to 
generate the scFv fragment (~ 800 bp). The optimization shown below 
involved using various DMSO concentrations. A 1 kb Plus DNA molecular 
weight marker was added and several DMSO concentrations [2-12% (v/v)] 
were investigated (Fig. 4.8a). The PCR mixture with a final DMSO 
concentration of 10% (v/v) proved to be the most optimal (with the clearest 
Spleen (V
κ3 + 42JoB )                          Bone marrow (Vκ3 + 42JoB )
Ladder  1.5    3     4  (mM MgCl2)            Ladder  0     6%   8%   12% (DMSO)
400 bp
400 bp
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band at the correct position, 800 bp, with less non-specific bands). This was 
therefore used for the large-scale SOE-PCR of the scFv gene.  
PComb3XSS vector was restriction digested with SfiI using the protocol 
described in section 2.2.3.7. The digested pComb vector (~ 3,400 bp) and 
Stuffer fragments (~ 1,400 bp) as well as the PCR SOE (~ 800 bp) product 
were resolved on 1% (w/v) agarose gel (Fig. 4.8b). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8a Optimization of SOE-PCR for both spleen (SP) and bone marrow 
(BM) scFv fragments. The PCR optimization was performed using a series of 
DMSO concentrations (2%, 4%, 6%, 8%, 10% and 12%). The annealing 
temperature was set at 56°C. The optimal condition selected was 10% DMSO. 
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Fig. 4.8b A large-scale SOE-PCR was performed and the PCR product was 
extracted as described in section 2.2.3.5. A clear band (~ 800 bp) in lane SP and 
BM indicated the SOE-PCR product. In lane pComb3XSS, the upper band 
between 3,000 bp and 4,000 bp indicated the pComb3XSS vector and lower 
band near 1,650 bp marker band indicated the stuffer fragment. SP = spleen, 
BM = bone marrow. 
 
4.2.2.3 Rabbit scFv library construction and subsequent enrichment via 
bio-panning 
 
SOE PCR products were gel purified, digested, and ligated into pComb3XSS 
(section 2.2.3.5-2.2.3.7), which facilitates the expression, detection and 
purification of soluble scFv during phage display. The ligated sample was 
ethanol precipitated and then transformed into electrocompetent E. coli 
XL1-Blue cells by electroporation, as described in section 2.2.3.8.  
Four transformed rabbit scFv libraries were generated and stored at -80°C. The 
rabbit-CKPH spleen scFv library size was 2.5 x 108 colony forming units 
(cfu)/mL; rabbit-CKPH spleen and bone marrow pre-mixed scFv library size: 
3.5 x 109 cfu/mL and the DARP spleen scFv library size was 5 x107 cfu/mL. 
The DARP bone marrow library size was 6.4 x 107 cfu/mL.  
800 bp
1,650 bp
3,000 bp
5,000 bp
pComb3XSS + 
stuffer
pComb3XSS
Stuffer
Ladder    SP     BM    (SOE)                                    Ladder pComb3XSS                             
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Recombinant rabbit anti-P2X3-257 scFv colonies were successfully selected 
from the rabbit-DARP scFv library by performing five rounds of phage display 
biopanning (immunotube-based and streptavidin-labelled magnetic bead-based 
biopanning) against immobilised P2X3–biotin conjugate as described in section 
2.2.3.10 (Table 4.2a-b). However, rabbit-CKPH scFv were not successfully 
obtained after five rounds of phage display biopanning with conditions shown 
in table 4.3c.  
 
Table 4.2a Immunotube-based biopanning with rabbit-DARP scFv library. 
Coated P2X3-257-biotin concentrations, phage input and output titres of each 
round of biopanning are shown. 
 
 [Neutravidin] 
nM 
[P2X3-257-biotin] 
Nm 
Input Output 
Round 1 200 400 1.03 x 1013 7.00 x 105 
Round 2 100 200 7.90 x 1012 1.30 x 106 
Round 3 20 40 4.90 x 1012 9.00 x 104 
Round 4 10 20 7.30x 1012 6.00 x 105 
 
Table 4.2b Streptavidin-labelled magnetic bead-based biopanning with 
rabbit-DARP scFv library. Coated P2X3-257-biotin concentration, phage input 
and output titres of each round of biopanning are shown. 
 
 [P2X3-257-
biotin] nM 
[P2X3-257-biotin] 
ug/mL 
Input Output 
Round 1 400 1.00 1.03 x 1013 1.80 x 106 
Round 2 200 0.50 8.10 x 1012 1.06 x 106 
Round 3 40 0.10 1.03 x 1013 4.00 x 105 
Round 4 20 0.05 1.06 x 1013 1.20 x 106 
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Table 4.2c Immunotube-based biopanning with rabbit-CKPH scFv library. 
Coated P2X3-257-biotin concentration, phage input and output titres of each 
round of biopanning are shown. 
 
 [Neutravidin] 
nM 
[P2X3-257-biotin] 
nM 
Input Output 
Round 1 10,000 20,000 5.00 x 1012 9.70 x 105 
Round 2 1,000 2,000 7.50 x 1012 1.50 x 105 
Round 3 400 800 8.60 x 1012 1.80 x 105 
Round 4 40 80 1.85 x 1013 2.00 x 105 
Round 5 20 40 4.00 x 1013 8.00 x 104 
 
Phage output titres may indicate successful enrichment of specific scFv, since 
increasing numbers of phage should remain bound to the antigen which will 
lead to higher output titres. After comparison of Table 4.3a, Table 4.3b and 
Table 4.3c, the output titres for both immunotube-based and 
streptavidin-labelled magnetic beads-based biopanning of rabbit-DARP scFv 
library (106) were almost 100 times higher than that of immunotube-based 
biopanning of rabbit-CKPH scFv library (104). This may suggest successful 
enrichment of specific scFv with rabbit-DARP scFv library, while unsuccessful 
enrichment of specific scFv with rabbit-CKPH scFv library, which needs to be 
further examined by both polyclonal and monoclonal phage ELISA. 
 
4.2.2.4 Rabbit polyclonal phage ELISA 
 
The precipitated input phage particles from each round of panning were then 
tested for P2X3-257 binding via a polyclonal phage ELISA (section 2.2.3.10). 
Phage pools were dissolved in sterile 1% (w/v) BSA and 0.1% (w/v) KLH to 
‘deplete’ potential cross-reacting scFvs. All the phage pools were analyzed 
against P2X3-257-biotin, P2X3-257-BSA, neutravidin, bovine serum albumin 
(BSA), keyhole limpet hemocyanin (KLH) (BSA and KLH were conjugated to 
immunise P2X3-257). Neutravidin, BSA and KLH-coated wells were used to 
identify cross-reactivity. 
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The scFv-displaying phage were detected using a HRP-conjugated mouse 
anti-M13 secondary antibody (1:1,000 dilution) and the absorbance read at 450 
nm following a 20 min incubation with TMB. The increase of absorbance from 
the second round (Fig. 4.9a) suggested the enrichment of P2X3-257-specific 
scFvs. Little binding was observed against neutravidin, BSA or KLH. 
The largest enrichment of anti-P2X3-257 polyclonal phage pool were detected 
in the fourth round of phage panning for both immunotube-based and 
streptavidin-labelled magnetic bead-based biopanning of the rabbit-DARP 
scFv library (Fig. 4.9a). No enrichment of anti-P2X3-257 polyclonal phage 
pool was observed for the rabbit-CKPH scFv library (Fig. 4.9b). 
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Fig. 4.9a Polyclonal phage ELISA involving all precipitated phage input 
samples from each round of panning of the rabbit DARP anti-P2X3-257 scFv 
library. The phage pools from each round of panning were tested in a direct 
ELISA format against the biotin and BSA conjugates of the target antigen 
(P2X3-257). Neutravidin, BSA and KLH were also tested as negative controls. 
Bound phage was detected with the HRP-conjugated anti-M13 secondary 
antibody and the absorbances measured at 450 nm. A significant absorbance 
signal increased in round 3 and 4 suggesting the presence of anti-P2X3-257 
scFv-phage fragments. P0 = before panning, P1-4 = phage panning round 1-4. 
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Fig. 4.9b Polyclonal phage ELISA involving all precipitated phage input 
samples from each round of panning of rabbit CKPH anti-P2X3-257 scFv 
library. The phage pools from each round of panning were tested in a direct 
ELISA format against the biotin and BSA and bTg conjugates of target antigen 
(P2X3-257). Neutravidin, BSA, KLH and bTg were used as negative controls. 
Bound phage was detected with an HRP-conjugated anti-M13 secondary 
antibody and the absorbance read at 450 nm. No significant absorbance signal 
increased in pan five suggested no presence of anti-P2X3-257 scFv-phage 
fragment. P = Phage, P0-5 = Phage from round 0-5. 
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4.2.2.5 Soluble expression, direct ELISA and inhibition ELISA of rabbit 
anti-P2X3 scFv colonies 
 
At this stage, scFvs expressed in XL1-Blue contained the geneIII product (pIII) 
which was used in phage display selection but may cause problem with scFv 
unsoluble expression. The pIII needed to be deleted for scFv soluble expression, 
which can be achieved in Top10F´ cells. Therefore, the pan 4 output phage was 
infected into Top10F´ cells (section 2.2.3.12) for analysis of solubly expressed 
scFv colonies via monoclonal ELISA (section 2.2.3.13).  
189 single colonies were then grown, solubly expressed and incorporated into a 
direct ELISA to identify scFv candidates for specificity analysis. The 
scFv-enriched lysate was tested against P2X3-257-biotin, the target protein. 
HRP-labelled anti-HA antibody (1:2,000 dilution) was added as secondary 
antibody. Figure 4.10 showed up to 51% of colonies had absorbance values 
more than three-fold higher than that of the negative controls, namely, 
neutravidin, BSA, KLH. Hence, 51% of scFv colonies have the capacity to 
bind P2X3-257.  
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Fig. 4.10 Direct soluble ELISA involving scFv-enriched lysates expressed by 
189 rabbit scFv clones against P2X3-257-biotin after 5 rounds of biopanning. 
A green horizontal line marked at the absorbance value of 0.5 indicated the 
background level (three fold of negative controls: neutravidin, BSA, KLH). 97 
positive clones were detected indicating that 51% of the total colonies showed 
positive binding against P2X3-257. Each vertical bar represents a single anti- 
P2X3-257 scFv antibody. The red circles represent the clones chosen for further 
experiment. 
 
4.2.2.6 Cross-reactivity analysis of the soluble anti-P2X3-257 scFv 
antibodies 
 
For cross-reactivity analysis, 13 positive colonies selected from the previous 
step were tested against P2X3-257-biotin, P2X3-257-BSA, neutravidin and 
BSA (section 2.2.3.13). All the 13 clones showed no cross-reactivity to the 
carrier protein (BSA) or detection protein (neutravidin), but shown specific 
binding to P2X3-257 (Fig. 4.11). 
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Fig. 4.11 ELISA analysis of cross-reactivities of anti-P2X3-257 scFv antibodies. 
Crude bacterial lysate was used as the primary antibody and HRP-labelled 
anti-HA antibody (1:2,000 dilution) was added as secondary antibody. The 
96-well plate was coated with either 2 µg/mL P2X3-257-biotin, P2X3-257-BSA, 
neutravidin or BSA. All 13 antibodies bound specifically to P2X3-257 without 
cross-reaction to BSA or neutravidin. 
 
4.2.2.7 Diversity analysis of panned rabbit scFv library via restriction 
mapping 
 
‘Restriction mapping’ of the scFv genes provided a simple method for 
analyzing the diversity of the enriched library. It involved amplification of the 
scFv gene using a ‘colony-pick’ PCR (Fig. 4.12a) to prove the 10 randomly 
picked colonies contained scFv insert fragments (~ 800 bp). The negative 
control produced no scFv insert fragments, indicating the absence of any 
potential contamination. 
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The high-frequency cutting enzymes AluI was applied for digesting each of the 
successfully amplified scFv gene products, and produced a restriction pattern 
specific to each different scFv gene sequence (Fig. 4.12b). High clonal 
heterogeneity, which was observed within the enriched library, indicated a high 
level of scFv antibody diversity (section2.2.3.14). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.12a ‘Colony-pick’ PCR showed amplification of 10 scFv gene inserts 
from rabbit anti-P2X3 scFv colonies. Lane 1 contained 1 Kb Plus DNA 
molecular weight ladder (Invitrogen), lane 2 contained the negative control 
(without scFv colony) and lanes 3-11 contained scFv insert amplifications from 
randomly selected colonies. N = negative control and lanes C1-10 = clones 
1-10. 
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Fig. 4.12b Restriction mapping profile of 10 rabbit scFv gene inserts. Lane 1 
contained 1 Kb Plus DNA molecular weight ladder (Invitrogen) and lanes 2-11 
contained scFv gene inserts cut with the high-frequency cutting enzyme AluI. 
Lanes C1-10 = clone 1-10. 
 
4.2.2.8 Sequence alignment of eleven randomly selected rabbit anti-P2X3 
scFv fragments 
 
To avoid inter-contamination of scFv colones, three of positive colones (D11, 
F10, F11 and H7) from step 3.2.2.6 were chosen for re-plating LB agar plates 
(100 g/mL carbenicillin) to obtain single colonies. After overnight incubation 
at 37°C, single coloines were picked to culture for sequencing.  
Plasmids extracted from overnight culture of single colonies D11A-D, F10A-D, 
F11A-D and H7A-D were sequenced by Source BioScience. Five colonies 
could not be sequenced (perhaps their plasmids were not successfully extracted 
or purified or they were contaminated) but the remaining eleven scFv colonies 
gave three distinctly different sequences and one heterogeneity existed in the 
complementary-determining (CDR) regions. These two sequences were then 
applied for further experiments (F11A and H7C). All the CDR regions, linker, 
His-tag, HA-tag and differences among them are shown in Fig. 4.13. 
Ladder  C1  C2  C3  C4  C5  C6  C7  C8  C9  C10 
149 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
150 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.13 Sequence alignment of 11 rabbit anti-P2X3-257 scFv antibodies. The 
three CDR regions for variable light (CDR-L) regions are highlighted in yellow; 
and variable heavy (CDR-H) regions are highlighted in gray. The 
glycine-serine linker, highlighted in red, fused the variable heavy and light 
regions together. A hexa-histidine tag (pink) and a HA epitope tag (dark green) 
were incorporated at the carboxyl (C) terminus of the scFv fragment for 
purification and characterization. Five amino acid differences (blue) were 
observed among these sequences and one difference exist in the CDR regions. 
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4.2.2.9 Anti-P2X3-257 scFv F11A and H7C purification using IMAC 
 
The two rabbit anti-P2X3-257 scFv colonies (F11A and H7C) whose sequences 
varied in the CDR regions were expressed in large-scale and then purified by 
IMAC (section 2.2.3.15). Highly pure scFv fragments from both colonies were 
obtained after IMAC purification, with little non-specific protein 
contamination as indicated by few contaminating bands (Fig. 4.14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.14 SDS-PAGE analysis of anti-P2X3-257 scFv antibody colonies (F11A 
and H7C) purified by IMAC. The elution fraction (E) contained bands of 25 
kDa (scFv), which indicated anti-P2X3-257 scFv antibody fragments were 
successfully extracted and purified. The presence of band around 25 kDa in 
lane E indicated the anti-P2X3-257 scFv antibodies were extracted and purified 
successfully. MW = molecular weight markers; F-T = ‘flow-through’; W = 
wash; E = elution. F11A and H7C = Rabbit anti-P2X3-257 scFv clone F11A 
and H7C. 
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4.2.2.10 Titres and IC50 of anti-P2X3-257 scFvs testing via ELISA 
 
The titres of anti-P2X3-257 scFvs (H7C and F11A) were analyzed using crude 
lysate against P2X3-257-biotin as described in section 2.2.3.16. The titre (three 
times greater than the background in wells containing control protein, 
neutravidin) for F11A was 1:100, and for H7C was 1:400 (Fig. 4.15a). 
The binding affinity was evaluated by IC50: (the concentration at which 
half-maximal inhibition of antibody-antigen interactions by competingantigen 
is achieved). With indirect competition ELISA (with competing free P2X3-257 
peptide), the value of IC50 for anti-P2X3-257 scFvs H7C and F11A was 
approximately 100 (0.04 nM) and 120 ng/mL (0.05 nM), respectively (Fig. 
4.15b). 
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Fig. 4.15a Direct ELISA analysis of titres of anti-P2X3-257 scFv antibody from 
colonies F11A and H7C. An ELISA plate was coated with 5 µg/mL 
P2X3-257-biotin conjugate. A series of dilutions ranging from 1:2 to 1:1,000 of 
the crude lysate were diluted in 1 x PBST. HRP-labeled anti-HA antibody 
(1:2,000 dilution) was applied as secondary antibody. The titre was 1:100 for 
F11A, and 1:400 for H7C as the titres were determined as the lysate 
dilutionrequired to produce a signal 3 times greater than the background signal. 
F11A and H7C = Rabbit anti-P2X3-257 scFv clone F11A and H7C. 
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Fig. 4.15b Competitive ELISA analysis of IC50 of anti-P2X3-257 scFv antibody 
colonies F11A and H7C. An ELISA plate was coated with 5 µg/mL 
P2X3-257-biotin conjugate and blocked with 5% (w/v) milk in PBST. Various 
concentration of P2X3-257 free peptide (2, 4, 10, 20, 40, 100, 200, 400, 1,000, 
2,000 ng/mL) was added to a fixed concentration of anti-P2X3-257 scFvs (H7C, 
10,000 ng/mL; F11A, 20,000 ng/mL). HRP-labeled anti-HA antibody was 
applied as secondary antibody. The IC50 was 100 ng/mL (0.04 nM) for H7C 
and 120 ng/mL (0.05) for F11A. F11A and H7C = two different rabbit 
anti-P2X3-257 scFv colonies. F11A and H7C = Rabbit anti-P2X3-257 scFv 
clone F11A and H7C. The results are the mean ± standard deviation (S.D.), 
where n=3. 
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4.2.2.11 Rabbit scFv stability was analysed and compared with different 
storage conditions 
 
As the H7C scFv showed a higher titre than the F11A scFv, H7C was chosen 
for further experiments. The purified H7C scFv stability was analysis by 
storage at five different conditions:  
(1) In 1 volume of glycerol at 4°C.  
(2) In 1% (w/v) BSA at 4°C.  
(3) In 10% (v/v) protein inhibitor cocktail (p.i.c.) at 4°C.  
(4) In 1% (w/v) BSA +1% (v/v) protein inhibitor cocktail at 4°C.  
(5) In 1% (w/v) BSA at -80°C.  
After analyzing scFv titre against P2X3-biotin using ELISA (section 2.2.3.18) 
on day 1, day 19, day, day 30, day 60 and day 90, scFv was proved to be stable 
for three months in conditions (1) (2) and (5), after three months, using ELISA 
against P2X3-biotin with a titre of around 1:100 (Fig. 4.16). 
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Fig. 4.16 ELISA analysis of scFv stability by titring scFv after three months. 5 
µg/mL P2X3-257-biotin was coated overnight at 4°C. An ELISA plate was 
coated with 5 µg/mL P2X3-257-biotin conjugate and blocked with 5% (w/v) 
milk in PBST. A range of scFv dilution was performed and then applied scFv 
as primary antibody, followed by HRP-labelled anti-HA secondary antibody 
(1:2,000 dilution). H7C anti-P2X3-257 scFv was stable at following three 
conditions after three months using ELISA against anti-P2X3-biotin with titre 
around 1:100 [scFv: glycerol = 1: 1 (v: v) at 4°C; scFv with 1% BSA (w/v) at 
4°C and scFv with 1% BSA (w/v) at -80°C]. 
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4.2.3 Generation of mouse recombinant scFv antibodies 
 
Mouse can generate anti-human antibody with great antibody diversity and 
only around 6 weeks were needed for immunization to achieve best immune 
response (which is about 12 weeks for rabbit). For these reasons, mice were 
also chosen for recombinant anti-human P2X3 scFv antibodies generation. 
 
4.2.3.1 Mouse serum antibody titre 
 
The immunisation procedure for mice was followed as described in section 
2.2.1.2. Three mice were immunised with P2X3-257-BSA conjugate and 
another three were immunised with P2X3-60-BSA conjugate. Bleeds were 
taken seven days after the final boost, and the serum anti-P2X3 titre was 
performed using a direct ELISA format to detect IgG antibodies against two 
P2X3 extracellular domains, P2X3-257 and P2X3-60 (section 2.1.6.1). An 
ELISA plate was coated with 5 µg/mL P2X3-257/60-biotin conjugate. A series 
of dilutions ranging from 1:500 to 1:4,000,000 of the mouse sera in 1 x PBST 
were tested against P2X3-60/257-biotin in a direct ELISA format [the sera were 
diluted using 1% (w/v) BSA to ‘deplete’ potential cross reacting antibodies]. 
HRP-labeled anti-mouse IgG was applied as the secondary antibody.  
For mouse number 1 the sera titre (three times greater than the background in 
wells containing control proteins, neutravidin and BSA) against P2X3-60 was 
1:20,000 and for mouse number 2 and 3 was 1:20,000. The sera titre of mouse 
number 4 and 5 against P2X3-257 was 1:400,000 (Fig. 4.17), which indicated a 
good immune response. This would infer production of mRNA suitable for the 
creation of a recombinant anti-P2X3-257 antibody library. However, there was 
a lower level titre against P2X3-60. Thus, an anti-P2X3-257 scFv may be 
generated from mice.  
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Fig. 4.17 Mouse anti-P2X3-257/60 antibody titre after the 4th boost (2 µg/mL 
P2X3-257/60-biotin was coated for screening). The titre for anti-P2X3-257 Ab 
was 1:400,000, and the titre for anti-P2X3-60 Ab was from 1:40,000 to 
1:80,000. P2X3-60 M1, M2 and M3 = P2X3-60 immunised mouse numbers 1 to 
3, P2X3-257 M4 and M5 = P2X3-257 immunised mouse numbers 4 and 5 
 
4.2.3.2 Optimization of mouse variable heavy and light chain amplification 
 
Mice were sacrificed after the fourth boost, and total RNA extracted from the 
spleens and then reverse transcripted to cDNA. RNA (8.4 mg) and cDNA (0.39 
mg) were obtained from the P2X3-257 immunised mice and 6.9 mg RNA and 
0.32 mg cDNA were obtained from the P2X3-60 immunised mice. RNA was 
stored at -80°C and cDNA stored at -20°C. 
Subsequently, the amplification of the variable heavy (VH) and variable light 
(VL) genes using mice spleen cDNA as template (section 2.2.3.3.2) was 
performed. The VH and VL amplifications were resolved on a 1% (w/v) agarose 
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gel and single bands at 386-440 bp (VH chain) and 375-402 bp (VL chain) were 
observed (Fig.4.18). A large-scale PCR amplification was then performed, 
using the conditions described in section 2.2.3.4, for each of the variable chains 
in their respective buffers. 
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Fig. 4.18 Selection of optimal magnesium concentration for variable VH and 
VL (κ and λ light chains) gene amplification. The magnesium concentrations 
selected for amplification 3 mM for the variable heavy chain, 2 mM for the κ 
chain and 4 mM for the λ light chain. Lanes 1-5 = clones 1-5. 
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4.2.4 Generation of chicken polyclonal antibodies 
 
As chickens can achieve better immune responses to human proteins than 
rabbit and mouse, based on their phylogenetical distance and it is more 
convenient to harvest large amounts of IgY from egg yolk, chickens were 
chosen to anti-human P2X3-257/60 antibody generation. 
 
4.2.4.1 Chicken serum titre 
 
Four female chickens were immunised as described in section 2.2.1.3. One 
chicken died before any injection; another chicken was immunised with 
P2X3-60-KLH conjugate and the other two were immunised with 
P2X3-257-BSA conjugate. Chicken bleeds were taken seven days after the 
third boost and the serum anti-P2X3 titre was performed using a direct ELISA 
format to detect IgG antibodies against the two P2X3 extracellular domains, 
P2X3-257 and P2X3-60 (section 2.1.6.1).  
An ELISA plate was coated with 5 µg/mL P2X3-257/60-biotin conjugate. A 
series of dilutions ranging from 1:500 to 1:4,000,000 of the avian serum 
diluted in 1 x PBST were tested against P2X3-60/257-biotin in a direct ELISA 
format [the sera were diluted using 1% (w/v) BSA or 0.1% KLH (w/v) to 
‘deplete’ potential cross reacting antibodies]. HRP-labeled anti-chicken IgY 
was applied as the secondary antibody. 
All the three immunized chickens gave low specific responses to P2X3 after the 
third boost as indicated by the serum titre obtained (Fig. 4.19a-c) (titre was 
three times greater than the background in wells containing control proteins, 
BSA and KLH). Thus, neither polyclonal antibody purification nor RNA 
extraction was performed after the chickens were sacrificed.  
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Fig. 4.19a Serum titre after the third boost of the second chicken immunised 
with P2X3-60-KLH. No specific response to P2X3-60 was detected. 
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Fig. 4.19b Serum titre after the third boost of the third chicken which 
immunised with P2X3-257-BSA. No specific response to P2X3-257 was 
detected. 
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Fig. 4.19c Serum titre after the third boost of the fourth chicken which 
immunized with P2X3-257-BSA. No specific response to P2X3-257 was 
detected. 
 
4.3 Discussion  
 
Over the last twenty years, antibody genes have been cloned, genetically 
manipulated and expressed in E. coli. Antibody expression in E. coli has 
several advantages e.g. large quantities of antibody fragments can be produced 
quickly at low cost. Furthermore, recombinant antibody technology offers the 
possibility of production of anti-human protein antibodies with both high 
specificity and affinity for application in human disease diagnosis and therapy 
(de Lalla et al., 1996).  
It is reported that over 151 recombinant therapeutics have been approved by 
the FDA or by the European Medicines Agency for different clinical 
indications (Huang et al., 2012). ScFv antibodies have been widely used as 
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delivery agents due to their small size and high specificity. In most cases, the 
scFv recombinant antibody fragment was used for targeted therapy through 
fusing to different proteins or genes. Wittel et al. (2005) reported that the scFv , 
sc(Fv)2, is stable in vivo and has significant potential for diagnostic and 
therapeutic applications. Liu et al. (2009) developed a novel strategy to 
optimize genetically delivered immunotoxin molecular therapy for cancer, 
using a recombinant adenovirus vector to deliver an immunotoxin gene 
e23(scFv)-PE40 to the oncogene c-erbB-2 (also known as Her2/neu), which is 
overexpressed in mammary tumors. Schoonooghe et al. (2009) developed an 
anti-MUC1 Fab-scFv antibody with better penetration into the tumour 
compared with a full-size monoclonal antibody resulting in better anti-cancer 
therapeutics. MUC1 (a tumour-associated antigen on the surface of cells) has 
been used as a specific antibody target for immunotherapy of human 
malignancies. Chen et al. (2010) produced a stable anti-human CD44v6 scFv 
by selecting from a human phage-displayed scFv library. It can effectively and 
specifically target CD44v6-expressing cancer cells. Yao et al. (2012) 
successfully use a scFv for targeted intracellular delivery of small interfering 
RNAs (siRNAs) as anti-cancer drugs to disseminated Her2-positive breast 
cancer cells. These examples clearly demonstrate the capability and 
applicability of scFv-based targeting. 
Inflammatory pain results from the activation of cascades, which mediate the 
inflammatory responses (involving the local vascular and immune systems and 
other cells at the injured site), and chemoreceptors (sensory receptors that 
transduce a chemical signal into an action potential) (Kidd and Urban, 2001). It 
is a major challenge for health providers to address this issue as pain sufferers 
represent ~20% of the adult population (Breivik et al., 2006). There remains an 
unmet need for effective, non-addictive, pain treatments, as traditionally-used 
non-steroidal anti-inflammatory drugs are short-acting and can cause serious 
side effects. 
The P2X purinoceptor 3 (P2X3) is a member of the purinergic receptor family 
for adenosine 5'-triphosphate (ATP). It plays a pivotal role in processing pain 
signals, being highly and selectively expressed in nociceptive sensory neurons, 
e.g. in the dorsal root and trigeminal ganglia (North, 2004). Furthermore, several 
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reports have demonstrated anti-nociceptive effects of P2X3 antagonists in 
different models of inflammatory pain, in vivo, consistent with the involvement 
of P2X3 receptors in inflammatory pain (Cockayne et al., 2000; Wirkner et al., 
2007). Knockout of the P2X3 receptor results in aberrant inflammatory pain in 
mice, with reduced formalin-induced pain behaviour and associated enhanced 
thermal hyperalgesia in chronic inflammation (Souslova et al., 2000). 
Downregulation of P2X3 by antisense oligonucleotides inhibited the 
development of mechanical hyperalgesia in both inflammatory and neuropathic 
pain rat models (Barclay et al., 2002). It was then suggested that an extracellular 
domain of the P2X3 receptor could be a promising target for delivering a drug to 
inhibit the release of pain peptides (North, 2003).  
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Table 4.3 Commercial anti-P2X3 antibodies (Labome, 2012). 
 
 
Company Antibody type Antigen 
Santa Cruze 
Biotechnology 
Goat/rabbit IgG Epitope mapping within an extracellular 
domain of human P2X3 
Abcam Rabbit IgG A 15 amino acid peptide 
corresponding to amino acids 383-397 
of the C-terminus of rat P2X3 
Thermo Scientific 
Pierce Products 
Rabbit IgG A 15 amino acid peptide 
corresponding to amino acids 383-397 
of the C-terminus of rat P2X3 
EMD Millipore Rabbit/ guinea pig IgG A 15 amino acid peptide 
corresponding to amino acids 383-397 
of the C-terminus of rat P2X3 
Abnova Rabbit IgG A 15 amino acid peptide 
corresponding to amino acids 383-397 
of the C-terminus of humanP2X3 
LifeSpan 
Biosciences 
Rabbit IgG A 15 amino acid peptide 
corresponding to amino acids 383-397 
of the C-terminus of either human or rat 
P2X3 
US Biological Rabbit/ guinea pig IgG A 15 amino acid peptide 
corresponding to amino acids 383-397 
of the C-terminus of either human or rat 
P2X3 
Biorbyt Rabbit IgG A 15 amino acid peptide 
corresponding to amino acids 383-397 
of the C-terminus of human P2X3 
GeneTex Rabbit IgG A 15 amino acid peptide 
corresponding to amino acids 383-397 
of the C-terminus of rat P2X3 
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The transmembrane protein, P2X3, should be bound by anti-P2X3 antibodies 
against extracellular domains (Val60-Phe301). Hence a drug attached to 
anti-P2X3 antibodies should be delivered to P2X3 and then to the pain 
signalling pathway (Koshimizu et al., 2002). To date, only Santa Cruze 
Biotechnology (U.S.A.) has generated polyclonal anti-P2X3 antibodies against 
the extracellular domain (Table 4.3). However, a polyclonal antibody 
preparation (150 kDa) may be too large to deliver drugs like BoNT (150 kDa) 
effectively into cells to target the pain signalling pathway. A smaller antibody, 
for instance a scFv (25 kDa), should be an ideal candidate as the delivery agent 
for targeted treatment. 
The scFv contains variable regions of antibody heavy (VH) and light chains 
(VL). The scFv recombinant antibody fragment is well known to have potential 
as a drug-delivery agent for targeted therapy through fusing with different 
proteins or genes.  
Due to the reasons already cited previously, anti-P2X3 extracellular domain 
scFv antibodies were generated. Two extracellular P2X3 peptide conjugates 
(P2X3-257-BSA and P2X3-60-BSA/KLH) were selected to immunise rabbits, 
mice and chickens. Rabbits and mice showed a high immune response towards 
P2X3-257, but a low immune response to P2X3-60. Rabbit anti-P2X3-257 
antibody serum titre was higher than that of other rabbit polyclonal antibody 
generated by Yu (2000). Mouse anti-P2X3-257 antibody serum titre was higher 
than that of the mouse polyclonal antibodies generated by Yu (2000) and 
Zhang (2006) (Table 3.4). The higher serum titres indicated higher and 
potentially more specific responses to immunised antigens which suggested 
higher levels of specific mRNA for the generation of recombinant antibodies. 
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Table 4.4 Comparison of serum titres of different antigen-immunised animals. 
 
Animal species Antigen Serum titre 
Rabbit Human P2X3-257 1:20,000 
Rabbit Human immunodeficiency 
virus type-1-PND  
1:6,400-12,800 
(Yu et al., 2000) 
Mouse Human P2X3-257 1:400,000 
Mouse Human P2X3-60 1: 40,000 to 1: 80,000 
Mouse Human immunodeficiency 
virus type-1-PND 
1:12,800-25,600 
(Yu et al., 2000) 
Mouse Myxobolus rotundus  1:8,000 to 1:16,000 
(Zhang et al., 2006) 
 
 
After sacrificing rabbits, RNA extracted from both the spleen and bone marrow, 
and cDNA synthesis was performed. Rabbit cDNA was used to generate a 
number of scFv libraries with libraries sizes from 5 x 107 to 3.5 x 108, which 
was higher than that of other reported libraries , i.e. 2.0 x 106 (Gómez et al., 
2005) and 1.4 x 108 (Robert et al., 2006). Recombinant antibody (scFv) 
selection against P2X3-257 was successfully carried out using phage display 
technology. After five rounds of bio-panning, followed by a polyclonal phage 
ELISA, monoclonal ELISA, cross reactivity analysis, diversity analysis, DNA 
sequencing, scFv purification, scFv titre determination  and competitive 
ELISAs, two anti-P2X3-257 scFv clones (F11A and H7C) with good sensitivity 
and binding affinity were selected.  
It was found that the anti-P2X3-257 scFv H7C had better specificity with an 
IC50 (0.04 nM) which was 218 times lower than that of anti-P2X3-257 
polyclonal antibodies (IC50 8.70 nM) (Fig. 3.15b). This improvement is much 
better than the work of Sabin et al. (2010). In Sabin’s work, he generated an 
anti-human heptad repeat 1 (HK20) scFv antibody with IC50 values ranging 
from 6 to 737 nM, which was 1-2 times lower compared to anti-HK20 
polyclonal antibodies (IC50 7 to 1173 nM) (Table 3.5).  
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Table 4.5 Comparison of IC50 between the polyclonal antibody preparation and 
the scFv antibody. 
 
Antibody IC50 (Nm) IC50 increased 
from IgG to scFv 
Rabbit anti-P2X3-257 polyclonal 
antibodies 
8.70 
Anti-P2X3-257 scFv (H7C) 0.04 
>217 times 
HK20 polyclonal antibodies 7 to 1173 
HK20 scFv 6 to 737 
1-2 times 
 
This research describes the first reports of the generation of a recombinant 
anti-P2X3 scFv antibody, and the first recombinant antibody against an 
extracellular domain of P2X3 (Val257 - Asp276), using phage display. More than 
90% of commercial and published anti-P2X3 antibodies are polyclonal 
antibodies against a fifteen-amino acid peptide sequence (Val383-His397) 
identical to the carboxyl-terminus of the P2X3 receptor intracellular domain. 
However the anti-P2X3 scFv antibodies, which can perform internalization into 
neuron cells through binding to the P2X3 extracellular domain, are crucial for 
long-term targeted therapeutics. Hence, the rabbit anti-P2X3-257 scFvs 
generated in this research, which with high specificity and affinity, provide a 
promising delivery agent for targeting diagnosis or therapy for inflammatory 
pain. The anti-P2X3 scFv antibodies will be used for targeted delivery of BoNTs 
to nociceptive sensory neurons for targeted treatment of inflammatory pain. 
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   Chapter 5 
  Optimisation and 
Characterization of ScFv 
Antibody in Vitro
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5.1 Introduction 
 
In this chapter the characterisation of the H7C scFv and its modification to 
improve expression are described. 
After rabbit anti-P2X3 scFv clones F11A and H7C were successfully selected 
through phage display, the specificity and affinity of these two clones were 
confirmed by ELISA. In vitro analysis was performed to select the best clone 
by using Western blotting and immunofluorescence staining with rat DRG cells. 
F11A and H7C gave similar results with Western blotting and 
immunofluorescence staining. Clone H7C was chosen for further 
characterisation as its IC50 was slightly better than that of F11A.  
The expression level of the anti-P2X3 scFv increased by 3.5 fold after Cys80 of 
clone H7C was mutated to Ala (MH7C). Western blotting, 
immunofluorescence, fluorescence-activated cell sorting (FACS) and 
immunohistochemical techniques were then applied for in vitro analysis of the 
specificity of the anti-P2X3 scFv.  
Using Western blotting, the P2X3 specific band at the correct position (50-55 
kDa) was successfully detected. With immunofluorescent staining, anti-P2X3 
scFv antibody-specific binding to P2X3 was demonstrated by very good 
co-localisation of staining on both the DRG cell bodies and fibres with 
commercial anti-P2X3 polyclonal antibody. In FACS analysis the scFv showed 
high binding-specificity to rat DRG-expressed P2X3, which was indicated by a 
dramatically shifted peak in comparison to the negative control. 
Immunohistochemical analysis demonstrated that the membrane of DRG cells 
in rat dorsal root ganglions, rat cortical neurons and human bladder neurons 
were positively stained by commercial anti-P2X3 antibody, rabbit-DARP 
polyclonal antibody and Alexa-594-labelled rabbit anti-P2X3 scFv antibody. 
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5.2 Results 
 
5.2.1 Western blotting and immunofluorescent staining analysis of scFv 
specificity to root ganglion cells (DRGs) expressed P2X3 
 
The binding specificity of anti-P2X3-257 scFv antibody colonies F11A and 
H7C for DRGs expressing P2X3 was confirmed by both Western blotting and 
immunofluorescent staining using the strategy described in section 2.2.3.17. 
Using Western blotting, the P2X3-specific band was successfully detected at 
the expected position with a molecular weight of 50-55 kDa (Fig. 5.1a). 
Immunofluorescent staining showed that specific binding of anti-P2X3-257 
scFv antibodies to P2X3 with by very good co-localisation of staining with 
commercial anti-P2X3 polyclonal antibody staining on the surface of DRG 
cells (Fig. 5.1b). 
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Fig. 5.1a Western blot analysis of purified anti-P2X3 scFv antibody specificity 
for P2X3 expressed by rat DRGs. DRGs were isolated from postnatal day 4 rats 
and cultured for 2 days in vitro before harvesting in LDS-sample buffer and 
analysis by SDS-PAGE and Western blotting (160 µg/lane). The membranes 
were stained by purified anti-P2X3 scFv, followed by HRP-labelled anti-HA 
secondary antibody (1:2,000 dilution). For the positive control, commercial 
anti-P2X3 antibody (1:300 dilution) was applied, followed by HRP-labelled 
anti-rabbit secondary antibody (1:1,000 dilution). For the negative control, 
anti-goat IgG (1:1,000 dilution) was added instead of anti-P2X3 antibody. MW 
= molecular weight markers; positive = positive control; negative = negative 
control; F11A and H7C = Rabbit anti-P2X3-257 scFv clones F11A and H7C. 
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Fig. 5.1b Immunofluorescence staining of cultured rat DRGs by anti-P2X3 
scFv antibody. Images were viewed in an inverted microscope in 
epifluorescence modes (A, C, E and G) and by phase contrast (B, D, F and H). 
Rat DRG cells grown in 24 wells plate for 5 days in vivo were fixed and 
stained by purified anti-P2X3 scFvs F11A (E and F) and H7C (G and H), then 
incubated with fluorescein-labelled anti-HA mAb (3F10) (2 µg/mL). For the 
positive control, commercial rabbit anti-P2X3 Ab (1:50 dilution) was added 
instead of the antibody lysate (C and D). For the negative control, anti-goat 
IgG (1:1,000 dilution) was added instead of anti-P2X3 Ab (A and B). F11A and 
H7C = Rabbit anti-P2X3-257 scFv clone F11A and H7C. Original 
magnification x 20; scale bars are 50 µm. 
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5.2.2 Improvement of scFv expression by mutation of Cys80 to Ala 
 
5.2.2.1 Mutation of Cys80 to Ala for anti-P2X3 scFv H7C 
 
There are four constant cysteines (Cys) in scFvs to form intrachain disulphide 
bridges in the variable light and variable heavy chain, respectively. However, 
in anti-P2X3 scFv H7C, there are five cysteines. This extra cysteine may lead 
to non-specific disulfide bond formation and result in poor expression levels. 
Based on the approach of Konterman and Dübel (2010), Cys80 was identified to 
be an extra Cys. It was decided to mutate it to Ala, as Ala80 was found in other 
scFvs (Guo et al., 2012).  
The Cys80 was mutated to alanine (Ala) by reverse PCR. The PCR mutated 
products were then transformed into Top 10 electrocompetent cells (section 
2.2.3.19). Plasmid DNA from a total of 6 clones was extracted, SfiΙ-digested 
and analyzed on a 1% agarose gel (Fig. 5.2a). Positive clones were then 
sequenced. After the required amino acid sequence was obtained (Fig. 5.2b), 
the mutated anti-P2X3 scFv clone and non-mutated anti-P2X3 scFv clones were 
cultured (in 500 mL volume) and purified.  
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.2a SfiΙ digestion of DNA from mutated scFv clone 1-6. After separation 
on a 1% agarose gel, all the six colonies showed to be positive indicated by 
correctly digested bands at 4,000 bp, for undigested pComb3xss with scFv, 
3,200 bp for pComb3xss and 800 bp for the scFv. Lanes C1-C6 = clones 1-6. 
Ladder  C1    C2   C3    C4    C5   C6 
4,000 bp
3,000 bp
1,000 bp
pComb3XSS + scFv (～4,000 bp)
pComb3XSS (～3,000 bp)
scFv (～800 bp)
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Fig. 5.2b Sequence of mutated anti-P2X3 scFv. The anmino acid sequence was 
compared with that of non-mutated anti-P2X3 scFv. The cysteine at position 80 
(in red) was successfully mutated to alanine without any other mutation being 
made. 
 
5.2.2.2 Comparison of anti-P2X3-257 scFv expression levels before and 
after mutation  
 
The scFv antibody titre against P2X3-257-biotin was measured using crude 
bacterial lysate from a 2 L culture (section 2.2.3.16). The titre for 
anti-P2X3-257 scFv H7C preparation before mutation was 1:100 and 1:1,000 
after mutation (Fig. 5.3).  
The protein concentrations after purification (section 2.2.3.15) were measured 
using a BCA kit (section 2.2.2.3). For the mutated anti-P2X3 scFv the 
concentration was 978.2 µg/mL and for the non-mutated anti-P2X3 scFv 277.7 
µg/mL (in a total volume of 3 mL). 
The expression level of mutated anti-P2X3 scFv was found to be much higer 
than the non-mutated anti-P2X3 scFv with a better antibody titre (1:1,000 vs. 
1:100) and higher protein concentration (978.2 µg/mL vs. 277.7 µg/mL) (titre 
was three times greater than the background in wells containing control protein, 
neutravidin). 
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Fig. 5.3 Direct ELISA analysis of titres of the mutated and non-mutated 
anti-P2X3 scFvs. The anti-P2X3 scFv antibody titre responses (three times 
greater than negative control) to the P2X3-257-biotin conjugate were tested 
before and after mutation. An ELISA plate was coated with 5 µg/mL 
P2X3-257-biotin conjugate. A series of dilutions ranging from 1:4 to 1:4,000 of 
the crude lysate of the anti-P2X3-257 scFv (before and after mutation) were 
made in 1 x PBST, followed by addition of HRP-labeled anti-HA secondary 
antibody. The neutravidin controls were used to detect the possible 
non-specific binding of scFv to neutravidin/biotin. For the neutravidin control 
the wells were coated with neutravidin (2.5 µg/mL) instead of the 
P2X3-257-biotin conjugate. The lysate titre for anti-P2X3-257 scFv H7C before 
mutation was 1:100 and 1:1,000 after mutation. 
 
 
0.00
0.20
0.40
0.60
0.80
1.00
1.20
1 10 100 1000 10000
Dilution range of scFv crude lysate
A
bs
or
ba
nc
e 
(4
50
 n
m
)
Non-mutated H7C
scFv
Mutated H7C scFv
Neutravidin control
(for non-mutated
scFv)
Neutravidin control
(for mutated scFv)
ScFv and controls 
179 
 
5.2.2.3 Western blotting and immunofluorescent staining analysis of 
mutated scFv (MH7C) specificity to rat DRGs-expressed P2X3 
 
The binding specificity of mutated anti-P2X3-257 scFv antibody H7C to DRGs 
expressed P2X3 was confirmed by both Western blotting and 
immunofluorescence staining, using the strategy described in section 2.2.3.17. 
For Western blotting, the P2X3-specific band was successfully detected at the 
right position and molecular weight (50-55 kDa) (Fig. 5.4a). For 
immunofluorescent staining, specific binding of mutated anti-P2X3-257 scFv 
antibody to P2X3 was demonstrated by very good co-localisation with 
commercial anti-P2X3 polyclonal antibody staining on the surface of DRG 
cells (Fig. 5.4b). 
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Fig. 5.4a Western blot analysis of purified mutated anti-P2X3-257 scFv 
antibody specificity for P2X3 expressed by rat DRGs. DRGs were isolated 
from postnatal day 4 rats and cultured 2 days in vitro before harvesting in 
SDS-sample buffer and analysis by SDS-PAGE and Western blotting (160 
µg/lane). The membranes were stained by purified mutated anti-P2X3-257 scFv, 
followed by anti-HA-HRP-labelled secondary antibody (1:2,000 dilution). For 
the positive control, commercial anti-P2X3 polyclonal antibody (1:300 dilution) 
was applied, followed by HRP-labelled anti-rabbit secondary antibody (1:1,000 
dilution). For the negative control, anti-goat IgG (1:1,000 dilution) was added 
instead of anti-P2X3 antibody. MW = molecular weight markers. 
 
 
 
 
 
 
 
 
 
 
130 
100 
70 
250
55 
35 
25 
15 
P2X3
(50-55 kDa)
kDa
MW Positive control             MW Mutated scFv MW Negative control 
181 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.4b Immunofluorescence staining of cultured rat DRGs by anti-P2X3-257 
scFv antibody. Images were viewed in an inverted microscope in 
epifluorescence modes (A and C) and by phase contrast (B and D). Rat DRG 
cells, grown in 24 wells plate for 5 days, in vivo were fixed and stained with 
the purified mutated anti-P2X3-257 scFv, followed by incubation with 
fluorescein-labelled anti-HA mAb (3F10) (2 µg/mL) (A and B). For the 
negative control (C and D), anti-goat IgG (1:1,000 dilution) was added instead 
of anti-P2X3 Ab. Original magnification x 20; scale bars are 50 µm. 
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5.2.3 Rabbit anti-P2X3-257 antibody co-staining of rat DRGs with 
commercial rabbit anti-P2X3 intracellular domain antibody 
 
Confocal microscopic studies were applied to demonstrate specific binding of 
anti-P2X3-257 scFv antibody to rat DRG neuron-expressed P2X3. DRG cells 
cultured for 5 days were fixed and blocked, as described in section 2.2.4.5. 
Then Alexa-594 labelled-scFv was added, followed by permeabilisation and 
addition of commercial rabbit anti-P2X3 intracellular domain polyclonal 
antibody, followed by Alexa Fluor-488-labelled goat anti-rabbit polyclonal 
secondary antibody (Fig. 5.5a). For Rabbit-DARP anti-P2X3-257 polyclonal 
antibody, Alexa Fluor-576-labelled goat anti-rabbit polyclonal secondary 
antibody was added before permeabilisation and addition of commercial 
antibody (Fig. 5.5b). The specific binding of anti-P2X3-257 antibodies to P2X3 
was demonstrated by very good co-localisation with commercial anti-P2X3 
polyclonal antibody staining on the surface of DRG cells and fibers. 
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Fig. 5.5a Confocal micrographic analysis demonstrating co-localisation of 
staining and antibody-specific binding of rabbit-DARP anti-P2X3 polyclonal 
antibody to P2X3. Rat DRG cultures, grown in 24 wells plate for 5 days, were 
fixed and stained by rabbit-DARP anti-P2X3-257 polyclonal antibody (A, D; 
red) and commercial rabbit anti-P2X3 intracellular domain polyclonal antibody 
(B, E; green), followed by Alexa Fluor-546-labelled goat anti-rabbit secondary 
antibody (1:1,000 dilution) and Alexa Fluor-488-labelled goat anti-rabbit 
secondary antibody (1:1,000 dilution). Specific binding of scFv to P2X3 
expressed by rat DRG cell bodies (A-C) and fibres (D-F) was demonstrated by 
good co-localisation (C, F; yellow) with staining of commercial antibody. 
Original magnification x 40; scale bars are 10 µm. 
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Fig. 5.5b Confocal micrographic analysis demonstrating co-localisation of 
staining and antibody-specific binding of anti-P2X3 scFv to P2X3. Rat DRG 
cultures, grown in 24 wells plate for 5 days, were fixed and stained by 
Alexa-594 labelled-scFv  (A, D; red) and commercial rabbit anti-P2X3 
intracellular domain polyclonal antibody (B, E; green), followed by Alexa 
Fluor-488-labelled goat anti-rabbit secondary antibody (1:1,000 dilution). 
Specific binding of scFv to P2X3 expressed by rat DRG cell bodies (A-C) and 
fibres (D-F) was demonstrated by good co-localisation (C, F; yellow) with 
staining of commercial antibody. Original magnification x 40; scale bars are 5 
µm. 
 
5.3.4 Analysis of binding specificity of anti-P2X3 scFv to rat 
DRG-expressed P2X3 using flow cytometry 
 
The specificity of scFv antibody for binding to P2X3 expressed on rat DRG cell 
surface was analysed using FACS Calibur-based assays as described in section 
2.2.3.21. It was shown that scFv (50 µM) which was labelled with Alexa-594 
had high binding-specificity to rat DRG-expressed P2X3 based on FACS data, 
which showed peaks shifted dramatically from negative control to positive 
control. The median fluorescence intensity of scFv (573 A.U.) was 
approximately 4.0 times higher than negative control (145 A.U.) and 1.2 times 
A B C 
D E F 
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higher than positive control (459 A.U.) (Fig. 3). For the negative control, DRG 
cells were treated with only secondary antibody, which tested for non-specific 
binding of secondary antibody on treated cells. For positive control, 
commercial rabbit anti-P2X3 polyclonal antibody (50 µM) was applied instead 
of the scFv. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.7 Flow cytometric analysis of scFv-specific binding to P2X3 expressed 
on rat DRG cells. The x-axis represents the intensity of the fluorescence and 
the y-axis the number of cells. Rat DRG cells were stained with 
Alexa-594-labelled scFv (10 µM). For negative control, Alexa-594-labelled 
goat anti-rabbit antibody was added instead of Alexa-594-labelled scFv. Flow 
cytometric curves showed DRG cells stained by scFv (red), commercial rabbit 
anti-P2X3 polyclonal antibody (black) and unstained (gray image). 
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5.3.5 Immunohistochemical analysis demonstrated anti-P2X3 scFv 
antibody specific to sensory neurons 
 
Tissue slides of rat (P1) DRG and rat brain (18 weeks) were immunostained 
with anti-P2X3 antibody on an automated platform (section 2.2.8). The brown 
staining indicated antibody–antigen complex which was detected using a 
polymer-based kit with DAB, while the red fluorescence staining indicated 
Alexa-594-labelled scFv-P2X3 complex. The membrane of DRG cells in rat 
dorsal root ganglion (Fig. 5.8), rat brain cortical cells (Fig. 5.9) and urothelium 
cells of human bladder (Fig. 5.10) were stained by commercial anti-P2X3 
antibody, rabbit-DARP polyclonal antibody and Alexa-594-labelled rabbit 
anti-P2X3 scFv antibody. The Alexa-594-labelled rabbit anti-P2X3 scFv 
antibody shared the same staining pattern with commercial anti-P2X3 antibody. 
Therefore, it can then be concluded that this anti-P2X3 scFv antibody 
effectively binds to sensory neurons, DRG cells and successfully detects P2X3 
expression in adult rat brain.  
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           Staining of rat DRG neurons 
 
                                
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.8 Sections from rat DRG demonstrating MH7C scFv antibody binding 
specificity. Formalin-fixed, paraffin-embedded surgical specimens obtained 
from a 1 day old rat were immunostained with anti-P2X3 antibody after antigen 
heat treatment. The membranes of DRG cells were positively stained by 
rabbit-DARP polyclonal antibody (C) and Alexa-594-labelled rabbit anti-P2X3 
scFv antibody (E), indicated by the same staining pattern as with commercial 
anti-P2X3 antibody (A). This staining disappeared following preincubating 
antibodies with their specific antigenic P2X3 peptides (B, D, F). Haematoxylin 
was used for nuclear staining. Original magnification x 40; scale bars are 10 
µm. 
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                Staining of rat brain cortical neurons 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.9 Sections from rat brain demonstrating MH7C scFv antibody binding 
specificity. Formalin-fixed, paraffin-embedded surgical specimens obtained 
from a 18 week old rat were immunostained with anti-P2X3 antibody after 
antigen heat treatment. The membranes of brain cortical neurons were 
positively stained by rabbit-DARP polyclonal antibody (C) and 
Alexa-594-labelled rabbit anti-P2X3 scFv antibody (E), indicated by the same 
staining pattern as with commercial anti-P2X3 antibody (A). This staining 
disappeared following preincubating antibodies with their specific antigenic 
P2X3 peptides (B, D, F). Haematoxylin was used for nuclear staining. Original 
magnification x 40; scale bars are 5 µm. 
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        Staining of human bladder urothelium 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.10 Sections from human bladder demonstrate MH7C scFv antibody 
binding specificity. Formalin-fixed, paraffin-embedded surgical specimens 
obtained from human bladder (provided by Beaumont Hospital) were 
immunostained with anti-P2X3 antibody after antigen heat treatment. The 
membranes of cells in bladder urothelium were positively stained by 
rabbit-DARP polyclonal antibody (C) and Alexa-594-labelled rabbit anti-P2X3 
scFv antibody (E), indicated by the same staining pattern as with commercial 
anti-P2X3 antibody (A). This staining disappeared following preincubating 
antibodies with their specific antigenic P2X3 peptides (B, D, F). Haematoxylin 
was used for nuclear staining. Original magnification x 40; scale bars are 10 
µm. 
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5.3 Discussion 
 
This chapter described successful modification of the rabbit anti-P2X3-257 
scFv, MH7C, for greater specificity, which was proved by Western blotting, 
immunofluorescence, flow cytometry and histochemical staining. 
After sequencing the selected scFvs, an additional Cys (Cys80) was discovered 
as part of the structure which may have lead to low expression levels, 
non-specific disulfide-bond formation and scFv s (Popkov et al., 2003; Shen et 
al., 2005). The Cys80 was then mutated to Ala, as Ala80 was reported in other 
rabbit scFvs (Moon et al., 2011). After mutation, the crude bacterial lysate titre 
was 4 times higher than that of non-mutated scFv and the expression level of 
anti-P2X3 scFv increased by 3.5 fold (from 278 µg/mL to 978 µg/mL) when 
compared with that of non-mutated anti-P2X3 scFv. This result indicated that 
the Cys80 in rabbit scFv resulted in low expression levels consistent with the 
results of Popkov (2003) and Shen (2005). 
Usinf Western blotting, Xiang et al. (2008) detected P2X3 in DRG protein 
extracts. In this chapter, the P2X3-specific band was successfully detected by 
anti-P2X3-257 scFv antibody, MH7C, at the expected position and molecular 
weight (50-55 kDa).  
Vulchanova et al. (1998) successfully detected P2X3 on the membrane of rat 
DRG cells by outlining cell bodies with strong fluorescent staining. The 
specific binding of anti-P2X3-257 scFv antibody MH7C to rat DRG 
neuron-expressed P2X3 was demonstrated by confocal microscopic studies by 
very good co-localisation with commercial anti-P2X3 polyclonal antibody 
staining on the surface of DRG cells and fibers.   
Flow cytometry is biophysical technology widely used in biomarker detection 
and protein engineering. Yuahasi et al. (2012) applied flow cytometry to detect 
P2X2 expression. The peak of cells with high P2X2 expression shifted greatly 
from peaks of negative controls due to increased fluorescent staining.  
Likewise, Alexa-594-labelled scFv had high binding-specificity to rat 
DRG-expressed P2X3 based on flow cytometry data, which showed peaks 
shifted dramatically from the negative control to the positive control profiles. 
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Histochemical (IHC) staining is used by all anatomical and surgical 
pathologists to confirm cell types (Idikio, 2010). After formalin fixing and 
paraffin embedding (FFPE), the state of the proteins in a tissue sample may be 
altered, which may lead to non-specific binding (high background staining), 
and may then mask the detection of the target antigen (Marshall et al., 2009). 
This may cause non-specific staining background in brain negative controls. 
However, after preincubation of antibodies with specific P2X3 peptides, all of 
the staining on the membrane of rat (P1) DRG cells, rat (18 weeks) brain 
neurons and human bladder neuron cells disappeared (staining by commercial 
anti-P2X3 antibody, rabbit-DARP polyclonal antibody and Alexa-594-labelled 
rabbit anti-P2X3 scFv antibody). Moreover, as rabbit-DARP polyclonal 
antibody and Alexa-594 labelled rabbit anti-P2X3 scFv antibody shared a 
similar staining pattern with commercial anti-P2X3 antibody and published 
data (Pearson and Carroll, 2004; Cheung et al., 2005; Liu et al., 2009), it can 
be concluded that both rabbit-DARP polyclonal antibody and anti-P2X3 scFv 
antibody effectively bind to both human and rat-expressed P2X3. 
It was reported that P2X3 receptor protein was expressed in embryonic (E16) 
and neonatal rat brain (P7 and P14) but was not in adult rats (Kidd et al., 1998). 
However, in this research, the cortical neuron membrane in FFPE brain tissue 
slides from a 18 weeks female Sprague-Dawley rat were positively stained by 
commercial rabbit anti-P2X3 commercial polyclonal antibody, rabbit-DARP 
(the rabbit that was later used for scFv library construction) polyclonal 
antibody and rabbit anti-P2X3-257 scFv antibody.  
The anti-P2X3 antibody used by Kidd et al. was rabbit polyclonal antibody 
against a peptide (DSGAYSIGH) corresponding to the predicted amino acids 
389-397 of the rat P2X3 receptor (Lewis et al., 1995), generated by the Regal 
Group (Surrey, U.K.). The commercial antibody used in this research was a 
rabbit polyclonal antibody against amino acids 383-397 
(VEKQSTDSGAYSIGH) of the rat P2X3 receptor (Chen et al., 1995), which 
was 6 amino acids (VEKQST) more than Kidd’s antigen. Polyclonal and scFv 
antibodies generated in this research are from a rabbit immunised with a 
peptide with amino acids 257-276 of the human P2X3 receptor (Koshimizu et 
al., 2002). The homology of the chosen P2X3 peptide sequence with P2X1-7 
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was analysed using the Basic Local Alignment Search Tool (BLAST) and 
compared with rat (Roberts and Evans, 2004) and human (North, 2002) amino 
acid sequences. No similarity was found with amino acids 383-397 of rat 
P2X1-7 receptor; and a low identity of 10% was observed in comparison to 
amino acids 257-276 of the human P2X1-7 receptor. No or low identity 
indicated that the antibodies generated against the chosen peptides have a low 
possibility of cross-reactivity to P2X1,2,4-7 receptor. The reason why Kidd’s 
antibody cannot recognize adult rat brain may be because 6 amino acids 
(VEKQST) are absent and therefore not part of the binding epitope of the 
respective antibody. This result further provides the possibility of using 
anti-P2X3 scFv as a target delivery agent for treatment of inflammation in the 
brain, which can lead to vision loss, weakness and paralysis (Aktas et al., 
2007). 
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Chapter 6 
 
Generation of BoNT-anti-P2X3 
Antibody Fusion Protein 
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6.1 Introduction 
 
In this chapter, proof of principle for targeting the translocation and protease 
domains from botulinum neurotoxin type A (or D) [LC-HN/A or LC-HN/D] via 
an anti-P2X3 antibody (polyclonal antibodies and scFv antibody) to sensory 
neurons was provided. The targeting efficiency and selectivity of 
BoNT-anti-P2X3 antibodies was evaluated by comparing DRGs susceptibility to 
BoNT/A and BoNT/D. 
BoNT/A and BoNT/D inhibit inflammatory pain peptide release [calcitonion 
gene-related peptide (CGRP) and substance P (SP)] by cleavage of their 
specific intracellular SNAREs [i.e. synaptosomal-associated protein (SNAP-25) 
and vesicle-associated membrane protein (VAPM)] (Aoki and Guyer, 2001). 
BoNT/A cleaves near the C-terminus of SNAP-25 at Gln197-Arg198. BoNT/D 
cleaves the extra-vesicular loop of VAMP at Lys59-Leu60. The entry of 
BoNT/A and BoNT/D into cells is mediated by binding to synaptic vesicle 
protein 2 (SV2). SV2s are expressed by sensory neurons as well as cholinergic 
neurons, sympathetic neurons and non-neuronal cells (Dong et al., 2006; Peng 
et al., 2011), therefore, treatment with only BoNT/A or BoNT/D may result in 
unwanted ‘off-targeting effects’. Hence, a specific targeting agent is needed.  
In this study, rabbit polyclonal or scFv antibody, which recognise the 
extracellular domain of P2X3, were utilised as targeting agents for specific 
delivery of LC-HN/A or LC-HN(-HCN)/D to pain-signalling DRG neurons. 
Before genetically fusing rabbit anti-P2X3 scFv with BoNT, the principle of 
this approach was proven by conjugating rabbit anti-P2X3 polyclonal antibody 
with LC-HN/A, to determine if the LC-HN/A-anti-P2X3 polyclonal antibody 
construction had the desired endopeptidase activity. Rabbit anti-P2X3 
polyclonal antibody was purified using both a protein A agarose and a P2X3 
antigen-affinity column (section 2.2.2 and section 3.2.1.2). Anti-P2X3 
polyclonal antibody was biotinylated using an EZ-Link 
sulfo-NHS-LC-biotinylation kit (section 2.2.6.1) and then conjugated to the 
purified botulinum toxin serotype A-core streptavidin (LC-HN/A-CS) (section 
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2.2.5.1). It was shown that the anti-P2X3 polyclonal antibody-LC-HN/A 
conhugate had higher endopeptidase activity than LC-HN/A alone, as shown by 
detection of increased cleavage of SNAP-25 in rat DRG cells, compared to 
LC-HN/A only.  
The scFv gene was then fused to LC-HN/D and LC-HN-HCN/D, and expressed 
as a fusion protein in BL21-DE3. After purification, using immobilised metal 
ion affinity chromatography (IMAC), BoNT-scFv fusion constructs were 
incubated with cultured DRGs for 24 hours, before cleavage of their respective 
substrates was analysed using Western blotting. The results proved that the 
fused proteins did enter into sensory neuron DRGs and cleaved VAMP2 in a 
dose-dependent fashion, but little improvement was found when compared 
with control proteins, LC-HN/D and LC-HN-HCN/D. This may be caused by the 
poor disulphide bond formation capacity of BL21-DE3, which then leads to 
protein dysfunction. 
The MH7C scFv gene was then fused to LC-HN/A and LC-HN-HCN/A, as 
BoNT/A-cleaved SNAP-25 was easier to quantify than VAMP2. These fusion 
proteins were expressed in Origami 2(DE3) in order to improve their activity, 
as Origami 2(DE3) was reported to enhance disulphide bond formation (Larsen 
et al., 2008). The LC-HN-HCN/A-MH7C fusion was then purified using 
streptavidin-agarose resin. In vivo data showed this novel construct had higher 
endopeptidase activity than LC-HN-HCN/A control protein, as shown by 
detection of increased cleavage of SNAP-25 in rat DRG cells. It subsequently 
inhibits release of inflammatory pain peptides, SP and CGRP, from cultured rat 
DRG neuronal cells, and lacks cytotoxicity in vivo when evaluated by 
intraperitoneal injection of 1 µg quantities. This supports its potential safety for 
the use in treatment applications.  
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6.2 Results 
 
6.2.1 Successful expression and purification of LC-HN/A-core streptavidin 
(CS)  
 
6.2.1.1 SDS-PAGE analysis of expression and purity of LC-HN/A-CS  
 
There is a Trypzean cleavage site between BoNT light and heavy chains. 
Before cleavage into light and heavy chains, BoNT is in a single chain (SC) 
form at which lacks biologically activity. After cleavage, BoNT is in a di-chain 
(DC) form at which in biologically activity. 
Single chain LC-HN/A-core streptavidin (CS5) proteins were expressed and 
purified using IMAC (section 2.2.5.1). The single chain form of LC-HN/A-core 
streptavidin was then converted to the biologically active di-chain form by 
incubating with Trypzean (1:250 dilution) at 27°C for 40 mins. Trypsin 
inhibitor (100-fold concentration) was added to the solution to inactive the 
Trypzean. The molecular weight for the nicked protein was about 115 kDa. 
Intensely stained bands at the correct molecular weight positions, i.e. 115 kDa 
(before addition of dithiothreitol, DTT) and 65 kDa and 50 kDa (after addition 
of DTT to break disulfide bonds) were successfully detected) (Fig. 6.1). 
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Fig. 6.1 The LC-HN/A-core streptavidin sample were analysed by 4-12% 
SDS-PAGE. One µg/well of LC-HN/A-core streptavidin preparations (before 
and after nicking; with or without DTT) were loaded into each lane before 
Coomassie staining. [SC = single chain; DC = di-chain form; DTT = 
dithiothreitol; MW = molecular weight markers; HN-CS5 = core streptavidin 
conjugated light chain and translocation domain of botulinum toxin; LC = light 
chain of botulinum toxin and CS = core streptavidin.] 
 
6.2.2 LC-HN/A-anti-P2X3 rabbit IgG conjugates 
 
6.2.2.1 SDS-PAGE analysis of LC-HN/A-CS-anti-P2X3 rabbit IgG 
conjugates 
 
After mixing biotinylated anti-P2X3 rabbit polyclonal antibody (section 3.2.1.2) 
and LC-HN/A-CS at 4°C for two hours in order to achieve sufficient binding 
(section 2.2.6.4), conjugates were detected by both SDS-PAGE and Western 
blotting (Fig. 5.3). The strong bands migrated to the expected position [260 
kDa (LC-HN/A-CS-anti-P2X3 IgG) before addition of DTT; 65 kDa (HN/A-CS), 
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50 kDa (antibody heavy chain and LC/A) and 25 kDa (antibody light chain) 
after addition of DTT] were successfully detected (Fig. 6.2). 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Fig. 6.2 SDS-PAGE analysis of anti-P2X3-pAb-CS conjugates. The presence 
of a band at about 260 kDa (LC-HN/A-CS-anti-P2X3 IgG) before addition of 
DTT and three bands after addition of DTT, i.e. 65 kDa (HN/A-CS), 50 kDa 
(antibody heavy chain and LC/A, respectively) and 25 kDa (antibody light 
chain). LC/A = light chain of botulinum toxin serotype A; HN/A = translocation 
domain of botulinum toxin serotype A; CS = core streptavidin; IgG = rabbit 
anti-P2X3 polyclonal antobody; DTT = dithiothreitol and MW = molecular 
weight markers. 
 
6.2.2.2 Immunofluorescent staining analysis of LC-HN/A-anti-P2X3 rabbit 
IgG conjugates specificity targeting to DRG-expressed P2X3 
 
The specificity of LC-HN/A-anti-P2X3 IgG conjugates to P2X3 expressed in 
DRGs were confirmed by immunofluorescent staining. Cultured DRGs 
(cultured for 5 days) were fixed, permeabilized and blocked, as described in 
section 2.2.6.6. The LC-HN/A-anti-P2X3 IgG was applied (1:50 dilution), 
followed by Alexa Fluor-546-labelled goat anti-rabbit secondary antibody 
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(1:200 dilution). The green fluorescence signals indicated DRG cells were 
positively stained by LC-HN/A-anti-P2X3 IgG conjugates (Fig. 6.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.3 Immunofluorescent staining of cultured DRG by LC-HN/A-anti-P2X3 
rabbit IgG conjugates. Samples were viewed in an Olympus IX71 inverted 
microscope by phase contrast (B, D) and in fluorescence mode (A, C). Rat 
DRGs, grown in 24 wells plate for 5 days in vivo (5 DIV), were fixed and 
stained by LC-HN/A-anti-P2X3 IgG (1:50 dilution), followed by Alexa 
Fluor-546 labelled goat anti-rabbit secondary antibody (1:200 dilution). For the 
negative control, anti-goat IgG (1:1,000 dilution) was added instead of 
anti-P2X3 antibody (C, D). Scale bars are 50 µm. 
 
6.2.2.3 LC-HN/A cleaves more SNAP-25 in cultured DRGs after 
conjugation to rabbit anti-P2X3 IgG 
 
A series of concentrations of LC-HN/A-anti-P2X3 IgG and LC-HN/A-CS 
control (0, 10, 100 and 1,000 nM) in 250 µL were added to rat DRG cultures 
(P5, 6 DIV) and incubated for 24 hours at 37°C in 5% (v/v) CO2, as described 
LC-HN/A-anti-P2X3 pAb 
Negative control 
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in 2.2.6.7, in order to demonstrate the dose-dependent cleavage of SNAP-25. 
Observation of the cleaved form of SNAP-25 starts to occur following 
exposure to 100 nM of LC-HN/A-CS, while for LC-HN/A-anti-P2X3 IgG it 
occurs at 10 nM. The presence of a greater amount of the cleaved form of 
SNAP-25 with LC-HN/A-anti-P2X3 IgG compared LC-HN/A-CS indicates that 
the suspectibility of LC-HN/A is improved by conjugation to anti-P2X3 IgG. 
Thus, the concept that anti-P2X3 IgG can target BoNT to sensory neurons for 
inflammatory pain treatment was successfully demonstrated in vitro (Fig. 6.4).  
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.4 Western blot analysis of cleavage of SNAP-25 by LC-HN/A-anti-P2X3 
IgG and LC-HN/A-CS in cultured rat DRGs. After Western blotting, the 
membrane was stained by mouse anti-SNAP-25 (SMI-81; 1:1,000 dilution) and 
mouse anti-syntaxin-1 (HPC-1; 1:1,000 dilution), followed by addition of 
alkaline phosphatase-conjugated anti-mouse IgG (1:5,000 dilution). Syntaxin 1 
was used as an internal control. The SNAP-25 cleaved form (~ 25 kDa; lower 
band) was enhanced with increased concentrations of LC-HN/A from 0 to 1,000 
nM. Lanes 1-4, LC-HN/A-CS at concentrations of 1, 10, 100 and 1,000 nM, 
respectively; lane 5, molecular weight markers; lanes 6-10, LC-HN/A- 
anti-P2X3 IgG at concentrations of 1,000, 100, 10, 1 and 0 nM, respectively. 
LC-HN/A-CS = core streptavidin-conjugated light chain and translocation 
domain of botulinum toxin serotype A and LC-HN/A-anti-P2X3 IgG = 
anti-P2X3 IgG-conjugated light chain and translocation domain of botulinum 
toxin serotype A.  
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6.2.3 Successful expression and purification of BoNT/D-scFv fusion 
protein with and without the N-terminal binding domain 
(LC-HN-HCN/D-anti-P2X3 scFv and LC-HN/D-anti-P2X3 scFv) 
 
6.2.3.1 Selection of positive BoNT/D-scFv clones  
 
After genetic linkage of LC-HN-HCN/D and LC-HN/D with the anti-P2X3 scFv 
through PCR, the PCR product was extracted and purified, followed by 
transformation into Top 10 cells and plating on agar plates (with 30 µg/mL 
kanamycin) (section 2.2.7.1). Single clones were picked (6 clones for each 
fusion) and plasmids were extracted and purified for selection of positive 
clones through agarose gel electrophoresis. All the six clones of LC-HN/D-scFv 
were shown to be positive (8 Kb), and five clones of LC-HN-HCN/D-scFv 
showed to be positive (9 Kb) (Fig. 6.5). Sequences of clones 6 (LC-HN-HCN/D) 
and clone 7 (LC-HN/D) were verified by DNA sequencing and chosen for 
large-scale. 
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Fig. 6.5 Agarose gel analysis of positive BoNT/D scFv clones. After separation 
on a 1% agarose gel, all six clones of LC-HN/D-scFv were shown to be positive, 
as indicated by bands at 8 Kb, while five clones of LC-HN-HCN/D-scFv showed 
positive expression indicated by correctly sized bands at 9 Kb. Lanes 1-12 = 
clones 1-12. 
 
6.2.3.2 Western blot analysis of small-scale fusion expression 
 
The expressing of LC-HN-HCN/A-scFv and LC-HN/A-scFv in 1mL crude 
bacterial lysates was analysed using Western blotting, as described in section 
2.2.7.2. Strong bands at the correct positions (150 kDa for LC-HN-HCN/A-scFv 
and 125 kDa for LC-HN/A-scFv) were successfully detected (Fig. 6.6). 
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Fig. 6.6 Western blot analysis of LC-HN-HCN/D-scFv and LC-HN/D-scFv 
expression. Crude bacterial lysates from LC-HN-HCN/D-scFv and 
LC-HN/D-scFv culture were loaded onto SDS-PAGE. After Western blotting, 
the membranes were stained by HRP-labelled mouse-anti-His antibody. The 
presence of a band at about 150 kDa (LC-HN-HCN/D-scFv) and 125 kDa 
(LC-HN/D-scFv) indicated that the LC-HN-HCN/D-scFv and LC-HN/D-scFv 
fusions were successfully expressed. LC-HN-HCN/D-scFv = light chain, 
translocation domain and N-terminal binding domain of botulinum toxin type 
D; LC-HN/D-scFv = light chain, translocation domain of botulinum toxin type 
D and MW = molecular weight markers. 
 
6.2.3.3 SDS-PAGE analysis of fusion protion expression and purification 
 
There is a Thrombin cleavage site between BoNT light and heavy chains. It 
was previously explained that BoNT in the single chain (SC) form has no 
biologically activity, whereas the di-chain (DC) from has biological activity. 
The hybrid proteins LC-HN/D-scFv and LC-HN-HCN/D-L-scFv were expressed 
in E. coli (BL21-DE3 strain) using auto-induction medium and were purified 
by IMAC only. The pooled samples were only partially nicked by incubation 
with Thrombin [1 mg intact hybrid protein/2 units Thrombin; 1/1,000 (v/v)] to 
convert single chain (SD) to the biologically active di-chain form (DC) (section 
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2.2.7.1). At the end of the incubation, APMSF was added to the reaction at a 
final concentration of 250 µM to inactivate Thrombin.  
For LC-HN/D-scFv, the intense bands at the correct positions [125 kDa 
(LC-HN/D-scFv) before nicking; 75 kDa (HN/D-scFv) and 50 kDa (LC) after 
nicking and addition of dithiothreitol (DTT) to break disulfide bonds] were 
detected (Fig. 6.7), which indicated successful expression and purification of 
these toxin-scFv conjugates.  
For LC-HN-HCN/D-scFv, the intense bands at the correct position [150 kDa 
(LC-HN-HCN/D-scFv) before nicking; 100 kDa (HN-HCN/D-scFv) and 50 kDa 
(LC) after nicking and addition of dithiothreitol (DTT) to break disulfide bonds] 
were detected (Fig. 6.7), which indicated successful expression and purification 
of these toxin-scFv conjugates. 
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Fig. 6.7 SDS-PAGE analysis of expression and purification of hybrid proteins 
LC-HN/D-scFv and LC-HN-HCN/D-L-scFv in E. coli (BL21-DE3). The protein 
and proteolytic fragments migrated to the expected positions. LC = light chain 
of botulinum toxin; HN/D = translocation domain of botulinum toxin type D; 
HCN/D = N-terminal binding domain of botulinum toxin type D; L = linker; 
DTT = dithiothreitol; SC = single chain of botulinum toxin; DC = double chain 
of botulinum toxin and MW = molecular weight markers. 
 
6.2.3.4 Comparision of VAMP2 cleavage in cultured DRGs for 
LC-HN-HCN/D and LC-HN/D before and after fusion with anti-P2X3-scFv 
 
Rat DRGs, cultured for 5 days, were incubated with different concentrations of 
BoNT/D-scFv fusion proteins (LC-HN-HCN/D-MH7C and LC-HN/D-MH7C) 
and control proteins (0, 1.6, 8, 40, 200 and 1,000 nM) for 24 hours to cleave 
pain-related vesicle-associated membrane protein (VAMP2). Cells were then 
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solubilized in 2 x LDS sample buffer and subjected to SDS-PAGE and then 
Western blotting, as described in section 2.2.7.4.  
VAMP2 cleavage (reduction of band-intensity at position of ~ 18 kDa) was 
detected using mouse anti-VAMP2 (V2) antibody, followed by addition of 
associated HRP-labelled goat anti-mouse IgG. SNARE protein, syntaxin 1 (~ 
35 kDa; another inflammatory pain-related SNARE protein expressed with 
VAMP2 in vesicular membranes), was used as an internal control due to the 
lack of cleavage. The amount of VAMP2 in the loaded sample was indicated 
by dividing the density of VAMP2 by the density of syntaxin 1. The density of 
each band was analysed using ImageJ software (National Institutes of Health, 
U.S.A.). Syntaxin 1 was simultaneously detected by mouse anti-syntaxin-1 
(HPC-1).  
Fig 6.8 showed that increasing BoNT/D-scFv and BoNT/D control 
concentrations cleaved VAMP2, as indicated by reduction of the VAMP2 band 
(~ 18 kDa). Little improvement was observed after fusion with MH7C. The 
half-maximal effective concentration (EC50) for both LC-HN-HCN/D-MH7C 
and LC-HN-HCN/D was around 200 nM (Fig. 6.8a) and for LC-HN/D-MH7C 
and LC-HN/D it ranged from 40 to 200 nM (Fig. 6.8b). This lack of efficacy of 
MH7C scFv in BoNT/D delivery may be caused by BL21-DE3 E. coli 
expression levels, as it is reported that BL21-DE3 may give rise to improper 
disulphide bond formation and, thus, poor stability, folding and functionality of 
BL21-DE3-expressed LC-HN/D-MH7C and LC-HN-HCN/D-MH7C, which 
contain three functional disulphide bonds (Thangudu et al., 2008). Origami 
2(DE3) cells will be used for fusion protein expression since it was reported 
that these cells can be used to enhance disulphide bond formation (Larsen et al., 
2008). 
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Fig. 6.8a Western blot comparison of VAMP2 cleavage by 
LC-HN-HCN/D-MH7C and LC-HN-HCN/D in cultured rat DRGs. Rat DRGs 
cultured for 5 days were exposed to different concentrations of 
LC-HN-HCN/D-MH7C and LC-HN-HCN/D (0, 1.6, 8, 40, 200 and 1,000 nM) for 
24 hours. (A) After Western blotting, the membrane was stained with mouse 
anti-VAMP2 and mouse anti-syntaxin-1 antibody, followed by addition of 
alkaline phosphatase-conjugated anti-mouse IgG secondary antibody. (B) The 
EC50 for both LC-HN-HCN/D-MH7C and LC-HN-HCN/D was determined as 
being 200 nM. The results are the mean ± standard deviation (S.D.), where n = 
3. 
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Fig. 6.8b Western blot comparison of VAMP2 cleavage by LC-HN/D-MH7C 
and LC-HN/D in cultured rat DRGs. Rat DRGs cultured for 5 days were 
exposed to different concentrations of LC-HN/D-MH7C and LC-HN/D (0, 1.6, 
8, 40, 200 and 1,000 nM) for 24 hours. (A) After Western blotting, the 
membrane was stained with mouse anti-VAMP2 and mouse anti-syntaxin-1 
antibody, followed by addition of alkaline phosphatase-conjugated anti-mouse 
IgG secondary antibody. (B) The EC50 for both LC-HN/D-MH7C and LC-HN/D 
was determined as being between 200 to 1000 nM. The results are the mean ± 
standard deviation (S.D.), where n = 3. 
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6.2.4 Generation of control proteins LC-HN/A and LC-HN-HCN/A 
 
Control proteins were required for comparison of endopeptidase activity (the 
ability to cleave SNAREs) with the BoNT/A-scFv fusions. LC-HN/A and 
LC-HN-HCN/A were cloned, expressed and purified as negative controls.  
 
6.2.4.1 Western blot analysis of small-scale control protein expression 
 
Plasmids of LC-HN-HCN/A and LC-HN/A clones, in Top 10 competentant cells, 
were extracted, purified and sequenced. The positive clones were then 
transformed into BEL21-DE3. Eight clones were picked for each fusion. 
LC-HN-HCN/A and LC-HN/A expression in 1mL crude bacterial lysates was 
analysed using Western blotting, as described in section 2.2.7.2. The strong 
bands at the correct positions (125 kDa for LC-HN-HCN/A and 100 kDa for 
LC-HN/A) were successfully detected for all the 16 clones (Fig. 6.9). Clone 5 
and 13 were then picked for large-scale expression. 
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Fig. 6.9 Western blot analysis of LC-HN-HCN/A and LC-HN/A expression. 
Crude bacterial lysates from LC-HN-HCN/A and LC-HN/A cultures were loaded 
onto SDS-PAGE. After Western blotting, the membranes were stained by 
rabbit-anti-LC/A antibody. The presence of bands at about 125 kDa 
(LC-HN-HCN/A) and 100 kDa (LC-HN/A) indicated that the LC-HN-HCN/A and 
LC-HN/A were successfully expressed. LC-HN-HCN/A-scFv = light chain, 
translocation domain and N-terminal binding domain of botulinum toxin type 
A; LC-HN/A-scFv = light chain, translocation domain of botulinum toxin type 
A; lanes 1-16 = clones 1-16 and MW = molecular weight markers.  
 
6.2.4.2 SDS-PAGE analysis of fusion protein expression and purification 
 
The control protein, LC-HN-HCN/A, was expressed in E. coli (BL21-DE3 strain) 
using auto-induction medium and purified by IMAC (Fig. 6.10A) and ion 
exchange chromatography (Fig. 6.10B). The pooled samples were only 
partially nicked by incubation with Thrombin to convert the single chain (SD) 
to the biologically active di-chain form (DC) (section 2.2.7.1). At the end of 
incubation, APMSF was added into the reaction, with a final concentration of 
250 µM, to inactivate Thrombin. The intense bands at the correct position [125 
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kDa (LC-HN-HCN/A) before nicking; 75 kDa (HN-HCN/A) and 50 kDa (LC) 
after nicking (to break light chain and heavy chain and addition of DTT to 
break disulfide bonds)], respectively, were successfully detected (Fig. 6.10C), 
which indicated successful expression and purification of LC-HN-HCN/A. 
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Fig. 6.10 SDS-PAGE analysis of expression and purification of control protein 
LC-HN-HCN/A in E. coli (BL21-DE3). (A) After purification by IMAC, a 
strong band at the expected position (125 kDa) was obtained, however, some 
non-specific contaminatory bands were also present. (B) A highly purified 
sample was obtained using ion exchange chromatography. (C) The protein and 
proteolytic fragments migrated to the expected positions [125 kDa 
(LC-HN-HCN/A) before nicking, and after nicking, without DTT; 75 kDa for 
HN-HCN/A and 50 kDa for LC after nicking with DTT to break disulfide bonds]. 
LC = light chain of botulinum toxin; HN/A = translocation domain of 
botulinum toxin type A; HCN/A = N-terminal binding domain of botulinum 
toxin type A; DTT = dithiothreitol; F-T = ‘flow-through’; Lanes W1-2 = 
washes 1-2; Lanes E1-3 = elutions 1-3 and MW = molecular weight markers. 
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6.2.5 Successful expression and purification of LC-HN-HCN/A-MH7C 
fusion protein 
 
6.2.5.1 Selection of positive LC-HN-HCN/A-MH7C clones  
 
After genetic linkage of LC-HN-HCN/A and LC-HN/A with the anti-P2X3 scFv 
MH7C through PCR, the PCR product was extracted and purified, followed by 
transformation into E. coli strain, Origami™ 2(DE3) cells and plating out on 
agar plates (with 30 µg/mL kanamycin) (section 2.2.7.1). Five clones were 
picked from each fusion. After expression, plasmids were purified for selection 
of positive clones through agarose gel electrophoresis. All of the 5 clones of 
LC-HN/A-scFv (8 Kb) and 4 clones of LC-HN-HCN/A-scFv (9 Kb) were shown 
to be positive (Fig. 6.11). The sequence of clone 7 (LC-HN-HCN/A-scFv) was 
verified by DNA sequencing and it was then chosen for large-scale production. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.11 Agarose gel analysis of positive BoNT/A scFv clones. After 
separation on a 1% agarose gel, all the five clones of LC-HN/A-scFv were 
shown to be positive, as indicated by bands at 8 Kb. Four clones of 
LC-HN-HCN/A-scFv showed positive expression as indicated by correctly sized 
bands at 9 Kb. Lanes1-10 = clones 1-10. 
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6.2.5.2 Optimisation of fusion protein expression and purification 
 
6.2.5.2.1 SDS-PAGE analysis of fusion expression using auto-induction 
medium 
 
The hybrid protein LC-HN-HCN/A-MH7C was then expressed in E. coli 
[Origami™ 2(DE3) strain] using auto-induction medium. Fusion expression 
was analysed using Western blotting with 1.5 mL crude bacterial lysates from 
7 picked single clones (section 2.2.7.2). The intense band at the correct position 
(165 kDa, LC-HN-HCN/A-MH7C) was successfully detected for all the 7 clones 
(Fig. 6.12). Clone 3, which gave highest expression level, was then picked for 
large-scale expression. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.12 Western blot analysis of LC-HN-HCN/A-MH7C expression. Crude 
bacterial lysates from 7 clones of LC-HN-HCN/A-MH7C culture were loaded 
onto SDS-PAGE. After Western blotting, the membranes were stained by 
HRP-labelled mouse anti-His antibody. The presence of bands at 165 kDa 
indicated that the LC-HN-HCN/A-MH7C was successfully expressed. LC = light 
chain of botulinum toxin; HN/A = translocation domain of botulinum toxin type 
A; HCN/A = N-terminal binding domain of botulinum toxin type A; Lanes C1-7 
= clones 1-7 and MW = molecular weight markers. 
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6.2.5.2.2 Large-scale fusion expression using auto-induction medium and 
purification with IMAC 
 
LC-HN-HCN/A-MH7C (clone 3) was cultured in a volume of 4 L of 
auto-induction medium and then purified by IMAC (section 2.2.5.1). However, 
no clear band was detected at the expected position of 165 kDa (Fig. 6.13). It is 
possible for example that the fusion protein may be degraded by certain 
enzymes released by E. coli (Origami) during expression and overnight 
induction. However, lower induction temperatures and shorter induction times 
will be considered in order to significantly reduce fusion protein degeneration 
by enzymes. SB medium with 0.1 mM IPTG induction will be used instead of 
auto-induction medium. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.13 SDS-PAGE analysis of large-scale expression and purification of 
hybrid proteins LC-HN-HCN/A-MH7C in E. coli [Origami™ 2(DE3) strain]. No 
protein or fragment migrated to the expected position at 165 kDa equivalent to 
LC-HN-HCN/A-MH7C. LC = light chain of botulinum toxin; HN/A = 
translocation domain of botulinum toxin type A; HCN/A = N-terminal binding 
domain of botulinum toxin type A; F-T = ‘flow-through’; Lanes W1-2 = wash 
1-2; Lanes E 1-3 = elution 1-3 and MW = molecular weight markers. 
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6.2.5.2.3 Optimisation of fusion expression in SB medium with 
IPTG-induction 
 
SB medium with 0.1 mM IPTG induction was used for LC-HN-HCN/A-MH7C 
fusion expression instead of auto-induction medium. After OD600 nm reached 
6.0, 0.1 mM IPTG was added for protein induction at 16°C. Five mL of culture 
was harvested after 1, 2, 3, 4, 5, 6, 7 and 8 hours and overnight, respectively. 
Both ELISA and Western blotting were then performed using crude lysates of 
these samples. The sample which had been induced for 4 hours, showed the 
best titre against P2X3-257 (Fig. 6.14) and had the strongest binding at the right 
position (165 kDa) (Fig 6.15). Hence, a four-hour IPTG induction using SB 
medium was used for large-scale fusion expression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.14 ELISA analysis of LC-HN-HCN/A-MH7C expression by titration of 
crude lysates after IPTG-induction for 1-8 hours and overnight. An ELISA 
plate was coated with 2 µg/mL P2X3-257-BSA conjugate and blocked with 5% 
(w/v) milk in PBST. A range of crude lysate dilutions were applied, followed 
by HRP-labelled mouse anti-His secondary antibody (1:1,000 dilution). 
Four-hour IPTG-induction gave the highest titre. Lanes 1-8H = induction times 
of 1-8 hours and O/N = overnight. 
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Fig. 6.15 Western blot analysis of LC-HN-HCN/A-MH7C expression with 
different IPTG-induction times. Crude bacterial lysates of 
LC-HN-HCN/A-MH7C culture, from 1-8 hours and overnight induction with 0.1 
mM IPTG, were loaded onto SDS-PAGE. After Western blotting, the 
membranes were stained by HRP-labelled mouse anti-His antibody. The 
presence of bands at 165 kDa indicated that the LC-HN-HCN/A-MH7C was 
successfully expressed and the 4-hour induction gave the highest expression 
level. LC = light chain of botulinum toxin; HN/A = translocation domain of 
botulinum toxin type A; HCN/A = N-terminal binding domain of botulinum 
toxin type A; Lanes 1-8H = induction times of 1-8 hours and O/N = overnight. 
 
6.2.5.2.4 Large-scale fusion expression with 4 hour IPTG-induction and 
purification using IMAC 
 
LC-HN-HCN/A-MH7C (4 L) was expressed for 4 hours with 0.1 mM 
IPTG-induction and then purified by IMAC only (section 2.2.5.1). However, 
no clear band was detected at the right position (165 kDa) by SDS-PAGE (Fig. 
6.16A). After Western blotting, the membrane was incubated with 
HRP-labelled mouse anti-His monoclonal antibody. The strong band of scFv at 
approximately 25 kDa may have resulted from the breakdown of the fusion 
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protein, and the other strong band above 250 kDa may be aggregated fusion 
protein (Fig. 6.16B). Therefore, for further optimization, the purification 
process will be performed in the cold room (4°C) instead of at room 
temperature to reduce fusion protein degeneration and aggregation, and 
streptavidin resin linked with biotinylated P2X3-257 will be applied instead of 
IMAC for purification. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.16 SDS-PAGE and Western blot analysis of expression and purification 
of hybrid proteins LC-HN-HCN/A-MH7C in E. coli [Origami™ 2(DE3) strain] 
with 4 hours IPTG induction. (A) No band at the right position for 
LC-HN-HCN/A-MH7C (165 kDa) was detected. (B) After Western blotting, the 
membranes were stained by mouse HRP-labelled anti-His monoclonal antibody. 
The presence of bands above 250 kDa indicted aggregation of 
LC-HN-HCN/A-MH7C maybe formed. LC = light chain of botulinum toxin; 
HN/A = translocation domain of botulinum toxin type A; HCN/A = N-terminal 
binding domain of botulinum toxin type A; F-T = ‘flow-through’; W = wash; E 
= elution and MW = molecular weight markers. 
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6.2.5.2.5 Fusion purification using streptavidin-agarose resin 
 
The hybrid protein LC-HN-HCN/A-MH7C was expressed in E. coli [Origami™ 
2(DE3) strain] using SB medium and induced with 0.1 mM IPTG. The fusion 
protein was then successfully purified by high affinity streptavidin resin after 
being linked with biotinylated P2X3-257 at 4°C instead of by IMAC at room 
temperature (section 2.2.2.2). The intense bands at the correct position [165 
kDa before addition of DTT to break disulfide bonds; 115 kDa 
(HN-HCN/A-MH7C) and 50 kDa (LC) after addition of DTT] were successfully 
detected (Fig. 6.17). This indicated successful expression and purification of 
these toxin-scFv conjugates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.17 SDS-PAGE analysis of expression and purification of hybrid proteins 
LC-HN-HCN/A-MH7C in E. coli [Origami™ 2(DE3) strain]. The protein and 
proteolytic fragments migrated to the expected positions [165 kDa for 
LC-HN-HCN/A-MH7C before addition of DTT; 50 kDa for LC and 115 kDa for 
HN-HCN/A-MH7C with DTT to break disulfide bonds]. LC = light chain of 
botulinum toxin; HN = translocation domain; HCN/A = N-terminal binding 
domain of botulinum toxin type A; DTT = dithiothreitol; F-T = ‘flow-through’; 
W = wash; E = elution and MW = molecular weight markers. 
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6.2.5.2.6 Western blot analysis of large-scale fusion expression 
 
Purified LC-HN-HCN/A-MH7C was identified using Western blotting, as 
described in section 2.2.7.2. Rabbit anti-LC/A polyclonal antibody was used as 
primary antibody. The strong bands at the expected positions (165 kDa for 
LC-HN-HCN/A-MH7Cwithout DTT; 50 kDa for LC with DTT to break 
disulfide bond) indicated that the LC-HN-HCN/A-MH7C was successfully 
expressed (Fig. 6.18). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.18 Western blot analysis of LC-HN-HCN/A-MH7C expression. Purified 
LC-HN-HCN/A-MH7C was loaded onto SDS-PAGE. After Western blotting, 
the membranes were stained by rabbit anti-LC/A polyclonal antibody. The 
presence of a band at about 165 kDa (LC-HN-HCN/A-MH7C) and 50 kDa 
(LC/A) after addition of DTT indicated that the LC-HN-HCN/A-MH7C was 
successfully expressed. LC-HN-HCN/A-MH7C = light chian translocation 
domain and N-terminal binding domain of botulinum toxin type A fused with 
anti-P2X3-257 scFv antibody MH7C; LC/A = light chain of botulinum toxin 
type A; DTT = dithiothreitol; E = elution of LC-HN-HCN/A-MH7C and MW = 
molecular weight markers. 
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6.2.5.3 In vivo analysis of toxicity of novel LC-HN-HCN/A -MH7C fusion 
via mouse lethality assay 
 
Intraperitoneal injection of 1 µg (1 x 10-3 LD50 units/mg,) of 
LC-HN-HCN/A-MH7C fusion protein did not cause any mouse mortality. 
Therefore, LC-HN-HCN/A -MH7C had dramatically reduced toxicity compared 
with full length BoNT/A, which causes mouse lethality with an LD50 value of 5 
pg (5 x 10-9 LD50 units/mg). 
 
6.2.5.4 ELISA analysis of antigen-binding efficiency of 
LC-HN-HCN/A-MH7C 
 
In order to demonstrate that MH7C scFv maintains P2X3-257 binding ability 
on fusion to LC-HN-HCN/A, P2X3-257-binding activity was analyzed using 
direct ELISA. An ELISA plate was coated with P2X3-257-BSA conjugates, as 
described in section 2.2.3.13. A range of concentrations of 
LC-HN-HCN/A-MH7C or MH7C scFv antibody was prepared and added into 
individual wells, followed by the HRP-labelled mouse anti-His secondary 
antibody. For the negative control, BSA and LC-HN-HCN were added. 
The LC-HN-HCN/A-MH7C limit of detection (LOD, three times greater than 
negative control) for P2X3-257 antigen peptide was 60 µM, which was similar 
to the LOD of MH7C scFv (40 µM) (Fig. 6.19). 
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Fig. 6.19 Determination of the binding capacity for the LC-HN-HCN/A-MH7C 
for P2X3-257. LC-HN-HCN/A-MH7C and MH7C scFv antibody gave similar 
binding profiles demonstrating that MH7C maintains P2X3-257 binding ability 
after fusion with LC-HN-HCN/A. The results are the mean ± standard deviation 
(S.D.); where n = 3. 
 
6.2.5.5 Cleavage of SNAP-25 in cultured DRGs for LC-HN-HCN/A before 
and after fusion with MH7C 
 
A series of concentrations of LC-HN-HCN/A-MH7C and LC-HN-HCN/A control 
(0, 0.01, 0.1, 1, 10 and 100 nM) were added to rat DRG cultures (P5, 6 DIV) 
and incubated for 24 hours at 37°C in 5% (v/v) CO2, as described in 2.2.6.7. 
Cells were then harvested in LDS-sample buffer and Western blotting of the 
cells was performed. The cleavage of SNAP-25 was detected using rabbit 
anti-SNAP-25 antibody which detects both cleaved SNAP-25 (~ 25 kDa) and 
full length SNAP-25 (~ 26 kDa). Observation of the cleaved form of SNAP-25 
starts to occur following exposure to 100 nM of LC-HN-HCN/A, while for 
LC-HN-HCN/A-MH7C it occurs at 0.1 nM. The presence of a greater amount of 
the cleaved form of SNAP-25 with LC-HN-HCN/A-MH7C compared 
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LC-HN-HCN/A indicates that the susceptibility of LC-HN-HCN/A is improved by 
fusing with MH7C. Thus, the concept that recombinant rabbit anti-P2X3-257 
scFv antibody, MH7C, can target BoNT/A to sensory neurons for 
inflammatory pain treatment was verified in vitro (Fig. 6.20).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.20 Western blot analysis of cleavage of SNAP-25 by 
LC-HN-HCN-HCC/B-scFv and LC-HN-HCN-HCC/B in cultured rat DRGs. After 
Western blotting, the membrane was stained by rabbit anti-SNAP-25 (1:1,000 
dilution), followed by addition of HRP-labelled anti-rabbit IgG (1:1,000 
dilution). The SNAP-25 cleaved form (~ 25 kDa; lower band) was enhanced 
with increased concentrations of LC-HN-HCN/A-MH7C from 0 to 100 nM. 
LC-HN-HCN/A-MH7C = light chain, translocation domain and N-terminal 
binding domain of botulinum toxin type A fused with anti-P2X3-257 scFv 
antibody MH7C and MW = molecular weight markers. 
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6.2.5.6 Inhibition of K
+
-stimulated release of calcitonin gene-related 
peptide (CGRP) highlights the anti-nociceptive potential of the 
LC-HN-HCN/A-MH7C fusion protein 
 
A range of concentrations of LC-HN-HCN/A-MH7C (0, 0.01, 0.1, 1, 10 and 100 
nM) were added into rat DRGs cultures (P5, 6 DIV) and incubated for 24 hours 
at 37°C in 5% (v/v) CO2, as described in section 2.2.7.4. K
+-evoked CGRP was 
monitored by EIA (section 2.2.7.4.2) after overnight incubation of toxins with 
rat DRG cultures. CGRP release was found to be significantly inhibited by 1 
nM LC-HN-HCN/A-MH7C (Fig. 6.21). K
+-evoked CGRP release was inhibited 
by LC-HN-HCN/A-scFv with a concentration dependence identical to that for 
SNAP-25 cleavage, which demonstrated potential pain treatment value for this 
novel fusion construct.  
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Fig. 6.21 LC-HN-HCN/A-MH7C inhibits Ca
2+-dependent CGRP release evoked 
from rat DRGs and cleaves SNAP-25. DRGs were exposed to BoNT/A and the 
release of CGRP was assayed over 10 minutes. The SNAP-25 cleavage ratio 
was calculated using digital images of the gels. An immunoblot showed 
cleavage of SNAP-25 by LC-HN-HCN/A-MH7C but much less was seen with 
the LC-HN-HCN/A control. The dose-response curve indicates BoNT/A-induced 
blockade of CGRP release evoked by 60 mM K+, which correlates with the 
percent of remaining SNAP-25. The results are the mean ± standard deviation 
(S.D.); where n = 3. 
 
6.3 Discussion 
 
About 20% of European and United States adult populations suffer from chronic 
inflammatory pain, while less than 30% of these patients can be treated by 
current therapies. The two widely used therapies are non-medication treatments 
(e.g. massage, physical therapy and acupuncture) and analgesic drug treatments, 
for instance, nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g. aspirin, 
ibuprofen and naproxen) and opioids. Non-medication treatments are more 
likely to involve physical trials, which may need long-term and frequent 
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treatment and are limited in their efficacy. NSAIDs act to reduce the production 
of prostaglandins (chemicals that promote inflammation, pain, and fever) and, 
hence, reduce inflammation and discomfort. The limitations of NSAIDs are 
gastrointestinal and cardiovascular harm. Opioids can relieve pain by decreasing 
perception of pain, decreasing reaction to pain and increasing pain tolerance. 
Opioids are limited in their serious side effects including sedation, respiratory 
depression, constipation and opioid dependence. Therefore, effective and 
specific therapeutics with higher efficacy and fewer side effects for chronic 
inflammatory pain are urgently needed (Breivik et al., 2006; Röhn et al., 2011).  
Antibody-drug conjugate, a novel type of targeted therapy, is widely used in 
clinical applications, and about 20 antibody conjugates are currently in clinical 
trials (Teicher and Chari, 2011). It consists of an antibody (or antibody 
fragment, for instance, scFv and Fab) linked to a drug (for instance, a toxin). 
The antibody enables the antibody-drug conjugates to bind to the specific 
protein or cells. The conjugates should then be internalized by the cell and the 
drug released for treatment. The side effects should be less due to antibody 
targeting (Chari et al., 1992). Antibody-drug conjugates are widely used in 
cancer therapy. Many companies have put tremendous efforts into research 
work on antibody-drug generation and modification for better efficacy. For 
instance, Seattle Genetics (U.S.A.) Pfizer (U.S.A.), Abbott (U.S.A.), 
Roche/Genentech (U.S.A.) to optimize their therapeutic toxins and 
non-cleavable linkers. ImmunoGen (U.S.A.) is currently interacting with 
Novartis (Switzerland) and Roche/Genentech (U.S.A.) for their 
tumor-activated prodrug (TAP) linker technology. Many antibody-drug 
conjugates have been approved for clinical applications (Table 6.1), and, based 
on this, an antibody fragment-drug targeted therapy model was applied in this 
research. 
It is demonstrated that P2X3 plays a crucial role in inflammatory pain 
signalling through ATP which is released by inflamed tissue (Xu and Huang, 
2002). Thus, P2X3 may be exploited as a promising molecular target for pain 
treatment (North, 2003). In this study, a target pain treatment principle was 
initially proved by conjugating translocation and protease domains of BoNT/A 
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and BoNT/D [LC-HN/A or LC-HN/D] with an anti-P2X3 antibody (against P2X3 
extracellular domain) and binding in vitro on rat DRG cells. 
Table 6.1 Antibody-drug conjugates have been approved or are in the process 
of approval for clinical use.  
 
Name of drug Disease for treatment Status in clinical 
trials 
Gemtuzumab ozogamicin 
(Mylotarg) 
Acute myelogenous 
leukemia 
Approved in 2000 
(U.S. Food and Drug 
Administration, 
2013) 
Brentuximab vedotin 
(Adcetris) 
Relapsed and refractory 
hodgkin lymphoma and 
anaplastic large cell 
lymphoma 
Approved in 2011 
(U.S. Food and Drug 
Administration, 
2013) 
ado-Trastuzumab 
emtansine (T-DM1; 
Kadcyla) 
Breast cancer Approved in 2013 
(U.S. Food and Drug 
Administration, 
2013) 
Inotuzumab ozogamicin 
(CMC-544) 
Non-Hodgkin’s lymphoma Phase III terminated 
(Tuma, 2011) 
Glembatumumab vedotin 
(CDX-011, 
CR011-vcMMAE) 
Melanoma and metastatic 
breast cancer 
Phase II terminated 
(Keir and Vahdat, 
2012) 
lorvotuzumab mertansine 
(IMGN901) 
CD56 cancers (e.g. 
small-cell lung cancer, 
ovarian cancer) 
Phase II terminated 
(Immunogen, 2013) 
IMGN242 
(huC242-DM4) 
Can Ag- expressing gastric 
cancer 
Phase II terminated 
(Qin et al., 2008) 
AEZS-108 (AN-152) Ovarian cancer Phase II terminated 
(Engel et al., 2012) 
PSMA ADC, PSMA with 
MMAE 
Metastatic prostate cancer Phase II terminated 
(Wang et al., 2011) 
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AVE9633 Relapsed/refractory acute 
myeloid leukemia 
Phase I terminated 
(Lapusan et al., 2012) 
SAR3419 B-cell non-Hodgkin’s 
lymphoma (NHL) 
Phase I terminated 
(Younes et al., 2012) 
Cantuzumab Mertansine 
(huC242-DM1) 
Colorectal, pancreatic, and 
non-small cell lung cancer 
Phase I terminated 
(Xie et al., 2004) 
CAT-8015 (anti-CD22) Acute lymphoblastic 
leukemia or non-Hodgkin's 
lymphoma 
Phase I terminated 
(Kreitman et al., 
2012) 
IMGN388 Solid tumor Phase I terminated 
(Immunogen, 2013) 
milatuzumab-doxorubicin Relapsed multiple myeloma Phase I terminated 
(Govindan et al., 
2013) 
SGN-75 (anti-CD70) Non-Hodgkin’s lymphoma 
or renal cell carcinoma 
Phase I terminated 
(Ryan et al., 2010) 
AGS-16M8F Renal cell carcinoma Phase I terminated 
(Gudas et al., 2010) 
Anti-CD22-MCC-DM1 Leukemia Preclinical trials 
initiated (Polson et 
al., 2010) 
ASG-22ME Bladder, breast, lung and 
pancreatic cancers 
Preclinical trials 
initiated 
(SeattleGenetics, 
2013) 
SGN-CD33A Acute myeloid leukemia 
(AML) 
Preclinical trials 
initiated 
(SeattleGenetics, 
2013) 
 
 
Botulinum neurotoxins (BoNTs), produced by Clostridium botulinum, are 
known to be highly potent inhibitors of regulated exocytosis of various cell 
mediators (Montal, 2010). There are seven serotypes of BoNTs (A - G) and 
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each contains three domains, a Zn2+-dependent protease light chain (LC) linked 
by a disulphide bond to a translocation moiety (HN) and a receptor binding 
domain (HC). The C-terminal half moiety of the binding domain (HCC) binds 
with high affinity to receptors on the pre-synaptic membrane. Little is known 
about the function of its N-terminal half moiety (HCN). HN forms a channel in 
the endosomal membrane and translocates its LC to the cytosol, after toxin 
binding and internalization into nerve terminals, The LC cleaves and 
inactivates SNAREs essential for exocytosis (Lacy and Stevens, 1998; Jin et al., 
2006). Toxin without HC (termed LC-HN) was shown to be non-toxic due to its 
inability to bind, whereas the replacement of the HC with a binding moiety 
delivered protease to the neurons (Foster, 2004). In this study, LC/A an LC/D 
successfully cleaved their specific SNAREs, SNAP-25 and VAMP2. LC-HN/A 
and LC-HN/D, which was used as negative control due to lack of toxicity, 
showed little SNAP-25 or VAMP2 cleavage.  
It was reported that BoNTs have potential value for pain treatment, including 
low back pain, fibromyalgia-myofascial pain, temporomandibular joint and 
orofacial pain. BoNT/A was proven to have potential for inflammatory pain 
treatment by inhibiting the release of pain-related peptides, calcitonin 
gene-related peptide (CGRP) and substance P (SP), through cleavage of its 
substrate, SNAP-25 (Datar et al., 2004; Meng et al., 2007). BoNT/D cleaves 
VAMP and then inhibits the release of substance P (SP) (Filipović et al., 2012). 
BoNT/A and BoNT/D have been used by many researchers for pain relief (Ney 
and Joseph, 2007; Evidente and Adler, 2010). However, both BoNT/A and 
BoNT/D bind to sensory neurons as well as cholinergic neurons, sympathetic 
neurons and non-neuronal cells, which may give unwanted ‘off-targeting 
effects’ (Peng et al., 2011). For instance, even certain types of pain (e.g. diabetic 
neuropathic pain, interstitial cystitis/bladder pain, visual numerical pain and 
inflammatory pain) can be relieved upon local injection of minute quantities of 
BoNT/A (Dolly et al., 2011). Side effects were common and included 
blepharoptosis, muscle weakness, neck stiffness, parasthesia, and skin tightness 
(Jackson et al., 2012). Therefore, targeting molecules which enable specific 
binding and entry into nociceptive neurons for effective relief of chronic pains 
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are warranted in order to reduce unwanted side effects. However, no research 
related to targeted BoNT for pain treatment has been reported to date. 
The biotin-streptavidin interaction is known to be one of the strongest 
non-covalent biological interactions, with high strength and specificity 
(Holmberg et al., 2005). Therefore, this method of linkage was chosen to join 
the rabbit anti-P2X3 IgG and LC-HN/A. Anti-P2X3-IgG-LC-HN/A cleaved 
more SNAP-25 than LC-HN/A, which demonstrated that the endopeptidase 
activity of anti-P2X3-IgG-LC-HN/A was higher than that of LC-HN/A (Fig. 5.4), 
thus, proving that anti-P2X3 antibody may be a promising targeting agent for 
BoNT.  
Anti-P2X3-scFv was then applied as a delivery moiety for targeted treatment of 
inflammatory pain by fusing with BoNT/D, using a molecular biological 
approach. The non-structural linker, (GGGGS)3, used to join BoNT and 
anti-P2X3 scFv gene, can also separate BoNT and scFv in the fusion construct 
to prevent incorrect interactions with functional domains (Greice et al., 2012). 
Since this is the first attempt to fuse and express botulinum toxin with a 
targeting antibody, no comparison can be made with another BoNT-antibody. 
ScFvs were previously applied for targeted therapy by fusion with other 
therapeutic proteins, and these fusion proteins proved to be more effective than 
therapeutic proteins alone, further decreasing non-specific side effects 
(Kreitman and Pastan, 2011; Chen et al., 2012; Sheng et al., 2012).  
The BL21-DE3 E. coli can offer high-level protein expression. However, there 
may be a potential problem with BL21-DE3-expressed fusion proteins if those 
proteins possess disulphide bonds, as disulphide bonds cannot be formed in the 
cytoplasm of BL21-DE3 cells (Zhang et al., 2010). Disulphide bonds are well 
known to be crucial for stability, folding and functionality of proteins and so 
improper formation of disulphide bonds may result in non-functional proteins 
(Thangudu et al., 2008). For this reason, the LC-HN/D-scFv and 
LC-HN-HCN/D-scFv (with three disulphide bonds), expressed in BL21-DE3, 
may have lower activity due to misfolding, which is then confirmed by 
comparing endopeptidase activity with LC-HN/D and LC-HN-HCN/D.  
Origami™ 2 host strains have mutations in both the thioredoxin reductase 
(trxB) and glutathione reductase (gor) genes, which greatly enhance disulfide 
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bond formation in cytoplasm (Larsen et al., 2008). Therefore, Origami™ 
2(DE3), from the Origami™ 2 strain, was used for expression of the novel 
fusion proteins for better disulphide bond formation. BoNT/A is also effective 
in treating chronic inflammatory pain and the SNAREs (SNAP-25) cleaved by 
BoNT/A is easier to detect than VAMP2 (Kaufman and Karceski, 2009). 
Hence, BoNT/A-anti-P2X3 scFv (LC-HN/A-MH7C and LC-HN-HCN/A-MH7C) 
were generated and transformed into Origami™ 2(DE3). Optimization of 
BoNT/A-scFv fusion protein expression and purification conditions were 
performed, including factors such as medium, induction temperature, induction 
time and purification resin. In this case, 0.1 mM IPTG-induction was proved to 
be better than auto-induction, as more fusion protein was obtained with less 
non-specific proteins. An induction temperature of 16°C gave less aggregation 
than 25°C (Azaman et al., 2010). Purification performed at 4°C gave rise to 
less protein breakdown and 4 hour inductions gave the highest fusion 
expression levels (Yan et al., 1996). Streptavidin resin, conjugated with 
biotinylated antigen, gave better fusion protein purification than IMAC. 
In vitro data demonstrated that anti-P2X3-257 antibody scFv MH7C 
specifically delivered the endopeptidase activity of BoNT/A to sensory neurons, 
as shown by the dose-dependent cleavage of SNAP-25 and the pronounced 
inhibition of neuropeptide release, which indicates its potential therapeutic 
efficacy of chronic inflammatory pain (e.g. arthritis and infections).  
This report represents the first attempt to selectively target the endopeptidase 
activity of clostridial neurotoxins to specific cell types through the genetic 
fusion with an antibody. Only one paper was published by the Duggan group 
(2002) for a similar purpose. Their conjugated purified recombinant LC-HN/A 
and Erythrina cristagalli lectin (ECL) which recognized terminal galactosyl 
residues at the protein level for selectively delivery of the endopeptidase activity 
of BoNT/A to primary nociceptive afferent neurons. Their work proved that the 
potent endopeptidase activity of BoNTs can be selectively retargeted to cells or 
pathways of interest for inhibition of neurotransmitter release, thus achieving 
pain treatment. However, the conjugation mixture of recombinant LC-HN/A and 
ECL easily leads to aggregation, which makes the LC-HN/A-ECL impure and 
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hard to quantify (Singh et al., 2011).  Genetic fusion can solve this problem and 
hence was applied in this study.  
The efficacy of this therapeutic needs further in vivo evaluation using 
established capsaicin-induced or formalin-induced rat inflammatory pain 
models. It was reported that P2X3 plays a crucial role in formalin-induced and 
capsaicin-induced inflammatory pain (Tsuda et al., 1999; Souslova et al., 2000) 
and both of the capsaicin receptor, VR1, and P2X3 are expressed in the same 
group of neuronal cells (Yiangou et al., 2001; Renton et al., 2003). Therefore, 
the efficacy of LC-HN-HCN/A-MH7C can be evaluated in vivo in 
capsaicin-induced or formalin-induced inflammatory pain models.  
In summary, this research represents the first attempt to conjugate botulinum 
toxin with a targeting anti-P2X3 antibody (both polyclonal antibodies and a 
scFv antibody fragment, MH7C), and successfully demonstrated the principle 
for targeted treatment of inflammatory pain This novel approach offers 
improvement over existing treatments which inject BoNT/A only (Dolly et al., 
2011) and could protect patients from serious side effects (Jackson et al., 2012), 
which result from nonspecific binding to cholinergic neurons, sympathetic 
neurons and non-neuronal cells (Peng et al., 2011). Patients who suffer from 
low back pain, fibromyalgia-myofascial pain, temporomandibular joint and 
orofacial pain may benefit from this novel therapeutic. 
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Overall Conclusions and 
Recommendations  
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7.1 Overall conclusions 
 
Biological techniques are widely used in medical research for understanding 
new diseases, in laboratory diagnostics and in drug development and 
immunological, cell biological, pharmacological and molecular biological 
approaches are applied in development of clinically applicable strategies for 
diagnostic and therapeutic purposes. Antibodies which target specific proteins 
or cells related to certain diseases play a crucial role have achieved remarkable 
clinical success. For over last twenty years, antibody genes have been cloned, 
genetically manipulated, and expressed to produce antigen-binding proteins. 
Recombinant antibodies (e.g. scFvs) play a crucial role in biomedical research 
and are often used as clinical therapeutic reagents because of their high 
specificity for target antigens, small size, and a lower negative response by the 
human immune system compared with natural antibodies (Jefferis, 2009). 
Antibody-drug conjugates are a relatively new form of targeted therapy and are 
becoming widely used in modern clinical applications (Teicher and Chari, 
2011). In the research described in this thesis, a scFv antibody was linked to a 
drug (i.e. botulinum neurotoxins). The antibody delivers the linked drug to the 
target cells, followed by internalization of conjugates by the cell and, finally 
the drug is available for therapy. Fewer side effects should be caused or 
expected because of antibody-mediated targeting (Chari et al., 1992).  
This study presents a first attempt to generate a recombinant scFv antibody, 
MH7C, against a peptide sequence of the extracellular domain of P2X3 (Val257 
- Asp276), using phage display. The MH7C scFv could be internalized through 
binding to the peptide sequence of the P2X3 extracellular domain, which is 
crucial for targeted therapeutic delivery. Most commercial and published 
anti-P2X3 antibodies are polyclonal antibodies against a fifteen-amino acid 
peptide sequence (Val383-His397) identical to the carboxyl-terminus of the P2X3 
receptor intracellular domain. The current finding also provided the first proof 
of principle using a scFv antibody for targeted delivery of the core BoNT/A 
therapeutic [LC-HN-HCN/A] to nociceptive sensory neurons. This conjugate 
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should have a much-improved therapeutic ‘safety-window’ for treatment of 
inflammatory pain. 
BoNT/A inhibits release of pain peptides (SP and CGRP) from sensory 
neurons by cleavage of its specific intracellular SNAP-25 (Aoki and Guyer, 
2001; Meng et al., 2007; Meng et al., 2009). The truncation of 9 amino acids at 
the C-terminus of SNAP-25 at Gln197-Arg198 provides a long-lasting (~24 
weeks) alleviation of chronic pain with reduced frequency of pain occurrence 
(Dodick et al., 2010). The novel targeted molecule generated overcame the 
broad-spectrum binding of the native entire BoNT/A which binds synaptic 
vesicle protein 2 (SV2), that is widely expressed by cholinergic, sympathetic, 
sensory neurons as well as multiple non-neuronal cells (Dong et al., 2006; 
Peng et al., 2011).  Therefore, treatment with BoNT/A for pain often resulted 
in unwanted ‘off-targeting effects’ (Jackson et al., 2012). These could be 
minimised by using the specific targeting strategy reported herein.  
An extracellular-domain Ile257-Pro301 (Zemkova et al., 2004), of the 
transmembrane protein was used to generate the anti-P2X3 receptor antibodies, 
so that the BoNT-based therapeutic attached should be selectively delivered to 
P2X3-expressing neurons and, hopefully, disrupt the pain signalling pathway 
(Koshimizu et al., 2002). Genetic fusion of LC-HN-HCN/A (Fig. 7.1a) and 
anti-P2X3 scFv antibodies against the extracellular domain of P2X3 proved to 
be successful by monitoring cleavage of pain-related protein, SNAP-25, in 
sensory neurons. The scFv to P2X3 was shown to bind, internalize and deliver 
LC/A for dose-dependent cleavage of SNAP-25 in sensory neurons (Fig. 7.1b). 
This binding proved to be specific, based on competition by the peptide used 
for antibody generation. Clearly, this would be an ideal candidate for a delivery 
agent for targeted treatment.  
After formalin fixing and paraffin embedding (FFPE), the state of the proteins 
in a tissue sample may be altered, which may lead to non-specific binding 
(high background staining), and may then mask the detection of the target 
antigen (Scicchitano et al., 2009). This may cause non-specific staining 
background in brain negative controls. However, after preincubation of 
antibodies with specific P2X3 peptides, all of the staining on the membrane of 
rat (P1) DRG cells, rat (18 weeks) brain neurons and human bladder neuron 
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cells disappeared (stained by commercial anti-P2X3 antibody, rabbit-DARP 
polyclonal antibody and Alexa-594-labelled rabbit anti-P2X3 scFv antibody). 
Moreover, as rabbit-DARP polyclonal antibody and Alexa-594-labelled rabbit 
anti-P2X3 scFv antibody shared a similar staining pattern with commercial 
anti-P2X3 antibody and published data (Pearson and Carroll, 2004; Cheung et 
al., 2005; Liu et al., 2009), it can be concluded that both rabbit-DARP 
polyclonal antibody and anti-P2X3 scFv antibody effectively bind to both 
human and rat cell-expressed P2X3. 
 
 
 
 
 
 
 
 
 
 
Fig. 7.1a Structure of LC-HN-HCN/A. LC-HN-HCN/A consists of one light chain 
(LC), one heavy chain translocation domain (HN) and C terminal binding 
domain (HCN). 
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Fig 7.1b Procedure of LC-HN-HCN/A and anti-P2X3 scFv fusion inhibits pain by cleavage of pain-related protein, SNAP-25. 
LC-HN-HCN/A delivered into sensory neuron by anti-P2X3 scFv through binding of P2X3 extracellulardomain, then internalizing via 
endocytosis. Light chain of BoNT/A is then released by heavy chain channel on vesicle, followed by binding and cleaving of SNAP-25. 
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In vitro data demonstrated that anti-P2X3-257 antibody scFv MH7C 
specifically delivered the endopeptidase activity of BoNT/A to sensory neurons, 
as shown by the dose-dependent cleavage of a pain-related protein, SNAP-25, 
and the detectable inhibition of the release of a pain peptide, CGRP, which 
indicates its potential therapeutic efficacy, as suggested by previous studies 
(Meng et al., 2007; Durham and Masterson, 2013). In vivo data showed this 
novel agent lacks significant cytotoxicity, which supports its safety for possible 
future use as an anti-nociceptive. Compared to traditional treatment which 
utilises injection of BoNT/A only (Dolly et al., 2011), this new therapeutic 
provides a more specific focus as the specific delivery agent, anti-P2X3-257 
scFv, is fused with BoNT/A to deliver drug into the inflammatory pain 
signalling pathway (Jarvis et al., 2002; Xu and Huang, 2002). This novel 
targeted treatment stops unwanted ‘off-targeting effects’, for instance, 
blepharoptosis, muscle weakness, neck stiffness, parasthesia, and skin tightness 
(Jackson et al., 2012), which is caused by non-specific binding of cholinergic 
neurons, sympathetic neurons and non-neuronal cells (Peng et al., 2011). The 
patients who suffer from diabetic neuropathic pain, chronic neuropathic pain, 
low back pain bladder pain and neck pain which can be treated using BoNT/A 
could benefit from this new intervention with more targeted treatment and less 
side effects (Jackson et al., 2012). 
It is the first report of selectively targeting the endopeptidase activity of 
clostridial neurotoxins to specific cell types through genetic fusion with an 
antibody. Duggan et al. (2002) tried to conjugate purified recombinant 
LC-HN/A and commercial Erythrina cristagalli lectin (ECL) which recognized 
terminal galactosyl residues for selectively delivery of the endopeptidase 
activity of BoNT/A to primary nociceptive afferent neurons. However, as 
recombinant LC-HN/A and a mixture of LC-HN/A and ECL tend to cause 
heavy aggregation, the LC-HN/A-ECL conjugate contained aggregates and was 
hard to quantify, which may be a significant negative issue for clinical analysis 
(Singh et al., 2011). The approach used in the research undertaken in this 
research i.e. fusion at the gene level, may solve this problem.  
Biological mechanisms may sometimes translate poorly from in vitro models 
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into clinical efficacy and effectiveness, which may relate to antibody 
specificity or affinity. However, this problem could be solved by scFv antibody 
modification, for instance, antibody light and heavy chain shuffling.  
The efficacy of this therapeutic will be further evaluated in the future using 
established capsaicin-induced or formalin-induced rat inflammatory pain 
models which showed sensitivity to the delivery agent P2X3 (Tsuda et al., 1999; 
Souslova et al., 2000).  
 
The key outcomes from this study can be summarized as following four 
sections: 
 
Section 1) Culture of rat DRG cells  
 
Rat DRG cells, having a high level of P2X3 expression (over 70% of the 
cultured DRGs stained positively for P2X3 by immunofluorescence) were 
successfully cultured. 
Cultured DRGs showed sensitivity to BoNT/A and BoNT/D, by cleavage of 
pain-related proteins SNAP-25 and VAMP2. Both polyclonal anti-P2X3 IgG 
and recombinant anti-P2X3 scFv antibodies demonstrated their specificity to 
P2X3 (expressed in cultured rat DRGs) by Western blotting and 
immunofluorescent staining of rat DRG-expressed P2X3. Thus, the cultured 
DRGs were proven to be a promising in vitro model for investigating the 
specificity and effect of this novel targeted therapeutic. 
 
Section 2) Generation of rabbit anti-P2X3-scFv recombinant antibodies 
 
Rabbit anti-P2X3 extracellular domain scFv recombinant antibodies, with high 
specificity and affinity, were successfully generated. 
Two extracellular P2X3 peptide conjugates (P2X3-257-BSA and 
P2X3-60-BSA/KLH) were selected for immunization of  rabbits, mice and 
chickens. Rabbits and mice showed a high immune response against P2X3-257, 
but a low immune response to P2X3-60, while chickens had low immune 
responses to both P2X3-257 and P2X3-60.  
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Rabbit polyclonal antibodies were purified using both protein A and 
streptavidin-agarose chromatography (bind P2X3-257/60-biotin to produce 
P2X3-257/60 column), and 8.67 mg (1.7 mg/mL) rabbit anti-P2X3 Ig was 
generated. 
A rabbit scFv library was successfully built, and phage display was used for 
selection of anti-P2X3-257 scFv recombinant antibodies. An anti-P2X3-257 
scFv clone, H7C, was proven to have high specificity to P2X3 using ELISA, 
Western blotting and immunofluorescence-based staining. The IC50 of the 
rabbit anti-P2X3-257 scFv (0.17 nM) was 51 times higher than that of 
polyclonal anti-P2X3-257 antibody (8.70 nM) (Fig. 3.15b), which indicated 
that a high affinity clone was isolated from this rabbit scFv library.  
 
Section 3) H7C anti-P2X3-257 scFv antibody was optimized and specificity 
was proved in vitro 
 
After mutation of Cys80 to Ala, the expression level of anti-P2X3 scFv was 
improved 3.5 fold (from 277.7 to 978.2 µg/mL) compared to the non-mutated 
scFv. 
Specificity of rabbit anti-P2X3-scFv antibody was successfully demonstrated in 
vitro by several approaches. Western blotting indicated specific binding of 
rabbit anti-P2X3-scFv antibody by detecting the specific P2X3 band at the 
correct position (50-55 kDa) (Fig. 5.1a). Immunofluorescence showed DRG 
cells staining positively with sharp green fluorescence, which was co-localised 
with commercial anti-P2X3 polyclonal antibody staining (Fig. 5.5). In addition, 
flow cytometric studies showed that median fluorescence intensity is 
dramatically increased to 425 W/m², which is 3.6 times higher than negative 
control (118 W/m²) and 1.2 times higher than positive control (356 W/m²) (Fig. 
5.7). Finally, immunohistochemical staining indicated that the membrane of 
DRG cells in rat dorsal root ganglions, rat cortical neurons and human bladder 
neurons were positively stained by commercial anti-P2X3 antibody, 
rabbit-DARP polyclonal antibody and Alexa-594-labelled rabbit anti-P2X3 
scFv antibody (Fig. 5.8-5.10). 
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Section 4) Conjugation of BoNT/A(or/D) with anti-P2X3 antibody 
 
Proof of principle of targeting of  BoNT/A(or/D) via anti-P2X3 polyclonal and 
scFv antibody (against the P2X3 extracellular domain) to inflammatory pain 
signaling pathway was shown.  
Rabbit anti-P2X3 IgG was conjugated with translocation and protease domains 
of BoNT/A (LC-HN/A). The novel conjugate ((LC-HN/A-anti-P2X3 IgG) was 
shown to have higher endopeptidase activity by increasing cleavage of 
SNAP-25 in rat DRG cells compared to LC-HN/A only.  
The scFv gene was then fused to BoNT/D and cloned into the PET29a vector. 
Two different forms of BoNT/D-anti-P2X3 scFv (LC-HN/D-scFv and 
LC-HN-HCN/D-L scFv) were successfully expressed in BL21-DE3 and purified 
by IMAC (Fig. 5.6). The purified BoNT/D-anti-P2X3 scFv fusion protein 
successfully cleaved its specific SNARE (VAMP2) on rat DRG cultures (Fig. 
5.7), but little improvement was found when compared with control proteins, 
LC-HN/D and LC-HN-HCN/D. This may be caused by poor disulphide bond 
formation ability of BL21-DE3, which then leads to protein dysfunction.  
In order to improve fusion activity, the MH7C scFv gene was fused to 
LC-HN/A and LC-HN-HCN/A, and then successfully expressed in Origami 
2(DE3), which was reported to enhance disulphide bond formation. The 
LC-HN-HCN/A-MH7C fusion was successfully purified using 
streptavidin-agarose resin and in vivo data showed this novel fusion had higher 
endopeptidase activity than the LC-HN-HCN/A control, thus demonstrating the 
endopeptidase activity of this novel fusion protein and indicating potential 
therapeutic efficacy. Lack of cytotoxicity in vivo was proved by intraperitoneal 
injection of 1 µg of the fused protein, which supports its potential safety in 
treatment applications.  
 
7.2 Recommendations for future work 
 
For future work, modification of scFv antibody will be made for better 
specificity and affinity. Fresh frozen tissue samples will be used instead of 
formalin fixing and paraffin embedded tissue samples. Finally, the efficacy of 
LC-HN-HCN/A-MH7C will be evaluated in vivo. 
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Biological mechanisms may sometimes translate poorly from in vitro models 
into clinical efficacy and effectiveness. Issues that may arise may be related to 
antibody specificity or affinity. These could be overcome by scFv antibody 
modification (e.g. antibody light and heavy chain shuffling may be performed 
to solve such problems). Chain shuffling is an in vitro recombination method 
which is frequently used as a tool for antibody modification (Joerm, 2003; 
Clackson et al., 2007). It was successfully and widely used on in vitro antibody 
fragment affinity maturation (Rojas et al., 2004). For scFv antibody light chain 
shuffling, the variable heavy chain gene of MH7C would be recombined with a 
wide variety of rabbit light-chain variable genes (Rojas et al., 2004). Otherwise, 
for heavy chain shuffling, the original variable light chain gene of MH7C 
would be recombined with a variable domain library of heavy chain genes 
(Kang et al., 1991). 
Non-specific binding (high background staining) is a common problem in 
formalin fixed and paraffin embedded (FFPE) tissue samples (caused by the 
altered state of the proteins) (Marshall et al., 2009). Freshly frozen (FF) 
samples could be used for further optimisation of immunohistochemical 
staining to achieve lower background. Instead of formalin fixation and paraffin 
embedding, fresh tissue samples of rat brain, rat spine and human bladder 
could be frozen directly in OCT® or Cryomatrix®. Tissue slides would then 
immunostained with anti-P2X3 antibody. The specific staining may be detected 
using a polymer-based kit with DAB (commercial anti-P2X3 antibody, 
rabbit-DARP polyclonal antibody) or red fluorescent staining 
(Alexa-594-labelled rabbit anti-P2X3 scFv antibody).  
In vivo data showed that the novel agent, LC-HN-HCN/A-MH7C, lacked 
significant cytotoxicity, which supports its safety for possible future use as an 
anti-nociceptive. However, the efficacy of this therapeutic needs to be further 
evaluated using inflammatory pain models. As both of capsaicin-induced or 
formalin-induced inflammatory pain models were proved to be sensitive to 
P2X3 receptor (Tsuda et al., 1999; Souslova et al., 2000), P2X3 targeted BoNT 
can work on a capsaicin-sensitive and formalin-sensitive pain models. 
Unfortunately, these in vivo rat pain models have not been successfully 
established by our collaborators to date. In the approach envisaged injection of 
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capsaicin or formalin into the rat hindpaw is performed to induce the relevant 
pain models. and an evaluation of pain behaviour carried out (Ortega-Álvaro et 
al., 2012) The addition of LC-HN-HCN/A-anti-P2X3-scFv should result in a 
decrease in the number of paw licking and jumping/ lifting events 
(Gangadharan et al., 2009).  
In order to prove LC-HN-HCN/A-anti-P2X3-scFv could inhibit sensory neuron 
sensitization selectively in vivo models, the rotarod test will be applied. The 
rotarod test is a safe and humane way to provide classical and sensitive index 
of motor dysfunction. In rotarod test, the animals are placed on textured drums 
to avoid slipping. When an animal drops onto the individual sensing platforms 
below, test results are recorded digitally and displayed on the front panel. 
Wild type BoNTs can bind to both motor and sensory neurons, and lead to 
muscle paralysis. The inflammatory pain model rats will run with low speed or 
fall down for rotarod test.  
Recombinant LC-HN-HCN/A which lack of C-terminal binding domain (HCC) 
does not have binding ability to cells, thus can not inhibit pain. The 
inflammatory pain model rats which still suffer pain will perform low speed or 
fall down for rotarod test.  
LC-HN-HCN/A-anti-P2X3 antibody will bind to P2X3, which specifically 
expressed on sensory neurons, followed by endocytosis and release of LC for 
inhibition of pain-related peptides, and then inhibit pain. If it is successful, the 
inflammatory pain model rats will not feel pain and perform normally and keep 
running for rotarod test. But if it is not inhibit afferent nerve sensitization 
selectively, but as well as motor neurons, the LC-HN-HCN/A-anti-P2X3 
antibody will work just as wild type BoNTs and cause muscle paralysis and 
lead to low speed or fall down for rotarod test.  
Patients with chronic inflammatory pain, caused by arthritis, penetration 
wounds, fractures, burns, vasoconstriction, infections and extreme cold, could 
benefit from this new targeted neurotherapeutic. 
 
 
244 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 8 
 
Biliography 
245 
 
 
Angeletti, R. (1999) Design of useful peptide antigens. J Biomol Tech., 10: 
2-10. 
 
Ahmad, Z.A., Yeap, S.K., Ali, A.M., Ho, W.Y., Alitheen, N.B. and Hamid, M. 
(2012). scFv antibody: principles and clinical application. Clin. Dev. Immunol., 
2012:980250-64. 
 
Aktas, O., Ullrich, O., Infante-Duarte, C., Nitsch, R. and Zipp, F. (2007). 
Neuronal damage in brain inflammation. Arch. Neurol., 64:185-9. 
 
Aoki, K.R. and Guyer, B. (2001). Botulinum toxin type A and other botulinum 
toxin serotypes: a comparative review of biochemical and pharmacological 
actions. Eur. J. Neurol., 8:21-29. 
 
Ayyar, B.V., Hearty, S. and O'Kennedy R. (2010). Highly sensitive 
recombinant antibodies capable of reliably differentiating heart-type fatty acid 
binding protein from noncardiac isoforms. Anal. Biochem., 407:165-71. 
 
Azaman, S.N.A., Ramanan, R.N., Tan, J.S., Rahim, R.A., Abdullah, M.P. and 
Ariff, A.B. (2010). Screening for the optimal induction parameters for 
periplasmic producing interferon-α2b in Escherichia coli. African J. Biotec., 
9:6345-6354. 
 
Barbas 3rd, C.F., Burton, D.R., Scott, J.K. and Silverman, G.J. (2001). Phage 
Display a Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold 
Spring Harbor, New York, U.S.A.. 
 
Barclay, J., Patel, S., Dorn, G., Wotherspoon, G., Moffatt, S., Eunson, L., 
Abdel'al, S., Natt. F., Hall, J., Winter, J., Bevan, S., Wishart, W., Fox, A. and 
Ganju, P. (2002). Functional downregulation of P2X3 receptor subunit in rat 
246 
 
sensory neurons reveals a significant role in chronic neuropathic and 
inflammatory pain. J. Neurosci., 22:8139-47. 
 
Beresford, G.W., Pavlinkova, G., Booth, B.J., Batra, S.K., Colcher D. (1999). 
Binding characteristics and tumor targeting of a covalently linked divalent 
CC49 single-chain antibody. Int. J. Cancer, 81:911-917. 
 
Berry, J.D., Rutherford, J., Silverman, G.J., Kaul, R., Elia, M., Gobuty, S., 
Fuller, R., Plummer, F.A. and Barbas, C.F. 3rd. (2003). Development of 
functional human monoclonal single-chain variable fragment antibody against 
HIV-1 from human cervical B cells. Hybrid Hybridomics, 22:97-108. 
 
Biocca, S., Ruberti, F., Tafani, M., Pierandrei-Amaldi, P. and Cattaneo, A. 
(1995). Redox state of single chain Fv fragments targeted to the endoplasmic 
reticulum, cytosol and mitochondria. Biotechnol., (N.Y.), 13:1110-5. 
 
Bothmann, H. and Pluckthun, A. (2000). The periplasmic Escherichia coli 
peptidylprolyl cis,trans-isomerase FkpA. I. Increased functional expression of 
antibody fragments with and without cis-prolines. J. Biol. Chem., 275:17100-5. 
 
Breivik, H., Collett, B., Ventafridda, V., Cohen, R. and Gallacher, D. (2006). 
Survey of chronic pain in Europe: prevalence, impact on daily life, and 
treatment. Eur. J. Pain, 10:287–333. 
 
Brown, M.C., Joaquim, T.R., Chambers, R., Onisk, D.V., Yin, F., Moriango, 
J.M., Xu, Y., Fancy, D.A., Crowgey, E.L., He, Y., Stave, J.W. and 
Lindpaintner, K. (2011). Impact of immunization technology and assay 
application on antibody performance--a systematic comparative evaluation. 
PLoS One., 6:e28718. 
 
Burnstock, G.. (2009). Purinergic receptors and pain. Curr. Pharm. Des., 
15:1717-35. 
 
247 
 
Burnstock, G.. (2000). P2X receptors in sensory neurones. Br. J. Anaesth., 
84:476-88.  
 
Burnstock, G.. (1996). A unifying purinergic hypothesis for the initiation of 
pain. Lancet, 347:1604-5. 
  
BVTech Plasmid. Plasmid map of pET-29_a_(+), (2012).  
http://www.biovisualtech.com/bvplasmid/pET-29_a_%28+%29.htm. 
 
Chari, R.V., Martell, B.A., Gross, J.L., Cook, S.B., Shah, S.A., Blättler, W.A., 
McKenzie, S.J. and Goldmacher, V.S. (1992). Immunoconjugates containing 
novel maytansinoids: promising anticancer drugs. Cancer Res., 52:127-31. 
 
Chen, C., Snedecor, B., Nishihara, J.C., Joly, J.C., McFarland, N., Andersen, 
D.C., Battersby, J.E. and Champion, K.M. (2004). High-level accumulation of 
a recombinant antibody fragment in the periplasm of Escherichia coli requires 
a triple-mutant (degP prc spr) host strain. Biotechnol. Bioeng., 85:463-74. 
 
Chen, C.C., Akopian, A.N., Sivilotti, L., Colquhoun, D., Burnstock, G. and 
Wood, J.N. (1995). A P2X purinoceptor expressed by a subset of sensory 
neurons. Nature (Lond.), 377:428-431. 
 
Chen, Y., Huang, K., Li, X., Lin, X., Zhu, Z. and Wu, Y. (2010). Generation of 
a stable anti-human CD44v6 scFv and analysis of its cancer-targeting ability in 
vitro. Cancer Immunol. Immunother., 59:933-42. 
 
Chen, H., Li, L. and Fang, J. (2012). Construction, expression and 
characterization of the fusion gene of super-antigen SEA and single chain Fv of 
the ND-1 monoclonal antibody against human colorectal cancer. Chin. J. Cell 
Mol. Immunol., 28:400-3. 
 
248 
 
Cheung, K.K., Chan, W.Y. and Burnstock, G. (2005). Expression of P2X 
purinoceptors during rat brain development and their inhibitory role on motor 
axon outgrowth in neural tube explant cultures. Neuroscience, 133:937-45. 
 
Chuang, Y.C., Tyagi, P., Huang, C.C., Yoshimura, N., Wu, M., Kaufman, J. 
and Chancellor, M.B. (2009). Urodynamic and immunohistochemical 
evaluation of intravesical botulinum toxin A delivery using liposomes. J. Urol., 
182:786-92. 
 
Cockayne, D.A., Hamilton, S.G., Zhu, Q.M., Dunn, P.M., Zhong, Y., 
Novakovic, S., Malmberg, A.B., Cain, G., Berson, A., Kassotakis, L., Hedley, 
L., Lachnit, W.G., Burnstock, G., McMahon, S.B. and Ford, A.P.D.W. (2000). 
Urinary bladder hyporeflexia and reduced pain-related behaviour in 
P2X3-deficient mice. Nature (Lond.), 407:1011-1015. 
 
Conroy, P.J., Hearty, S., Leonard, P. and O'Kennedy, R. (2009). Antibody 
production, design and use for biosensor-based applications. Semin. Cell Dev. 
Biol., 20:10-26. 
 
Crumling, M.A., Tong, M., Aschenbach, K.L., Liu, L.Q., Pipitone, C.M. and 
Duncan, R.K. (2009). P2X antagonists inhibit styryl dye entry into hair cells. 
Neuroscience, 161:1144-53. 
 
Datar, P., Srivastava, S., Coutinho, E. and Govil, G. (2004). Substance P: 
structure, function, and therapeutics. Current Topics in Med. Chem., 4:75-103. 
 
De Kruif, J. and Logtenberg, T. (1996). Leucine zipper ized bivalent and 
bispecific scFv antibodies from a semi-synthetic antibody phage display library. 
J. Biol. Chem., 271:7630-4. 
 
De Lalla, C., Tamborini, E., Longhi, R., Tresoldi, E., Manoni, M., Siccardi, 
A.G., Arosio, P. and Sidoli, A. (1996) Human recombinant antibody fragments 
249 
 
specific for a rye-grass pollen allergen: characterization and potential 
applications. Mol. Immunol., 33:1049-58. 
 
Devine, L., Sun, J., Barr, M.R. and Kavathas, P.B. (1999). Orientation of the Ig 
domains of CD8 alpha beta relative to MHC class I. J. Immunol., 162:846-51. 
 
Dodick, D.W., Schembri, C.T., Helmuth, M. and Aurora, S.K. (2010). 
Transcranial magnetic stimulation for migraine: a safety review. Headache, 
50:1153-63. 
 
Dolly, J.O., Wang, J.F., Zurawski, T.H. and Meng, J.H. (2011). Novel 
therapeutics based on recombinant botulinum neurotoxins to normalize the 
release of transmitters and pain mediators. F.E.B.S. J., 23:4454-66. 
 
Dong, M., Yeh, F., Tepp, W.H., Dean, C., Johnson, E.A., Janz, R. and 
Chapman, E.R. (2006). SV2 is the protein receptor for botulinum neurotoxin A. 
Science., 312:592-596. 
 
Duggan, M.J., Quinn, C.P., Chaddock, J.A., Purkiss, J.R., Alexander, F.C., 
Doward, S., Fooks, S.J., Friis, L.M., Hall, Y.H., Kirby, E.R., Leeds, N., 
Moulsdale, H.J., Dickenson, A., Green, G.M., Rahman, W., Suzuki, R., Shone, 
C.C. and Foster, K.A. (2002). Inhibition of release of neurotransmitters from 
rat dorsal root ganglia by a novel conjugate of a Clostridium botulinum toxin A 
endopeptidase fragment and Erythrina cristagalli lectin. J. Biol. Chem., 
277:34846-52. 
 
Durham, P.L. and Masterson, C.G. (2013). Two mechanisms involved in 
trigeminal CGRP release: implications for migraine treatment. Headache, 
53:67-80.  
 
Engel, J., Emons, G., Pinski, J. and Schally, A.V. (2012). AEZS-108: a 
targeted cytotoxic analog of LHRH for the treatment of cancers positive for 
LHRH receptors. Expert. Opin. Investig. Drugs., 21:891-9. 
250 
 
 
Evidente, V.G. and Adler, C.H. (2010). An update on the neurologic 
applications of botulinum toxins. Curr. Neurol. Neurosci. Rep., 10:338-44. 
 
Faulds, D. and Sorkin, E.M. (1994). Abciximab (c7E3 Fab). A review of its 
pharmacology and therapeutic potential in ischaemic heart disease. Drugs, 
48:583-98. 
 
Filipović, B., Matak I., Rojecky, L.B. and Lacković, Z. (2012). Central action 
of peripherally applied botulinum toxin type A on pain and dural protein 
extravasation in a rat model of trigeminal neuropathy. PLoS. One., 7:e29803. 
 
Fischer, W., Zadori, Z., Kullnick, Y., Gröger-Arndt, H., Franke, H., Wirkner, 
K., Illes, P. and Mager, P.P. (2007). Conserved lysine and arginine residues in 
the extracellular loop of P2X3 receptors are involved in agonist binding. Eur. J. 
Pharmacol., 576:7-17. 
 
Foran, P., Mohammed, N., Lisk, G.., Nagwaney, S., Lawrence, G., Johnson, E., 
Smith L., Aoki, K. R. and Dolly J.O. (2003) Evaluation of the Therapeutic 
Usefulness of Botulinum Neurotoxin N, C1, E, and F Compared with the Long 
Lasting Type A. J. Biol. Chem., 278:1363-71. 
 
Foster, K.A. (2004). The analgesic potential of clostridial neurotoxin 
derivatives. Expert. Opin. Investig. Drugs., 13:1437-43. 
 
Gangadharan, V., Agarwal, N., Brugger, S., Tegeder, I., Bettler, B., Kuner, R. 
and Kurejova, M. (2009). Conditional gene deletion reveals functional 
redundancy of GABAB receptors in peripheral nociceptors in vivo. Mol. Pain, 
5:68-79.  
 
Gao, G. and Jakobsen, B. (2000). Molecular interactions of coreceptor CD8 
and MHC class I: the molecular basis for functional coordination with the 
T-cell receptor. Immunol. Today, 21:630-6. 
251 
 
 
Geuijen C.A., Clijsters-van der Horst, M., Cox, F., Rood, P.M., Throsby, M., 
Jongeneelen, M.A., Backus, H.H., van Deventer, E., Kruisbeek, A.M., 
Goudsmit, J. and de Kruif, J. (2005). Affinity ranking of antibodies using flow 
cytometry: application in antibody phage display-based target discovery. J. 
Immunol. Methods, 302:68-77. 
 
Gómez, I., Miranda-Ríos, J., Arenas, I., Grande, R., Becerril, B., Bravo, A. and 
Soberón, M. (2009). Identification of scFv Molecules that Recognize Loop 3 of 
Domain II and Domain III of Cry1Ab Toxin from Bacillus thuringiensis. J. 
Biol. Chem., 284:32750-57. 
 
Govindan, S.V., Cardillo, T.M., Sharkey, R.M., Tat, F., Gold, D.V. and 
Goldenberg, D.M. (2013). Milatuzumab-SN-38 conjugates for the treatment of 
CD74+ cancers [published online ahead of print February 20 2013]. Mol. 
Cancer Ther., 
http://intl-mct.aacrjournals.org/content/early/2013/02/20/1535-7163.MCT-12-1
170.full.pdf+html. 
 
Grishin, E.V., Savchenko, G.A., Vassilevski, A.A., Korolkova, Y.V., Boychuk, 
Y.A., Viatchenko-Karpinski, V.Y., Nadezhdin, K.D., Arseniev, A.S., 
Pluzhnikov, K.A., Kulyk, V.B., Voitenko, N.V. and Krishtal, O.O. (2010). 
Novel peptide from spider venom inhibits P2X3 receptors and inflammatory 
pain. Ann. Neurol., 67:680-3. 
 
Gudas, J.M., Torgov, M., An, Z., Jia, X.C., Morrison, K.J., Morrison, R.K., 
Vincent, M., Yang, P., Kanner, S.B. and Jakobovits, A. (2010) Use of 
AGS-16M8F as a novel antibody drug conjugate (ADC) for treating renal 
cancers. J. Clin. Oncol., 28:e15014. 
 
Guo, Z., Bi, F., Tang, Y., Zhang, J., Yuan, D., Xia, Z. and Liu, J.N. (2006). 
Preparation and characterization of scFv for affinity purification of reteplase. J. 
Biochem. Biophys. Meth., 67:27-36.  
252 
 
 
Hamatake, M., Komano, J., Urano, E., Maeda, F., Nagatsuka, Y. and 
Takekoshi, M. (2010). Inhibition of HIV replication by a CD4-reactive Fab of 
an IgM clone isolated from a healthy HIV-seronegative individual. Eur. J. 
Immunol., 40:1504-9. 
 
He, J., Wang, Y., Feng, J., Zhu, X., Lan, X., Iyer, A.K., Zhang, N., Seo, Y., 
VanBrocklin, H.F. and Liu, B. (2010). Targeting prostate cancer cells in vivo 
using a rapidly internalizing novel human single-chain antibody fragment. J. 
Nucl. Med., 51:427-32. 
 
Heitner, T., Satozawa, N., McLean, K., Vogel, D., Cobb, R.R., Liu, B., 
Mahmoudi, M., Finster, S., Larsen, B., Zhu, Y., Zhou, H., Müller-Tiemann, B., 
Monteclaro, F., Zhao, X.Y. and Light, D.R. (2006). Obligate multivalent 
recognition of cell surface tomoregulin following selection from a multivalent 
phage antibody library. J. Biomol. Screen., 11:985-95.  
 
Hendriksen, C. and Hau, J. (2003). Production of polyclonal and monoclonal 
antibodies, 391-411, In: Handbook of Laboratory Animal Science. 2nd ed., 
Boca Raton: CRC Press LLC, U.S.A.. 
 
Herrmann, T., Grosse-Hovest, L., Otz, T., Krammer, P.H., Rammensee, H.G. 
and Jung, G.. (2008). Construction of optimized bispecific antibodies for 
selective activation of the death receptor CD95. Cancer Res., 68:1221-7. 
 
Hoebe, K., Janssen, E. and Beutler, B. (2004). The interface between innate 
and adaptive immunity. Nature Immunol., 5:971-4. 
 
Holliger, P. and Hudson, P.J. (2005). Engineered antibody fragments and the 
rise of single domains. Nature Biotechnol., 23:1126-36. 
 
253 
 
Holmberg, A., Blomstergren, A., Nord, O., Lukacs, M., Lundeberg, J. and 
Uhlén, M. (2005). The biotin-streptavidin interaction can be reversibly broken 
using water at elevated temperatures. Electrophoresis. 26:501-10. 
 
Honore, P., Mikusa., J., Bianchi, B., McDonald, H., Cartmell, J., Faltynek, C. 
and Jarvis, M.F. (2002). TNP-ATP, a potent P2X3 receptor antagonist, blocks 
acetic acid-induced abdominal constriction in mice: comparison with reference 
analgesics. Pain, 96:99-105. 
 
Huang, C.J., Lin, H. and Yang, X. (2012). Industrial production of recombinant 
therapeutics in Escherichia coli and its recent advancements. J. Ind. Microbiol. 
Biotechnol., 39:383-99. 
 
Hussain, S.F., Yang, D., Suki, D., Grimm, E. and Heimberger. A.B. (2006). 
Innate immune functions of microglia isolated from human glioma patients. J. 
Transl. Med., 4:15-23. 
 
Idikio, H.A. (2009). Immunohistochemistry in diagnostic surgical pathology: 
contributions of protein life-cycle, use of evidence-based methods and data 
normalization on interpretation of immunohistochemical stains. Int. J. Clin. 
Exp. Pathol., 3:169-76. 
 
Immunogen. Invester Information, (2013). 
http://investor.immunogen.com/releasedetail.cfm?ReleaseID=605760. 
 
Immunogen. Product Pipeline, (2013). 
http://www.immunogen.com/pipeline/lorvotuzumab-mertansine/. 
 
Jackson, J.L., Kuriyama, A. and Hayashino, Y. (2012). Botulinum toxin A for 
prophylactic treatment of migraine and tension headaches in adults: a 
meta-analysis. J.A.M.A., 307:1736-45.  
 
254 
 
Jarvis, M.F., Burgard, E.C., McGaraughty, S., Honore, P., Lynch, K., Brennan, 
T.J., Subieta, A., Van Biesen, T., Cartmell, J., Bianchi, B., Niforatos, W., Kage, 
K., Yu, H., Mikusa., J., Wismer, C.T., Zhu, C.Z., Chu, K., Lee, C.H., Stewart, 
A.O., Polakowski, J., Cox, B.F., Kowaluk, E., Williams, M., Sullivan, J. and 
Faltynek, C. (2002). A-317491, a novel potent and selective non-nucleotide 
antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and 
neuropathic pain in the rat. Proc. Natl. Acad. Sci. U.S.A., 99:17179-84. 
 
Jin, R., Rummel, A., Binz, T. and Brunger, A.T. (2006). Botulinum neurotoxin 
B recognizes its protein receptor with high affinity and specificity. Nature 
(Lond.), 444:1092-5. 
 
Kaan, T.K., Yip, P.K., Patel, S., Davies, M., Marchand, F., Cockayne, D.A., 
Nunn, P.A., Dickenson, A.H., Ford, A.P., Zhong, Y., Malcangio, M. and 
McMahon, S.B. (2010). Systemic blockade of P2X3 and P2X2/3 receptors 
attenuates bone cancer pain behaviour in rats. Brain, 133:2549-64. 
 
Kallenborn-Gerhardt, W. and Schmidtko, A. (2011). A novel signaling 
pathway that modulates inflammatory pain. J. Neurosci., 31:798-800. 
 
Kallberg, M., Wang, H., Wang, S., Peng, J., Wang, Z., Lu, H. and Xu, J. (2012) 
Template-based protein structure modeling using the RaptorX web server. 
Nature Protocols, 7:1511-1522. 
 
Kang, A.S., Jones, T.M. and Burton, D.R. (1991). Antibody redesign by chain 
shuffling from random combinatorial immunoglobulin libraries. Proc. Natl. 
Acad. Sci. U.S.A., 88:11120-3. 
 
Kawate, T., Michel, J.C., Birdsong, W.T. and Gouaux, E. (2009). Crystal 
structure of the ATP-gated P2X(4) ion channel in the closed state. Nature 
(Lond.), 460:592-8. 
 
255 
 
Keir, C.H. and Vahdat, L.T. (2012). The use of an antibody drug conjugate, 
glembatumumab vedotin (CDX-011), for the treatment of breast cancer. Expert. 
Opin. Biol. Ther., 12:259-63.  
 
Kidd, B.L. and Urban, L.A. (2001). Mechanisms of inflammatory pain. Br. J. 
Anaesth., 87:3-11. 
 
Kidd, E.J., Miller, K.J., Sansum, A.J. and Humphrey, P.P. (1998). Evidence for 
P2X3 receptors in the developing rat brain. Neuroscience, 87:533-9. 
 
Kim, K.J., Yoon, Y.W. and Chung, J.M. (1997) Comparison of three rodent 
neuropathic pain models. Exp. Brain Res., 113:200-6. 
 
Kimura, H., Kimura, M., Tzou, S.C., Chen, Y.C., Suzuki, K., Rose, N.R. and 
Caturegli, P. Expression of class II major histocompatibility complex 
molecules on thyrocytes does not cause spontaneous thyroiditis but mildly 
increases its severity after immunization. Endocrinol., 146:1154-62. 
 
Kontermann, R. and Dübel, S. (2010). Antibody Engineering, 2nd edition, 
44-45, Springer Press, Berlin, Germany. 
 
Koshimizu, T.A., Ueno, S., Tanoue, A., Yanagihara, N., Stojilkovic, S.S. and 
Tsujimoto, G..J. (2002). Heteromultimerization modulates P2X receptor 
functions through participating extracellular and C-terminal subdomains. J. 
Biol. Chem., 277:46891-9. 
 
Krautz-Peterson, G., Zhang, Y., Chen, K., Oyler, A.G., Feng, H. and 
Shoemaker, B.C. (2012). Retargeting Clostridium difficile Toxin B to 
Neuronal Cells as a Potential Vehicle for Cytosolic Delivery of Therapeutic 
Biomolecules to Treat Botulism. J. Toxicol., 2012:760142-50. 
 
256 
 
Kreitman, R.J. and Pastan, I. (2011). Antibody fusion proteins: anti-CD22 
recombinant immunotoxin moxetumomab pasudotox. Clin. Cancer Res., 
17:6398-405. 
 
Kreitman, R.J., Tallman, M.S., Robak, T., Coutre, S., Wilson, W.H., 
Stetler-Stevenson, M., Fitzgerald, D.J., Lechleider, R. and Pastan, I. (2012). 
Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox 
(CAT-8015 or HA22) in patients with hairy cell leukemia. J. Clin. Oncol., 
30:1822-8. 
 
Labome. P2X3 antibody product information from all suppliers, (2012). 
http://www.labome.com/gene/human/P2X3-antibody.html. 
 
Lacy, D.B., Tepp, W., Cohen, A.C., DasGupta B.R and Stevens, R.C. (1998). 
Crystal structure of botulinum neurotoxin type A and implications for toxicity. 
Nature Struct. Biol., 5:898-902. 
 
Lapusan, S., Vidriales, M.B., Thomas, X., de Botton, S., Vekhoff, A., Tang, R., 
Dumontet, C., Morariu-Zamfir, R., Lambert, J.M., Ozoux, M.L., Poncelet, P., 
San Miguel, J.F., Legrand, O., DeAngelo, D.J., Giles, F.J. and Marie, J.P. 
(2011). Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid 
conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. 
Invest. New Drugs, 30:1121-31.  
 
Larsen, M.W., Bornscheuer, U.T. and Hult, K. (2008). Expression of Candida 
antarctica lipase B in Pichia pastoris and various Escherichia coli systems. 
Protein Expr. Purif., 62:90-7. 
 
Lattová, E., Bartusik, D., Spicer, V., Jellusova, J., Perreault, H. and Tomanek, 
B. (2011). Alterations in glycopeptides associated with herceptin treatment of 
human breast carcinoma mcf-7 and T-lymphoblastoid cells. Mol. Cell 
Proteomics, 10:M111.007765. 
 
257 
 
Lavonas, E.J., Schaeffer, T.H., Kokko, J., Mlynarchek, S.L. and Bogdan, G.M. 
(2009). Crotaline Fab antivenom appears to be effective in cases of severe 
North American pit viper envenomation: an integrative review. B.M.C. Emerg. 
Med., 9:13-26. 
 
Leavenworth, J.W., Schellack, C., Kim, H.J., Lu, L., Spee, P. and Cantor, H. 
(2010). Analysis of the cellular mechanism underlying inhibition of EAE after 
treatment with anti-NKG2A F(ab')2. Proc. Natl. Acad. Sci. U.S.A., 107:2562-7. 
 
Lewis, C., Neidhart, S., Holy, C., North, R.A., Buell, G. and Surprenant, A. 
(1995). Coexpression of P2X2 and P2X3 receptor subunits can account for 
ATP-gated currents in sensory neurons. Nature (Lond.), 377:432-435. 
 
Liu, J., Li, J.D., Lu, J., Xing, J. and Li, J.T. (2011). Contribution of nerve 
growth factor to upregulation of P2X₃ expression in DRG neurons of rats with 
femoral artery occlusion. Am. J. Physiol. Heart Circ. Physiol., 301:H1070-9. 
 
Liu, X., Wu, J., Zhang, S., Li, C., and Huang, Q. (2009). Novel strategies to 
augment genetically delivered immunotoxin molecular therapy for cancer 
therapy. Cancer Gene Ther., 16:861-72. 
 
Lu, D., Jimenez, X., Zhang, H., Bohlen, P., Witte, L. and Zhu, Z. (2002). 
Fab-scFv fusion protein: an efficient approach to production of bispecific 
antibody fragments. J. Immunol. Methods, 267:213-26. 
 
Macdonald, G.C., Rasamoelisolo, M., Entwistle, J., Cizeau, J., Bosc, D., 
Cuthbert, W., Kowalski, M., Spearman, M. and Glover, N. (2009). A phase I 
clinical study of VB4-845: Weekly intratumoral administration of an 
anti-EpCAM recombinant fusion protein in patients with squamous cell 
carcinoma of the head and neck. Drug Des. Devel. Ther., 2:105-14. 
 
258 
 
Mahowald, ML, Krug, HE, Singh, JA and Dykstra, D. (2009). Intra-articular 
botulinum toxin type A: A new approach to treat arthritis joint pain. Toxicon., 
54:658-67. 
 
Malin, S.A., Davis, B.M. and Molliver, D.C. (2007). Production of dissociated 
sensory neuron cultures and considerations for their use in studying neuronal 
function and plasticity. Nature Protoc., 2:152-60. 
 
Mao, Y., Zhang, D.W., Wen, J., Cao, Q., Chen, R.J., Zhu, J. and Feng, Z.Q. 
(2012). A Novel LMP1 Antibody Synergizes with Mitomycin C to Inhibit 
Nasopharyngeal Carcinoma Growth in Vivo Through Inducing Apoptosis and 
Downregulating Vascular Endothelial Growth Factor. Int. J. Mol. Sci., 
13:2208-18. 
 
Mauskop, A. (2002). The Use of Botulinum Toxin in the Treatment of 
Headaches.  Current Pain and Headache Reports, 6:320-323.  
 
McCafferty, J., Griffiths, A.D., Winter, G. and Chiswell, D.J. (1990). Phage 
antibodies: filamentous phage displaying antibody variable domains. Nature 
(Lond.), 348:552-4. 
 
Mendez, M., Gross, W.K., Glenn, T.S., Garvin, L.J. and Carretero, A.O. (2011). 
Vesicle-associated Membrane Protein-2 (VAMP2) Mediates cAMP-stimulated 
Renin Release in Mouse Juxtaglomerular Cells. J. Biol. Chem., 286:28608-18. 
 
Meng, J.H., Ovsepian, S.V., Wang, J.F., Pickering, M., Sasse, A., Aoki, K.R., 
Lawrence, G.W. and Dolly, J.O. (2009). Activation of TRPV1 mediates 
calcitonin gene-related peptide release, which excites trigeminal sensory 
neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive 
potential. J. Neurosci., 29:4981-92. 
 
Meng, J.H., Wang J.F, Lawrence, G. and Dolly, J.O. (2007). Synaptobrevin I 
mediates exocytosis of CGRP from sensory neurons and inhibition by 
259 
 
botulinum toxins reflects their anti-nociceptive potential. J. Cell Sci., 
120:2864-74.  
 
Milner, C.M. and Campbell, R.D. (2001). Genetic organization of the human 
MHC class III region. Front. Bioscience, 6:914-26. 
 
Montal, M. (2010). Botulinum neurotoxin: a marvel of protein design. Annu. 
Rev. Biochem., 79:591-617.  
 
Moon, S.A., Ki, M.K., Lee, S., Hong, M.L., Kim, M., Kim, S., Chung, J., Rhee, 
S.G. and Shim, H. (2011). Antibodies against non-immunizing antigens 
derived from a large immune scFv library. Mol. Cells, 31:509-13. 
 
Morenilla-Palao, C., Planells-Cases, R., García-Sanz, N. and Ferrer-Montiel, A. 
(2004). Regulated exocytosis contributes to protein kinase C potentiation of 
vanilloid receptor activity. J. Biol. Chem., 279:25665-72. 
 
Morris, J.L., Jobling, P. and Gibbins, I.L. (2002). Botulinum neurotoxin A 
attenuates release of norepinephrine but not NPY from vasoconstrictor neurons. 
Am. J. Physiol. Heart Circ. Physiol., 283:H2627-35. 
 
Ney, J.P. and Joseph, K.R. (2007). Neurologic uses of botulinum neurotoxin 
type A. Neuropsychiatr. Dis. Treat., 3:785-798. 
 
North, R.A. (2003). The P2X3 subunit: a molecular target in pain therapeutics. 
Curr. Opin. Investig. Drugs, 4:833-40.  
 
North, R.A. (2004). P2X3 receptors and peripheral pain mechanisms. J. 
Physiol., 554:301-8. 
 
Nunez., R. (2001). Flow cytometry: principles and instrumentation. Curr. 
Issues Mol. Biol., 3:39-45. 
 
260 
 
Ortega-Álvaro, A., Berrocoso, E., Rey-Brea, R., Leza, J.C. and Mico, J.A. 
(2012). Comparison of the antinociceptive effects of ibuprofen arginate and 
ibuprofen in rat models of inflammatory and neuropathic pain. Life Sci., 
90:13-20. 
 
Pavlinkova, G., Beresford, G., Booth, B.J., Batra, S.K., Colcher, D.G., 
Pavlinkova, G., Beresford, B.J., Booth, S.K. and Batra, D.C. (1999). 
Charge-modified single chain antibody constructs of monoclonal antibody 
CC49: generation, characterization, pharmacokinetics, and biodistribution 
analysis. Nucl. Med. Biol., 26:27-34. 
 
Pearson, R.J. and Carroll, S.L. (2004). ErbB transmembrane tyrosine kinase 
receptors are expressed by sensory and motor neurons projecting into sciatic 
nerve. J. Histochem. Cytochem., 52:1299-311. 
 
Peng, L., Tepp, W.H., Johnson, E.A. and Dong, M. (2011). Botulinum 
neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors, 
PLoS. Pathog. 7:e1002008.  
 
Polson, A.G., Williams, M., Gray, A.M., Fuji, R.N., Poon, K.A., McBride, J., 
Raab, H., Januario, T., Go, M., Lau, J., Yu, S.F., Du, C., Fuh, F., Tan, C., Wu, 
Y., Liang, W.C., Prabhu, S., Stephan, J.P., Hongo, J.A., Dere, R.C., Deng, R., 
Cullen, M., de Tute, R., Bennett, F., Rawstron, A., Jack, A. and Ebens, A. 
(2010). Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable 
linker for the treatment of non-Hodgkin's lymphoma. Leukemia, 24:1566-73.  
 
Popkov, M., Mage, R.G., Alexander, C.B., Thundivalappil, S., Barbas, C.F. 3rd 
and Rader, C. (2003). Rabbit immune repertoires as sources for therapeutic 
monoclonal antibodies: the impact of kappa allotype-correlated variation in 
cysteine content on antibody libraries selected by phage display. J. Mol. Biol., 
325:325-35.  
 
261 
 
Qin, A., Watermill, J., Mastico, R.A., Lutz, R.J., O'Keeffe, J., Zildjian, S., Mita, 
A.C., Phan, A.T. and Tolcher, A.W. (2008). The pharmacokinetics and 
pharmacodynamics of IMGN242 (huC242-DM4) in patients with 
CanAg-expressing solid tumors. A.S.C.O. Meet Abstr., 26:3066. 
 
Radford, K.M., Virginio, C., Surprenant, A., North, R.A. and Kawashima, E. 
(1997). Baculovirus expression provides direct evidence for heteromeric 
assembly of P2X2 and P2X3 receptors. J. Neurosci., 17:6529-33.  
 
Renton, T., Yiangou, Y., Baecker, P.A., Ford, A.P. and Anand, P. (2003). 
Capsaicin receptor VR1 and ATP purinoceptor P2X3 in painful and nonpainful 
human tooth pulp. J. Orofac. Pain, 17:245-50. 
 
Roberts, J.A. and Evans, R.J. (2004). ATP binding at human P2X1 receptors. 
Contribution of aromatic and basic amino acids revealed using mutagenesis 
and partial agonists. J. Biol. Chem., 279:9043-55. 
 
Robert, R., Jacobin-Valat, M.J., Daret, D., Miraux, S., Nurden, A.T., Franconi, 
J.M. and Clofent-Sanchez, G. (2006). Identification of human scFvs targeting 
atherosclerotic lesions: selection by single round in vivo phage display. J. Biol. 
Chem., 281:40135-43. 
 
Rodenko, B., Toebes, M., Celie, P.H., Perrakis, A., Schumacher, T.N. and 
Ovaa, H. (2009). Class I major histocompatibility complexes loaded by a 
periodate trigger. J. Am. Chem. Soc., 131:12305-13. 
 
Rojas, G., Talavera, A., Munoz, Y., Rengifo, E., Krengel, U., Angström, J., 
Gavilondo, J. and Moreno, E. (2004). Light-chain shuffling results in 
successful phage display selection of functional prokaryotic-expressed 
antibody fragments to N-glycolyl GM3 ganglioside. J. Immunol. Methods.,  
293:71-83. 
 
262 
 
Ruan, H.Z, Moules, E. and Burnstock, G.. (2004). Changes in P2X3 
purinoceptors in sensory ganglia of the mouse during embryonic and postnatal 
development. Histochem. Cell Biol., 122:539-51. 
 
Ryan, M.C., Kostner, H., Gordon, K.A., Duniho, S., Sutherland, M.K., Yu, C., 
Kim, K.M., Nesterova, A., Anderson, M., McEarchern, J.A., Law, C.L. and 
Smith, L.M. (2010). Targeting pancreatic and ovarian carcinomas using the 
auristatin-based anti-CD70 antibody-drug conjugate SGN-75. Br. J. Cancer, 
103:676-84.  
 
Sabin, C., Corti, D., Buzon, V., Seaman, M.S., Lutje, H.D., Hinz, A., Vanzetta, 
F., Agatic, G., Silacci, C., Mainetti, L., Scarlatti, G., Sallusto, F., Weiss, R., 
Lanzavecchia, A. and Weissenhorn, W. (2010). Crystal structure and 
size-dependent neutralization properties of HK20, a human monoclonal 
antibody binding to the highly conserved heptad repeat 1 of gp41. PLoS. 
Pathog., 6:e1001195. 
 
Sacha, A.M., Brian, M.D. and Derek, C.M. (2007). Production of dissociated 
sensory neuron cultures and considerations for their use in studying neuronal 
function and plasticity. Nature Protocols, 2:152-160.  
 
Sandström, K., Haylock, A.K., Spiegelberg, D., Qvarnström, F., Wester, K. 
and Nestor, M. (2012). A novel CD44v6 targeting antibody fragment with 
improved tumor-to-blood ratio. Int. J. Oncol., 40:1525-32. 
 
Schoonjans, R., Willems, A., Schoonooghe, S., Leoen, J., Grooten, J. and 
Mertens, N. (2001). A new model for intermediate molecular weight 
recombinant bispecific and trispecific antibodies by efficient heteroization of 
single chain variable domains through fusion to a Fab-chain. Biomol. Eng., 
17:193-202. 
 
Schoonjans, R., Willems, A., Schoonooghe, S., Fiers, W., Grooten, J. and 
Mertens, N. (2000). Fab chains as an efficient heteroization scaffold for the 
263 
 
production of recombinant bispecific and trispecific antibody derivatives. J. 
Immunol., 165:7050-57. 
 
Schoonooghe, S., Kaigorodov, V., Zawisza, M., Dumolyn, C., Haustraete, J., 
Grooten, J. and Mertens, N. (2009). Efficient production of human bivalent and 
trivalent anti-MUC1 Fab-scFv antibodies in Pichia pastoris. B.M.C. 
Biotechnol., 11:70-83. 
 
Scicchitano, M.S., Dalmas, D.A., Boyce, R.W., Thomas, H.C. and Frazier, K.S. 
(2009). Protein extraction of formalin-fixed, paraffin-embedded tissue enables 
robust proteomic profiles by mass spectrometry. J. Histochem. Cytochem., 
57:49-860. 
 
SeattleGenetics. Pipeline, (2013). 
http://www.seattlegenetics.com/SGN-CD33A. 
 
SeattleGenetics. Pipeline, (2013). http://www.seattlegenetics.com/asg22me. 
 
Shen, Z., Stryker, A.G., Mernaugh, L.R., Yu, L., Yan, H. and Zeng, X. (2005). 
Single-Chain Fragment Variable Antibody Piezoimmunosensors. Anal. Chem., 
77:797-805. 
 
Sheng, W., Shang, Y., Miao, Q., Li, Y. and Zhen, Y. (2012). Anti-tumor 
efficacy of the scFv-based fusion protein and its enediyne-energized analogue 
directed against epidermal growth factor receptor. Anticancer Drugs, 
23:406-16.  
 
Sokolova, E., Skorinkin, A., Fabbretti, E., Masten, L., Nistri, A. and Giniatullin, 
R. (2004). Agonist-dependence of recovery from desensitization of P2X3 
receptors provides a novel and sensitive approach for their rapid up or 
downregulation. Br. J. Pharmacol., 141:1048-58. 
 
264 
 
Souslova, V., Cesare, P., Ding, Y., Akopian, A.N., Stanfa, L., Suzuki, R., 
Carpenter, K., Dickenson, A., Boyce, S., Hill, R., Nebenuis-Oosthuizen, D., 
Smith, A.J., Kidd, E.J. and Wood, J.N. (2000). Warm-coding deficits and 
aberrant inflammatory pain in mice lacking P2X3 receptors. Nature (Lond.), 
407:1015-7. 
 
Singh, P., Singh, M.K., Chauhan, V., Gupta, P. and Dhaked, R.K. (2011). 
Prevention of aggregation and autocatalysis for sustaining biological activity of 
recombinant BoNT/A-LC upon long-term storage. Protein Pept. Lett., 
18:1177-87. 
 
Smith, G.P. (1985). Filamentous fusion phage: novel expression vectors that 
display cloned antigens on the virion surface. Science, 228:1315-7. 
 
Spector, D.L. (2003). The dynamics of chromosome organization and gene 
regulation. Annu. Rev. Biochem., 72:573-608. 
 
Strome, S.E., Sausville, E.A. and Mann, D. (2007). A mechanistic perspective 
of monoclonal antibodies in cancer therapy beyond target-related effects. 
Oncologist, 12:1084-95. 
 
Sundukova, M., Vilotti, S., Abbate, R., Fabbretti, E. and Nistri, A. (2012). 
Functional differences between ATP-gated human and rat P2X3 receptors are 
caused by critical residues of the intracellular C-terminal domain. J. 
Neurochem., 122:557-67. 
 
Teicher, B.A. and Chari, R.V. (2011). Antibody conjugate therapeutics: 
challenges and potential. Clin. Cancer Res., 17:6389-97. 
 
Thangudu, R.R., Manoharan, M., Srinivasan, N., Cadet, F., Sowdhamini, R. 
and Offmann, B. (2008). Analysis on conservation of disulphide bonds and 
their structural features in homologous protein domain families. BMC Struct. 
Biol., 8:55-76. 
265 
 
 
The Merk Manual. Components of the Immune System, (2012). 
http://www.merckmanuals.com/professional/immunology_allergic_disorders/bi
ology_of_the_immune_system/components_of_the_immune_system.html. 
 
Townsend, S., Finlay, W.J.J., Hearty, S. and O'Kennedy R. (2006) Optimizing 
recombinant antibody function in SPR immunosensing. The influence of 
antibody structural format and chip surface chemistry on assay sensitivity. 
Biosens. Bioelectron., 22:268-74. 
 
Tsuda, M., Ueno, S. and Inoue, K. (1999). Evidence for the involvement of 
spinal endogenous ATP and P2X receptors in nociceptive responses caused by 
formalin and capsaicin in mice. Br J Pharmacol. 128:1497-504. 
 
Tuma, R.S. (2011). Enthusiasm for antibody-drug conjugates. J. Natl. Cancer 
Inst., 103:1493-4. 
 
Vulchanova, L., Riedl, M.S., Shuster, S.J., Stone, L.S., Hargreaves, K.M., 
Buell, G., Surprenant, A., North, R.A. and Elde, R. (1998). P2X3 is expressed 
by DRG neurons that terminate in inner lamina II. Eur. J. Neurosci., 10:3470-8. 
 
Wang, J.F., Meng, J.H., Lawrence, G.W., Zurawski, T.H., Sasse, A., Bodeker, 
M.O., Gilmore, M.A., Fernández-Salas, E., Francis, J., Steward, L.E., Aoki, 
K.R. and Dolly, J.O. (2008). Novel chimeras of botulinum neurotoxins A and 
E unveil contributions from the binding, translocation, and protease domains to 
their functional characteristics. J. Biol. Chem., 283:16993-7002.  
 
Wang, J., Zurawski, T.H., Meng, J., Lawrence, G., Olango, W.M., Finn, D.P., 
Wheeler, L. and Dolly, J.O. (2011). A dileucine in the protease of botulinum 
toxin A underlies its long-lived neuroparalysis: transfer of longevity to a novel 
potential therapeutic. J. Biol. Chem., 286:6375-85. 
 
266 
 
Wang, X., Ma, D., Olson, W.C. and Heston, W.D. (2011). In vitro and in vivo 
responses of advanced prostate tumors to PSMA ADC, an 
auristatin-conjugated antibody to prostate-specific membrane antigen. Mol. 
Cancer Ther., 10:1728-39.  
 
Wirkner, K., Sperlagh, B. and Illes, P. (2007). P2X3 receptor involvement in 
pain states. Mol. Neurobiol., 36:165-83. 
 
Wittel, U.A., Jain, M., Goel, A., Baranowska-Kortylewicz, J., Kurizaki, T., 
Chauhan, S.C., Agrawal, D.K., Colcher, D. and Batra, S.K. (2005). 
Engineering and characterization of a divalent single-chain Fv angiotensin II 
fusion construct of the monoclonal antibody CC49. Biochem. Biophys. Res. 
Commun., 329:168-76. 
 
Wu, Y.T. (2009). The co-receptor signaling model of HIV-1 pathogenesis in 
peripheral CD4 T cells. Retrovirology, 6:41-6. 
 
Xiang, Z., Xiong, Y., Yan, N., Li, X., Mao, Y., Ni, X., He, C., LaMotte, R.H., 
Burnstock, G. and Sun, J. (2008). Functional up-regulation of P2X3 receptors 
in the chronically compressed dorsal root ganglion. Pain. 140:23-34.  
 
Xie, H., Audette, C., Hoffee, M., Lambert, J.M. and Blättler, W.A. (2004). 
Pharmacokinetics and biodistribution of the antitumor immunoconjugate, 
cantuzumab mertansine (huC242-DM1), and its two components in mice. J. 
Pharmacol. Exp. Ther., 308:1073-82.  
 
Xiong, H., Li, L., Liang, Q.C., Bian, H.J., Tang, J., Zhang, Q., Mi, L. and Chen, 
Z.N. (2006). Recombinant chimeric antibody hCAb as a novel anti-human 
colorectal carcinoma agent. Mol. Med., 12:229-36. 
 
Xu, G.Y. and Huang, L.Y. (2002). Peripheral inflammation sensitizes P2X 
receptor-mediated responses in rat dorsal root ganglion neurons. J. Neurosci., 
22:93-102. 
267 
 
 
Yan, S.Z., Hahn, D., Huang, Z.H.and Tang, W.J. (1996). Two cytoplasmic 
domains of mammalian adenylyl cyclase form a Gs alpha- and 
forskolin-activated enzyme in vitro. J. Biol. Chem., 271:10941-5. 
 
Yao, Y.D., Sun, T.M., Huang, S.Y., Dou, S., Lin, L., Chen, J.N., Ruan, J.B., 
Mao, C.Q., Yu, F.Y., Zeng, M.S., Zang, J.Y., Liu, Q., Su, F.X., Zhang, P., 
Lieberman, J., Wang, J. and Song, E. (2012). Targeted delivery of 
PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis. 
Sci. Transl. Med., 4:130ra48. 
 
Yiangou, Y., Facer, P., Ford, A., Brady, C., Wiseman, O., Fowler, C.J. and 
Anand, P. (2001). Capsaicin receptor VR1 and ATP-gated ion channel P2X3 in 
human urinary bladder. B.J.U. Int., 87:774-9. 
 
Younes, A., Kim, S., Romaguera, J., Copeland, A., Farial Sde, C., Kwak, L.W., 
Fayad, L., Hagemeister, F., Fanale, M., Neelapu, S., Lambert, J.M., 
Morariu-Zamfir, R., Payrard, S. and Gordon, L.I. (2012). Phase I 
multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate 
SAR3419 administered by intravenous infusion every 3 weeks to patients with 
relapsed/refractory B-cell lymphoma. J. Clin. Oncol., 30:2776-82.  
 
Yu, T., Bai, Y., Dierich, M.P. and Chen, Y.H. (2000). Induction of high levels 
of epitope-specific antibodies by epitope/peptide candidate vaccines against 
human immunodeficiency virus type-1 (HIV-1). Microbiol. Immunol., 
44:105-10. 
 
Yuahasi, K.K., Demasi, M.A., Tamajusuku, A.S., Lenz, G., Sogayar, M.C., 
Fornazari, M., Lameu, C., Nascimento, I.C., Glaser, T., Schwindt, T.T., 
Negraes, P.D. and Ulrich, H. (2012). Regulation of neurogenesis and 
gliogenesis of retinoic acid-induced P19 embryonal carcinoma cells by P2X2 
and P2X7 receptors studied by RNA interference. Int. J. Dev. Neurosci., 
30:91-7.  
268 
 
 
Zemkova, H., He, M.L., Koshimizu, T.A. and Stojilkovic, S.S. (2004). 
Identification of ectodomain regions contributing to gating, deactivation, and 
resensitization of purinergic P2X receptors. J. Neurosci., 24:6968-78. 
 
Zhang, J.Y., Wang, J.G., Wu, Y.S., Li, M., Li, A.H. and Gong, X.L. (2006). A 
combined phage display scFv library against Myxobolus rotundus infecting 
crucian carp, Carassius auratus auratus (L.), in China. J. Fish Dis., 29:1-7. 
 
Zhang, L., Moo-Young, M. and Chou, P.C. (2010). Effect of aberrant disulfide 
bond formation on protein conformation and molecular property of 
recombinant therapeutics. Pure Appl. Chem., 82:149-159. 
 
Zhang, Z., Li, Z.H., Wang, F., Fang, M., Yin, C.C., Zhou, Z.Y. and Lin, Q. and 
Huang H.L. (2002). Overexpression of DsbC and DsbG markedly improves 
soluble and functional expression of single-chain Fv antibodies in Escherichia 
coli. Protein Expr. Purif., 26:218-28. 
 
Zhong, G., Zhang, S., Li, Y., Liu, X., Gao, R., Miao, Q. and Zhen, Y. (2010). 
A tandem scFv-based fusion protein and its enediyne-energized analogue show 
intensified therapeutic efficacy against lung carcinoma xenograft in athymic 
mice. Cancer Lett., 295:124-33. 
